<?xml version='1.0' encoding='UTF-8' ?>
<Trials_downloaded_from_ICTRP>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13670847
    </Internal_Number>
    <TrialID>NCT06218316
    </TrialID>
    <Last_Refreshed_on>29 January 2024
    </Last_Refreshed_on>
    <Public_title>Repetitive Transcranial Magnetic Stimulation Versus Botulinum Injection on Spasticity on Children With Diplegic Cerebral Palsy
    </Public_title>
    <Scientific_title>Combined Effect of Repetitive Transcranial Magnetic Stimulation and Botulinum Injection on Spasticity and Motor Functions of Children With Diplegic Cerebral Palsy
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>MTI University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20231228
    </Date_registration3>
    <Date_registration>28/12/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06218316
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>4 Years
    </Inclusion_agemin>
    <Inclusion_agemax>4 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 15, 2023
    </Date_enrollement>
    <Target_size>75
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Egypt
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  were diagnosed based on history taking including perinatal, developmental, and family&#x0D;&lt;br&gt;             history, general and neurological examination.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        The included children with clinical diagnosis of moderate spastic dialogic cerebral palsy&#x0D;&lt;br&gt;        with a MAS (1, 1+, 2) and GMFCS (II, III, IV) were participated in this study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Children who's contraindicated to rTMS treatment have metal implants such as internal&#x0D;&lt;br&gt;        pacemakers and intracranial scaffolds, and/or a history of epilepsy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Children who's Contraindicated for BTX-A treatment: hypersensitivity and local&#x0D;&lt;br&gt;             infection at the injection site.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Children which have received a local injection of BTX-A within 3 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Children with dyskinetic CP,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mental retardation,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  previous, seizure or contracture were excluded.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Spastic Diplegic Cerebral Palsy
    </Condition>
    <Intervention>Drug: botulinum toxin A;Device: Transcranial Magnetic Stimulation;Other: Rehabilitation Training Protocol
    </Intervention>
    <Primary_outcome>modified aswthor scale
    </Primary_outcome>
    <Secondary_outcome>Gross Motor Function Classification System
    </Secondary_outcome>
    <Secondary_ID>cairo university
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13631032
    </Internal_Number>
    <TrialID>NCT06128746
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>rTMS Treatment of Spasticity in Children With Cerebral Palsy/ Hemiplegia Due to ABI - a RCT
    </Public_title>
    <Scientific_title>Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Spasticity in Children With Hemiplegic Cerebral Palsy/ Hemiplegia Due to Acquired Brain Injury - a Randomized Controlled Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>The University of Hong Kong
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20231107
    </Date_registration3>
    <Date_registration>07/11/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06128746
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>7 Years
    </Inclusion_agemin>
    <Inclusion_agemax>18 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 13, 2024
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Hong Kong
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Winnie Wan Yee Tso, MBBS;Oscar Leung, MSocSc
    </Contact_Lastname>
    <Contact_Email>wytso@hku.hk;oscarlk@hku.hk
    </Contact_Email>
    <Contact_Tel>+85222554295;+85222554375
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients aged between 7 years and 18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of cerebral palsy with hemiplegia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Upper limb spasticity = 1&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  IQ = 50&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any contra-indications to rTMS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe spasticity (score of 4 or more in Ashworth scale)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Uncontrollable epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of Botulinum toxin A injection in previous 6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Upper limb casting in previous 6 months&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>CP (Cerebral Palsy)
    </Condition>
    <Intervention>Device: Repetitive Transcranial Magnetic Stimulation;Device: Sham Repetitive Transcranial Magnetic Stimulation
    </Intervention>
    <Primary_outcome>Modified Ashworth Scale;The range of motion scores
    </Primary_outcome>
    <Secondary_outcome>Zancolli scale;House functional classification scale;Gross motor function measure;Assisting hand assessment;Pediatric Quality of Life Cerebral Palsy module;MRI Brain: fMRI and DKI
    </Secondary_outcome>
    <Secondary_ID>rTMSCPHKU
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13503452
    </Internal_Number>
    <TrialID>NCT06090682
    </TrialID>
    <Last_Refreshed_on>23 October 2023
    </Last_Refreshed_on>
    <Public_title>Effect and Mechanism of Brain Stimulation for Parkinson's Disease With Cognitive Impairment
    </Public_title>
    <Scientific_title>Effect and Mechanism of Deep Brain Stimulation and Transcranial Magnetic Stimulation on Parkinson's Disease With Cognitive Impairment
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Tianjin Huanhu Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20231014
    </Date_registration3>
    <Date_registration>14/10/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06090682
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 1, 2023
    </Date_enrollement>
    <Target_size>200
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>China
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Zhao Guangrui, doctor;Yin Shaoya, doctor
    </Contact_Lastname>
    <Contact_Email>Guangrui-Zhao@hotmail.com;yinsya@hotmail.com
    </Contact_Email>
    <Contact_Tel>+86 18956405513;+86 18622139285
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        1. The clinical diagnosis of PD is consistent with the United Kingdom Parkinson's Disease&#x0D;&lt;br&gt;        Society Brain Bank criteria, with disease duration over 5 years, acute levodopa motor&#x0D;&lt;br&gt;        response =30%, and indication for STN-DBS.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria included patients with severe cognitive impairment, severe psychiatric&#x0D;&lt;br&gt;        disorders, acute levodopa motor response less than 30%, atypical parkinsonism, and&#x0D;&lt;br&gt;        contraindications to surgery.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Cognitive Impairment
    </Condition>
    <Intervention>Device: Deep Brain Stimulation(DBS) and Transcranial Magnetic Stimulation(TMS)
    </Intervention>
    <Primary_outcome>Montreal Cognitive Rating Scale(MoCA);verbal fluency test (VF)
    </Primary_outcome>
    <Secondary_outcome>the third part of the Unified Parkinson's Disease Rating Scale (UPDRS III)
    </Secondary_outcome>
    <Secondary_ID>TianjinHH-02
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13503240
    </Internal_Number>
    <TrialID>NCT06087926
    </TrialID>
    <Last_Refreshed_on>23 October 2023
    </Last_Refreshed_on>
    <Public_title>Apathy in Parkinson Disease TMS Study
    </Public_title>
    <Scientific_title>Investigation of Non-invasive Brain Stimulation for the Treatment of Apathy
    </Scientific_title>
    <Acronym>PDTMSAPATHY
    </Acronym>
    <Primary_sponsor>University of North Carolina, Chapel Hill
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20231011
    </Date_registration3>
    <Date_registration>11/10/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06087926
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>55 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 31, 2023
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Basic Science. Masking: Single (Participant). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Miriam Sklerov, MD;Anita Frohlich, LL.M.
    </Contact_Lastname>
    <Contact_Email>;frohlicha@neurology.unc.edu
    </Contact_Email>
    <Contact_Tel>;919-843-6880
    </Contact_Tel>
    <Contact_Affiliation>University of North Carolina, Chapel Hill;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of idiopathic Parkinson Disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  At least 5 years of symptoms.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  On dopaminergic medication for Parkinson Disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Stable on dopaminergic medication and other medications which may influence apathy&#x0D;&lt;br&gt;             (such as selective serotonin re-uptake inhibitors, stimulant medications) for at least&#x0D;&lt;br&gt;             4 weeks prior to first study visit and remain stable throughout the study period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hospital's study-specific informed consent must be obtained.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Must have capacity to provide informed consent in English.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For female participants, confirmation that they have not had a menstrual period in&#x0D;&lt;br&gt;             over 12 months, or that they will use an effective form of contraception during the&#x0D;&lt;br&gt;             study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to provide informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to perform effort task (determined during the titration session).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of dementia (Montreal Cognitive Assessment (MoCA) score &lt; 21).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of epilepsy or brain surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe tremor or dyskinesia that would interfere with EEG (determined by the PI).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with clinically significant medical or neurological conditions which may be&#x0D;&lt;br&gt;             an alternative cause of parkinsonism such as repeated brain injury, anti-dopaminergic&#x0D;&lt;br&gt;             medications, anoxic brain injury, or significant basal ganglia strokes.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of other known central nervous system disease that may interfere with&#x0D;&lt;br&gt;             performance or interpretation of EEG or TMS.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of any implanted metal devices including, but not limited to, pacemakers,&#x0D;&lt;br&gt;             deep brain stimulators, vagal nerve stimulators, bladder stimulators, or cochlear&#x0D;&lt;br&gt;             implants.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of medical contraindications to TMS such as implanted stimulators, history of&#x0D;&lt;br&gt;             mania or bipolar disorder, history of epilepsy.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Transcranial Magnetic Stimulation (TMS)
    </Intervention>
    <Primary_outcome>Change in goal-directed behavior after transcranial magnetic stimulation (TMS);Change in reward evaluation after transcranial magnetic stimulation (TMS)
    </Primary_outcome>
    <Secondary_outcome>Association between frontal midline theta EEG power and goal-oriented behavior;Association between frontal midline theta EEG power and reward evaluation
    </Secondary_outcome>
    <Secondary_ID>K23MH132884;23-1829
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Institute of Mental Health (NIMH)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13560585
    </Internal_Number>
    <TrialID>NCT06074614
    </TrialID>
    <Last_Refreshed_on>27 November 2023
    </Last_Refreshed_on>
    <Public_title>Neural Control of Breathing in Parkinson's Disease
    </Public_title>
    <Scientific_title>Neural Control of Breathing in Parkinson's Disease: an Exploratory Study
    </Scientific_title>
    <Acronym>NEURON-PD
    </Acronym>
    <Primary_sponsor>Radboud University Medical Center
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20231003
    </Date_registration3>
    <Date_registration>03/10/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06074614
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 30, 2023
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Netherlands
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Jonne Doorduin, PhD;Jonne Doorduin, PhD;Jonne Doorduin, PhD
    </Contact_Lastname>
    <Contact_Email>;jonne.doorduin@radboudumc.nl;jonne.doorduin@radboudumc.nl
    </Contact_Email>
    <Contact_Tel>;+31243611111;+31650155757
    </Contact_Tel>
    <Contact_Affiliation>Radboud University Medical Center;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Healthy subjects: competent adult (&gt;18 years) volunteers&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients: adult (&lt;18 years) patients with Parkinson's disease, clinically confirmed by&#x0D;&lt;br&gt;             a movement disorder specialised neurologist with Hoehn and Yahr staging 1 to 3&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Willingness and ability to understand nature and content of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to participate and comply with study requirements&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Healthy subjects: previous or ongoing diseases of the central nervous system&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients: previous or ongoing diseases of the central nervous system, other than&#x0D;&lt;br&gt;             Parkinson's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of or current psychiatric treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of or current brain surgery or epilepsy, unclusing deep brain stimulation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neuromuscular disorders&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pre-existing pulmonary disease, such as chronic obstructive pulmonary disease, asthma&#x0D;&lt;br&gt;             or pulmonary fibrosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  TMS incompatibility (metal parts in head or neck, skin allergies)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Implanted cardiac pacemaker or defibrillator, neurostimulator, cochlear implant or&#x0D;&lt;br&gt;             medical infusion device&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Large or ferromagnetic metal parts in the head (exept for a dental wire)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Smoking&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Diagnostic Test: Hypercapnic ventilatory response;Diagnostic Test: Respiratory related evoked potential;Diagnostic Test: Transcranial magnetic stimulation
    </Intervention>
    <Primary_outcome>Hypercapnic ventilatory response curve;Respiratory related evoked potential;Transcranial magnetic stimulation
    </Primary_outcome>
    <Secondary_outcome>FVC;FEV1;MIP;MEP
    </Secondary_outcome>
    <Secondary_ID>NL84745.091.23
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13167395
    </Internal_Number>
    <TrialID>ChiCTR2300073361
    </TrialID>
    <Last_Refreshed_on>10 July 2023
    </Last_Refreshed_on>
    <Public_title>The effect of low-frequency repetitive transcranial magnetic stimulation and continuous theta burst stimulation on sleep disturbances in Parkinson disease
    </Public_title>
    <Scientific_title>The effect of low-frequency repetitive transcranial magnetic stimulation and continuous theta burst stimulation on sleep disturbances in Parkinson disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
    </Scientific_title>
    <Primary_sponsor>The sixth affiliated hospital of wenzhou medical university
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230707
    </Date_registration3>
    <Date_registration>2023-07-07
    </Date_registration>
    <Source_Register>ChiCTR
    </Source_Register>
    <web_address>https://www.chictr.org.cn/showproj.html?proj=149474
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>80
    </Inclusion_agemax>
    <Inclusion_gender>Male
    </Inclusion_gender>
    <Date_enrollement>2019-01-01
    </Date_enrollement>
    <Target_size>rTMS group :40;cTBS group:40;control group:40;
    </Target_size>
    <Study_type>Interventional study
    </Study_type>
    <Study_design>Parallel
    </Study_design>
    <Phase>1
    </Phase>
    <Countries>china
    </Countries>
    <Contact_Firstname>hongwei wu
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>15 Dazhong Street, Lishui CityZhejiang, China 
    </Contact_Address>
    <Contact_Email>whwenjoy@163.com
    </Contact_Email>
    <Contact_Tel>+86 151 5868 9139
    </Contact_Tel>
    <Contact_Affiliation>The sixth affiliated hospital of wenzhou medical university
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: (3)non-motor symptoms in PD patients (with a focus on sleep symptoms).&lt;br&gt;The subjects were over 18 years old. In accordance with the clinical diagnostic criteria for Parkinson's disease proposed by the International Society for Movement Disorders in 2015 [26]; Pd patients with sleep disorders, namely the first item score of the Parkinson's disease sleep scale (PDSS); Consent and informed consent were obtained from all patients before enrollment.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Parkinsonian syndrome (including traumatic, neoplastic, drug-induced, toxic, vascular and hydrocephalus, etc.) and Parkinsonian plus syndrome; Patients with severe anxiety and depression; Patients with a history of epilepsy; With metal implants such as cardiac pacemakers; Patients with serious diseases of other systems; Poor or inappropriate compliance. 
    </Exclusion_Criteria>
    <Condition>parkinson  disease
    </Condition>
    <Intervention>rTMS group :TMS stimulation;cTBS group:continuous theta burst stimulation;control group:sham stimulation;
    </Intervention>
    <Primary_outcome>deep sleep time-DST;total sleep time-TST;Unified Parkinson's Disease Rating Scale -UPDRS3;Parkinson Disease Sleep Scale-PDSS;The Insomnia Severity Index-ISI;
    </Primary_outcome>
    <Secondary_outcome>The Self-rating Anxiety Scale-SAS;The Self-rating Depression Scale -SDS;
    </Secondary_outcome>
    <Source_Support>Basic Public Welfare Research Program of Zhejiang Province
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>31/07/2018
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>genlong zhong
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+86 189 5709 3295
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13587313
    </Internal_Number>
    <TrialID>NCT05967390
    </TrialID>
    <Last_Refreshed_on>19 December 2023
    </Last_Refreshed_on>
    <Public_title>Localized Analysis of Normalized Distance From Scalp to Cortex and Personalized Evaluation (LANDSCAPE)
    </Public_title>
    <Scientific_title>Localized Analysis of Normalized Distance From Scalp to Cortex and Personalized Evaluation (LANDSCAPE): A Project of MRI-informed Computational Head Model
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Chinese University of Hong Kong
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230615
    </Date_registration3>
    <Date_registration>15/06/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05967390
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>60 Years
    </Inclusion_agemin>
    <Inclusion_agemax>95 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 15, 2023
    </Date_enrollement>
    <Target_size>488
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Hong Kong
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Hanna LU, PhD;Hanna LU, PhD;Candy Wong
    </Contact_Lastname>
    <Contact_Email>;hannalu@cuhk.edu.hk;candy.wong@cuhk.edu.hk
    </Contact_Email>
    <Contact_Tel>;28314305;85226076063
    </Contact_Tel>
    <Contact_Affiliation>Chinese University of Hong Kong;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Right-handed as assessed by the Edinburgh Inventory&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to attend TMS interventions&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Independent in daily life activities&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Uncorrected visual or auditive deficits not allowing the realization of the test&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evolutive disease (such as cancer)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neurological or psychiatric antecedent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Counter-indication to MRI&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Aging;Dementia Alzheimers;Parkinson Disease;Dementia Frontotemporal;Depression in Old Age
    </Condition>
    <Intervention>Device: Transcranial Magnetic Stimulation
    </Intervention>
    <Primary_outcome>Scalp-to-cortex distance will be measured using geometric brain model
    </Primary_outcome>
    <Secondary_ID>2018.077;2018.077
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13130813
    </Internal_Number>
    <TrialID>ChiCTR2300072289
    </TrialID>
    <Last_Refreshed_on>18 June 2023
    </Last_Refreshed_on>
    <Public_title>Analysis of the efficacy of rTMS neuromodulation of early idiopathic facial nerve palsy
    </Public_title>
    <Scientific_title>Analysis of the efficacy of rTMS neuromodulation of early idiopathic facial nerve palsy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>The Fifth Affiliated Hospital of Zhengzhou University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230608
    </Date_registration3>
    <Date_registration>2023-06-08
    </Date_registration>
    <Source_Register>ChiCTR
    </Source_Register>
    <web_address>https://www.chictr.org.cn/showproj.html?proj=178312
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15
    </Inclusion_agemin>
    <Inclusion_agemax>80
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2021-01-01
    </Date_enrollement>
    <Target_size>Stimulation group:25;Control group:25;
    </Target_size>
    <Study_type>Interventional study
    </Study_type>
    <Study_design>Parallel
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>GuoYongkun
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>The Fifth Affiliated Hospital of Zhengzhou University
    </Contact_Address>
    <Contact_Email>yongkunhope@126.com
    </Contact_Email>
    <Contact_Tel>+86 159 3623 1876
    </Contact_Tel>
    <Contact_Affiliation>The Fifth Affiliated Hospital of Zhengzhou University
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: All patients were diagnosed according to the guidelines published by the American Academy of Otolaryngology-Head and Neck Surgery Foundation ( AAO-HNSF ) in 2013, and the inclusion criteria were: ?meeting the above diagnostic criteria; ?age 15-80 years old, regardless of gender; ?first-onset, unilateral facial palsy with a duration of less than 10 days and without any treatment; ?FNGS score =10; ?receiving repeated transcranial magnetic therapy and who signed the informed consent form.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Exclusion criteria: ?Patients with confirmed central facial palsy; ?Patients with other causes of peripheral facial palsy (e.g., surgical injury, posterior cranial fossa tumor, Lyme disease, Guillain-Barré syndrome, etc.); ?Exclusion of severe cardiac, hepatic, renal, and metabolic diseases, oncological diseases, psychiatric diseases, and pregnant and lactating female patients. ? Contraindications to transcranial magnetic stimulation therapy such as intracranial metallic foreign body, epilepsy history, pacemaker implantation, etc. (6) Patients with impaired consciousness and inability to cooperate with treatment.
    </Exclusion_Criteria>
    <Condition>Bell's palsy
    </Condition>
    <Intervention>Stimulation group:Conventional treatment+ Repetitive transcranial magnetic stimulation;Control group:Conventional treatment of Bell's palsy;
    </Intervention>
    <Primary_outcome>Facial Nerve Grading System2.0;
    </Primary_outcome>
    <Source_Support>Self-selected subject
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>17/04/2023
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>ZhangXiaojuan
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+86 371 6691 6790
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13078769
    </Internal_Number>
    <TrialID>ChiCTR2300069706
    </TrialID>
    <Last_Refreshed_on>29 May 2023
    </Last_Refreshed_on>
    <Public_title>Efficacy of transcranial magnetic stimulation combined with peripheral magnetic stimulation in the treatment of facial paralysis after stroke: a randomized double-blind controlled trial
    </Public_title>
    <Scientific_title>Efficacy of transcranial magnetic stimulation combined with peripheral magnetic stimulation in the treatment of facial paralysis after stroke: a randomized double-blind controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>Rennin Hospital, Wuhan University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230323
    </Date_registration3>
    <Date_registration>2023-03-23
    </Date_registration>
    <Source_Register>ChiCTR
    </Source_Register>
    <web_address>https://www.chictr.org.cn/showproj.html?proj=190875
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2023-03-31
    </Date_enrollement>
    <Target_size>Control group:30;Peripheral magnetic stimulation group:30;Transcranial magnetic stimulation group:30;Magnetic stimulation combined with treatment group:30;
    </Target_size>
    <Study_type>Interventional study
    </Study_type>
    <Study_design>Parallel
    </Study_design>
    <Phase>New Treatment Measure Clinical Study
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>Zhan Zhang
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>238 Jiefang Road, Wuchang District, Wuhan, Hubei 
    </Contact_Address>
    <Contact_Email>979649494@qq.com
    </Contact_Email>
    <Contact_Tel>+86 180 6256 7610
    </Contact_Tel>
    <Contact_Affiliation>Renmin Hospital of Wuhan University
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. The first stroke, and no previous history of facial paralysis;&lt;br&gt;2. Central facial paralysis after stroke;&lt;br&gt;3. The age is 18~80 years old, the course of disease is 2~8 weeks, and the vital signs are stable;&lt;br&gt;4. The revised House-Brackmann Grading System (HBGS-2) is rated as Grade III or above;&lt;br&gt;5. Clear consciousness and normal listening and understanding function;&lt;br&gt;6. The subject and/or guardian informed consent and signed the consent form.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Executive dysfunction;&lt;br&gt;2. Serious insufficiency of important organs such as heart, liver and kidney;&lt;br&gt;3. Previous history of craniocerebral trauma, skull defect, craniocerebral surgery;&lt;br&gt;4. Have a history of mental illness, dementia, epilepsy or family history;&lt;br&gt;5. There are tumors in the brain, increased intracranial pressure, metal and other foreign bodies in the brain, pacemaker implantation, cardiac stent implantation, cochlear implantation, and nasal feeding.
    </Exclusion_Criteria>
    <Condition>facial palsy after stroke
    </Condition>
    <Intervention>Control group:Routine rehabilitation treatment + Pseudo-magnetic stimulation;Peripheral magnetic stimulation group:Routine rehabilitation treatment + Peripheral magnetic stimulation;Transcranial magnetic stimulation group:Routine rehabilitation treatment + Transcranial magnetic stimulation;Magnetic stimulation combined with treatment group:Routine rehabilitation treatment + TMS and PMS;
    </Intervention>
    <Primary_outcome>House-Brackmann Grading System 2.0;Sunnybrook Facial Nerve Rating System;
    </Primary_outcome>
    <Secondary_outcome>Burres-Fisch facial nerve score;Facial disability Index;Self-rating Depression Scale;Self-rating Anxiety Scale;
    </Secondary_outcome>
    <Source_Support>No Funding
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/02/2023
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>979649494@qq.com
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Yuan Chen
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email>979649494@qq.com
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13156886
    </Internal_Number>
    <TrialID>NCT05713721
    </TrialID>
    <Last_Refreshed_on>3 July 2023
    </Last_Refreshed_on>
    <Public_title>Sensorimotor Integration in Monogenic Parkinson-dystonia Syndromes
    </Public_title>
    <Scientific_title>SensoMo-PD: Sensorimotor Integration in Monogenic Parkinson-dystonia Syndromes
    </Scientific_title>
    <Acronym>SensoMo-PD
    </Acronym>
    <Primary_sponsor>University Hospital Schleswig-Holstein
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230127
    </Date_registration3>
    <Date_registration>27/01/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05713721
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>100 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2023
    </Date_enrollement>
    <Target_size>120
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Anne Weissbach, MD;Anne Weissbach, MD;Anne Weissbach, MD
    </Contact_Lastname>
    <Contact_Email>;anne.weissbach@neuro.uni-luebeck.de;anne.weissbach@neuro.uni-luebeck.de
    </Contact_Email>
    <Contact_Tel>;+49 451 3101 8219;+49 451 3101 8219
    </Contact_Tel>
    <Contact_Affiliation>Institute of Systems Motor Science;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion criteria for mutation carriers:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pathogenic Parkin, PINK1, GCH1, or TAF1 gene variant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age &gt;18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion criteria for healthy control participants:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No movement disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age &gt;18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No medication with influences on the central nervous system&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age &lt;18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medication that reduces the seizure threshold&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson;Dystonia;DYT3;DYT5;PINK1 Gene Deletion;Dystonia, Familial
    </Condition>
    <Intervention>Device: Transcranial magnetic stimulation (TMS);Other: Video-based clinical examination;Other: 24 hours drug withdrawal of dopaminergic medication;Other: Evaluation of deep brain stimulation
    </Intervention>
    <Primary_outcome>Contrast sensorimotor integration in patients with three different monogenic Parkinson-dystonia syndromes.;Define whether asymptomatic mutation carriers show abnormalities in sensorimotor integration and clinical signs of Parkinson and dystonia upon video examination.;Correlate clinical symptom severity with changes in sensorimotor integration.;Evaluate treatment effects on sensorimotor integration, e.g., for PARK-Parkin/PARK-PINK1 and DYT/PARK-GCH1 chronic dopaminergic medication and for DYT/PARK-TAF1 deep brain stimulation effects.
    </Primary_outcome>
    <Secondary_ID>MJFF-022062
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Michael J. Fox Foundation for Parkinson's Research
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13586451
    </Internal_Number>
    <TrialID>NCT05705999
    </TrialID>
    <Last_Refreshed_on>19 December 2023
    </Last_Refreshed_on>
    <Public_title>Strengthening Tourette Treatment OPtions Using TMS to Improve CBIT, a Double-blind, Randomized, Controlled Study
    </Public_title>
    <Scientific_title>Strengthening Tourette Treatment OPtions Using TMS to Improve CBIT, a Double-blind, Randomized, Controlled Study
    </Scientific_title>
    <Acronym>STOP-TIC
    </Acronym>
    <Primary_sponsor>West Virginia University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230121
    </Date_registration3>
    <Date_registration>21/01/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05705999
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>100 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 2024
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Jessica Frey, MD;Jessica Frey, MD;Jessica Frey, MD
    </Contact_Lastname>
    <Contact_Email>;Jessica.frey@hsc.wvu.edu;Jessica.frey@hsc.wvu.edu
    </Contact_Email>
    <Contact_Tel>;304-598-6127;304-598-6127
    </Contact_Tel>
    <Contact_Affiliation>WVU RNI;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 18 years or older&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of Tourette Syndrome&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Moderate Tic Severity at baseline&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of metallic objects or neurostimulators in the brain&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of active seizures or epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Contraindications to receiving fMRI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to participate in CBIT due to other underlying cognitive or medical&#x0D;&lt;br&gt;             condition&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tourette Syndrome
    </Condition>
    <Intervention>Device: transcranial magnetic stimulation
    </Intervention>
    <Primary_outcome>Yale Global Tic Severity Scale (YGTSS);Modified Rush Videotape Tic Rating Scale (mRVTRS)
    </Primary_outcome>
    <Secondary_ID>2211680481
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Florida;Tourette Association of America
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>12972917
    </Internal_Number>
    <TrialID>NCT05599035
    </TrialID>
    <Last_Refreshed_on>17 April 2023
    </Last_Refreshed_on>
    <Public_title>Sleep Disorder in Parkinson Disease and rTMS
    </Public_title>
    <Scientific_title>Sleep Disorder in Parkinson Disease and rTMS
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Assiut University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20221025
    </Date_registration3>
    <Date_registration>25/10/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05599035
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 1, 2022
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: Triple (Participant, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Egypt
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Eman Khedr;Eman M Khedr, MD
    </Contact_Lastname>
    <Contact_Email>Emankhedr99@yahoo.com;emankhedr99@yahoo.com
    </Contact_Email>
    <Contact_Tel>010058506632;
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosis of PD was done according to UK Brain bank Criteria for diagnosis of PD. Out&#x0D;&lt;br&gt;             of them we selected only patients with sleep disturbance All patients fulfilled by&#x0D;&lt;br&gt;             Parkinson's disease sleep scale (PDSS).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with PD with disturbed conscious level, severe cognitive impairment,&#x0D;&lt;br&gt;             psychosis, and medical problems such as (Renal failure, Liver cell Failure,&#x0D;&lt;br&gt;             Respiratory Failure, and endocrinal impairment), patients with other types of&#x0D;&lt;br&gt;             Parkinsonism as (Multisystem atrophy, supranuclear palsy, and encephalitic&#x0D;&lt;br&gt;             Parkinsonism) and patients had contraindication of magnetic stimulation (metallic&#x0D;&lt;br&gt;             piece, pacemaker, epilepsy) were also excluded from the study&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Sleep Disorder;Parkinson Disease
    </Condition>
    <Intervention>Device: repititive transcranial magnetic stimulation
    </Intervention>
    <Primary_outcome>Parkinson's disease sleep scale (PDSS) (reference).;polysomenography
    </Primary_outcome>
    <Secondary_outcome>Beck Depression Inventory;Unified Parkinson's Disease Rating Scale (UPDRS);Cognitive assessment using minimental state examination (MMSE)
    </Secondary_outcome>
    <Secondary_ID>sleep disorder in parkinson
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13508443
    </Internal_Number>
    <TrialID>NCT05198076
    </TrialID>
    <Last_Refreshed_on>30 October 2023
    </Last_Refreshed_on>
    <Public_title>6 Month Follow up Study on the Changes of Postural Stability in Parkinsonian Patients in Response to High Frequency TMS.
    </Public_title>
    <Scientific_title>The Long Term Efficacy of High Frequency Repetitive Transcranial Magnetic Stimulation on Postural Stability in Parkinsonian Patients.
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Cairo University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220102
    </Date_registration3>
    <Date_registration>02/01/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05198076
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>55 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>Male
    </Inclusion_gender>
    <Date_enrollement>April 23, 2023
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Egypt
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Engy BadrEldin S Moustafa, PhD;Engy BadrEldin S Moustafa, PhD;Engy BadrEldin S Moustafa, PhD
    </Contact_Lastname>
    <Contact_Email>;engybm.saleh@cu.edu.eg;engybm.saleh@cu.edu.eg
    </Contact_Email>
    <Contact_Tel>;00201099445112;00201099445112
    </Contact_Tel>
    <Contact_Affiliation>Cairo University;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All included patients should fulfill the U.K Parkinson's Disease Brain Bank Criteria&#x0D;&lt;br&gt;             for idiopathic PD.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with mild to moderate disease severity according to UPRS and Modified Hoehn&#x0D;&lt;br&gt;             and Yahr staging&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Duration of illness from two to five years were included.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All included patients should be medically and psychologically stable and of adequate&#x0D;&lt;br&gt;             cardiac function.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All included patients should haven't receive any rTMS sessions before.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signed consent form should be taken from all included patients.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with implanted devices, serious medical illness or history of seizures were&#x0D;&lt;br&gt;             excluded.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with severe freezing phenomenon or severe tremors were excluded&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: High Frequency Repetitive Transcranial Magnetic Stimulation
    </Intervention>
    <Primary_outcome>Overall stability index (OSI);Antero-posterior Stability index (APSI);Medio-lateral stability index (MLSI);Directional control percent;Time to complete test
    </Primary_outcome>
    <Secondary_ID>P.T.REC/012/003448
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13064637
    </Internal_Number>
    <TrialID>NCT05198921
    </TrialID>
    <Last_Refreshed_on>22 May 2023
    </Last_Refreshed_on>
    <Public_title>The Effectiveness of Repetitive Transcranial Magnetic Stimulation for Spastic Diplegia Cerebral Palsy
    </Public_title>
    <Scientific_title>The Effectiveness of Repetitive Transcranial Magnetic Stimulation for the Treatment of Spastic Diplegia Cerebral Palsy Based on the Gross Motor Function in School-aged Children: A Randomized Controlled Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Universitat de Lleida
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20211227
    </Date_registration3>
    <Date_registration>27/12/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05198921
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Years
    </Inclusion_agemin>
    <Inclusion_agemax>12 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 2024
    </Date_enrollement>
    <Target_size>222
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Spain
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>CLAUDIA ARUMI
    </Contact_Lastname>
    <Contact_Email>claudia.arumi@hotmail.com
    </Contact_Email>
    <Contact_Tel>630004767
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Primary school children with diagnose of Spastic Diplegia CP&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  &gt; 1 on Mas in hip flexors, adductors and tibialis anterior of both lower extremities.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parents/legal guardians signed the Informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe mental retardation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Present epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Present any remedial surgery/medication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Less than 1 year post orthopaedic surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Less than 6 months post botulinum toxin type A injection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Present metallic implants&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Present any comorbidity unfit for the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Congenital disorders such as Down's syndrome, fragile-x syndrome or congenital&#x0D;&lt;br&gt;             anomalies&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cerebral Palsy, Spastic
    </Condition>
    <Intervention>Device: repetitive Transcranial Magnetic Stimulation;Device: sham repetitive Transcranial Magnetic Stimulation
    </Intervention>
    <Primary_outcome>Change in Gross Motor Function by the Gross Motor Function-66
    </Primary_outcome>
    <Secondary_outcome>Change in Functional Strength by the Functional Strength Measure;Change in Quality of Life by the Cerebral Palsy Quality of Life-Child;Change in Spasticity by the Modified-Modified Ashworth Scale.;Change in Impact on family by the Revised Impact on Family questionnaire
    </Secondary_outcome>
    <Secondary_ID>ULleida1
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>12981265
    </Internal_Number>
    <TrialID>NCT05205772
    </TrialID>
    <Last_Refreshed_on>24 April 2023
    </Last_Refreshed_on>
    <Public_title>Investigating Central Neurophysiologic Correlates of Non-Motor Symptoms of Parkinson's Disease
    </Public_title>
    <Scientific_title>Investigating Central Neurophysiologic Correlates of Non-Motor Symptoms of Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of North Carolina, Chapel Hill
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20211202
    </Date_registration3>
    <Date_registration>02/12/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05205772
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>50 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 1, 2022
    </Date_enrollement>
    <Target_size>45
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Basic Science. Masking: Single (Participant). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Miriam Sklerov, MD;Miriam Sklerov, MD
    </Contact_Lastname>
    <Contact_Email>;miri@email.unc.edu
    </Contact_Email>
    <Contact_Tel>;984-974-4401
    </Contact_Tel>
    <Contact_Affiliation>University of North Carolina, Chapel Hill
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Men and women between 50 and 90 years of age, without a diagnosis of severe dementia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Carry a diagnosis of idiopathic Parkinson's disease based on the United Kingdom&#x0D;&lt;br&gt;             Parkinson's Disease Society Brain Bank clinical diagnostic criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have had symptoms of Parkinson's disease for at least 3 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hospital's study-specific informed consent must be obtained&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Must have capacity to provide informed consent in English&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  For female participants, confirmation that a menstrual period has not occurred in over&#x0D;&lt;br&gt;             12 months, or that an effective form of contraception will be used during the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to provide informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe dementia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of epilepsy or brain surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe tremor or dyskinesia that would interfere with EEG as determined by the PI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parkinson's patients with clinically significant medical or neurological conditions&#x0D;&lt;br&gt;             which may be an alternative cause of orthostatic hypotension, such as neuropathy,&#x0D;&lt;br&gt;             renal failure, heart failure, cardiac arrhythmias, severe diabetes, or spinal cord&#x0D;&lt;br&gt;             injuries&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The investigators will exclude patients who are treated with medications which can&#x0D;&lt;br&gt;             significantly lower blood pressure or heart rate, such as antihypertensive&#x0D;&lt;br&gt;             medications, diuretics, and alpha-blocking medications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of other known central nervous system disease that may interfere with&#x0D;&lt;br&gt;             performance or interpretation of EEG or TMS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of any implanted metal devices including, but not limited to, pacemakers,&#x0D;&lt;br&gt;             deep brain stimulators, vagal nerve stimulators, bladder stimulators, or cochlear&#x0D;&lt;br&gt;             implants.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Autonomic Dysfunction;Depression
    </Condition>
    <Intervention>Device: transcranial magnetic stimulation
    </Intervention>
    <Primary_outcome>Change in frontal midline theta EEG power after brain stimulation;Superiority of stimulation at the medial prefrontal cortex and dorsolateral prefrontal cortex over stimulation at the control site;Correlation between the SCales for Outcomes in Parkinson's disease - Autonomic (SCOPA-AUT) total score and EEG;Correlation between the Orthostatic Hypotension Questionnaire (OHQ) and EEG;Correlation between degree of orthostatic hypotension and EEG
    </Primary_outcome>
    <Secondary_ID>21-0751
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>11967477
    </Internal_Number>
    <TrialID>NCT05134259
    </TrialID>
    <Last_Refreshed_on>28 February 2022
    </Last_Refreshed_on>
    <Public_title>rTMS in Spastic Hemiplegic Cerebral Palsy Children
    </Public_title>
    <Scientific_title>The Role of Repetitive Transcranial Magnetic Stimulation in Spastic Hemiplegic Cerebral Palsy in a Sample of Egyptian Children
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Al-Azhar University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20211120
    </Date_registration3>
    <Date_registration>20/11/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05134259
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>4 Years
    </Inclusion_agemin>
    <Inclusion_agemax>18 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2022
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Egypt
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Hossam M. Emam, professor;Ahmed A. Muhammad;Ahmed A. Muhammad
    </Contact_Lastname>
    <Contact_Email>;ahmed.a.muh@gmail.com;ahmed.a.muh@gmail.com
    </Contact_Email>
    <Contact_Tel>;0201093444878;0201093444878
    </Contact_Tel>
    <Contact_Affiliation>Faculty of Medicine, Al-Azhar University;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Willingness to participate.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Age group between 4 and 18 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. They are able to walk with limitation or holding on according to Gross Motor Function&#x0D;&lt;br&gt;             classification System (GMFCS) (level II, III, IV).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. All patients have mild to moderate spasticity according to modified Ashworth scale&#x0D;&lt;br&gt;             (Grade 1, 1+,2).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  All Children with:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. Perceptual defects (IQ&lt;70).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Use of botulinum toxin in the past 4 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. Convulsions.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               4. Other peripheral or central nervous system dysfunction.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               5. Fixed deformities in lower limbs.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               6. Clinically suspected active inflammatory or pathologic changes in lower limb&#x0D;&lt;br&gt;                  joints during the previous 6 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               7. Clinically suspected active medical problems, such as pneumonia, meningitis,&#x0D;&lt;br&gt;                  encephalitis, upper gastrointestinal bleeding, or urinary tract infection.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               8. Metabolic disorders, such as inborn error of metabolism, electrolyte, and&#x0D;&lt;br&gt;                  endocrine disorders.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               9. Metallic implants.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cerebral Palsy
    </Condition>
    <Intervention>Device: Repetitive Transcranial Magnetic Stimulation
    </Intervention>
    <Primary_outcome>Change in muscle spasticity
    </Primary_outcome>
    <Secondary_outcome>Change in gross motor function
    </Secondary_outcome>
    <Secondary_ID>0000043
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>12445611
    </Internal_Number>
    <TrialID>ChiCTR2100052642
    </TrialID>
    <Last_Refreshed_on>8 August 2022
    </Last_Refreshed_on>
    <Public_title>Repeated transcranial magnetic stimulation (rTMS) for idiopathic facial nerve palsy: a prospective, randomized controlled trial
    </Public_title>
    <Scientific_title>Efficacy and mechanism of repetitive transcranial magnetic stimulation (rTMS) in idiopathic facial palsy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>Yuebei People's Hospital
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20211102
    </Date_registration3>
    <Date_registration>2021-11-02
    </Date_registration>
    <Source_Register>ChiCTR
    </Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=136220
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>75
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2021-10-28
    </Date_enrollement>
    <Target_size>Experimental group:30;Control group:30;
    </Target_size>
    <Study_type>Interventional study
    </Study_type>
    <Study_design>Parallel
    </Study_design>
    <Phase>0
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>Liu Huiyu
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>133 Huiming Road South, Wujiang District, Shaoguan, Guangdong, China 
    </Contact_Address>
    <Contact_Email>liuhuiyudoctor@sohu.com
    </Contact_Email>
    <Contact_Tel>+86 13922599818
    </Contact_Tel>
    <Contact_Affiliation>Yuebei People's Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Diagnosed with Bell's palsy (idiopathic facial neuritis) and facial nerve damage by electromyography;&#x0D;&lt;br&gt;2. The first onset and unilateral paralysis;&#x0D;&lt;br&gt;3. Aged 18 to 75 years;&#x0D;&lt;br&gt;4. Those who voluntarily signed the informed consent form.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Clearly identified as a patient with central facial paralysis;&#x0D;&lt;br&gt;2. Facial paralysis caused by Lyme disease, encephalitis, tumor or trauma and other reasons;&#x0D;&lt;br&gt;3. Confused and unable to cooperate with the treatment of patients;&#x0D;&lt;br&gt;4. Contraindications for transcranial magnetic stimulation such as pregnancy or intracranial metal foreign body, history of epilepsy, implanted pacemaker, etc.;&#x0D;&lt;br&gt;5. Patients with poor treatment compliance.
    </Exclusion_Criteria>
    <Condition>facial nerve palsy
    </Condition>
    <Intervention>Experimental group:Repeated transcranial magnetic stimulation ;Control group:conventional therapy;
    </Intervention>
    <Primary_outcome>House-Brackmann;Portmann Easy Scoring;Toronto Facial Nerve Rating Scale;
    </Primary_outcome>
    <Source_Support>self-funded
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>19/08/2021
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Gao Linjun
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13434069
    </Internal_Number>
    <TrialID>JPRN-jRCTs052210061
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>cTBS for Pareidolias
    </Public_title>
    <Scientific_title>Investigating the effects of a single continuous theta burst stimulation (cTBS) to the frontal lobes in Parkinson's disease patients with pareidolia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
    </Scientific_title>
    <Primary_sponsor>Kimura Yasuyoshi
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210806
    </Date_registration3>
    <Date_registration>06/08/2021
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://jrct.niph.go.jp/latest-detail/jRCTs052210061
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>&gt;= 40age old
    </Inclusion_agemin>
    <Inclusion_agemax>&lt;= 80age old
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>06/08/2021
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>randomized controlled trial, single blind, placebo control, crossover assignment, basic science
    </Study_design>
    <Phase>2
    </Phase>
    <Contact_Firstname>Yasuyoshi
    </Contact_Firstname>
    <Contact_Lastname>Kimura
    </Contact_Lastname>
    <Contact_Address>2-15 Yamadaoka, Suita, Osaka 565-0871
    </Contact_Address>
    <Contact_Email>y-kimura@neurol.med.osaka-u.ac.jp
    </Contact_Email>
    <Contact_Tel>+81-6-6879-3571
    </Contact_Tel>
    <Contact_Affiliation>Osaka University Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) Diagnosed with Parkinson's disease according to MDS diagnosis criteria&lt;br&gt;2) Age between 40 and 80 years at the time of consent.&lt;br&gt;3) Diagnosed by NPT as having mild hallucinations (cut-off value: 2)&lt;br&gt;4) Consent has been obtained in writing by the patient.&lt;br&gt;5) The severity in the ON condition is less than or equal to 3 according to the modified Hoehn-Yahr scale and requires dopaminergic drug treatment with either levodopa, a dopamine agonist, or MAO-B inhibitor.&lt;br&gt;6) Stable medication for Parkinson's disease and anticholinesterase drugs (donepezil, rivastigmine, galantamine) within 30 days prior to the date of consent.&lt;br&gt;7) Able to remain ON antiparkinsonian medication for the duration of the study (&gt;2 hours)&lt;br&gt;8) The education in socioeconomic status is at least a secondary school diploma.&lt;br&gt;9) Have normal visual acuity with naked or corrected vision (Snellen index of 20/30 or less)
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1) Has cognitive decline (score 23 or below on MMSE)&lt;br&gt;2) Severe depressive symptoms (score of 28 or higher on BDI-II). Or BDI-II falls between 17 and 28 points and (1) scores at least 1 point on Question 9 (suicide question), or (2) is being treated for depression, or (3) the physician determines that&lt;br&gt;depression will affect the evaluation or protocol. If (1) applies or if the depression is severe, the patient should be consulted by a psychiatrist or psychosom atic medicine specialist.&lt;br&gt;3) Taking antipsychotic drugs (olanzapine, risperidone, clozapine), anticholinesterase drugs (donepezil, rivastigmine, galantamine).&lt;br&gt;4) Taking antipsychotics or other medications with the potential to cause parkinsonism within 60 days prior to enrollment in this study.&lt;br&gt;5) Atypical symptoms of Parkinson's disease, such as cerebellar symptoms, pyramidal tract signs, autonomic neuropathy, or supranuclear ocular dyskinesia, are present at the time of diagnosis or occur within 1 month of diagnosis.&lt;br&gt;6) A history of seizures, epilepsy, or unexplained loss of consciousness.&lt;br&gt;7) History of fainting spells.&lt;br&gt;8) Has been diagnosed as having an abnormal brain structure&lt;br&gt;9) Have metal implants implanted in the skull or spinal cord due to neurosurgery, etc.&lt;br&gt;10) Has a pacemaker, artificial heart, vagus nerve stimulator, deep brain stimulator, or ventricular shunt implanted in the body&lt;br&gt;11) Pregnant&lt;br&gt;12) Have received repetitive transcranial magnetic stimulation in the past&lt;br&gt;13) Have received electroconvulsive therapy in the past&lt;br&gt;14) Poorly controlled diabetes, heart disease or hypertension&lt;br&gt;15) Taking any medication not indicated for TMS at the time of enrollment in the study (imipramine, amitriptyline, doxepin, nortriptyline, maprofiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines (MDMA, ecstasy), Cocaine, phencyclidine, ketamine, gamma-hydroxybutyrate (GHB), theophylline, haloperidol)&lt;br&gt;16) There is dyskinesia that affects the quality of the evalutaion.&lt;br&gt;17) Other items that the principal investigator or sub-investigator deems inappropriate for this study.
    </Exclusion_Criteria>
    <Condition>Parkioson Disease &lt;br&gt;Parkinson Disease, Pareidolia;D010300;Parkinson Disease, Pareidolia
    </Condition>
    <Intervention>Single-session stimulation of continuous theta burst magnetic stimulation (cTBS) under neuronavigation system guidance: triple pulses at 20 ms intervals repeated every 200 ms for 40 s for a total of 600 pulses are used for transcranial repetitive magnetic stimulation (TMS) to the right dorsolateral prefrontal cortex. The stimulation intensity is 90% of active motor threshold (maximum stimulation intensity: 55% maximum stimulator output), and the stimulation conditions for sham stimulation are the same as for real stimulation except for the stimulus intensity (80% of real condition). The real and sham stimulation sessions should be separated by 1~8 weeks for each patient.;D050781;Transcranial Magnetic Stimulation
    </Intervention>
    <Primary_outcome>Amount of change in pareidolia score in NPT performed before and after cTBS stimulation
    </Primary_outcome>
    <Secondary_outcome>1) Safety - reports of adverse events since the start of cTBS&lt;br&gt;2) B-JLO - change in Benton's linear orientation judgment test score&lt;br&gt;3) sSTAI - change in a simplified state-trait anxiety test score&lt;br&gt;4) EEG at rest and during NPT (eyes closed)&lt;br&gt;5) Face discrimination (D-prime) in NPT&lt;br&gt;6) Time spent gazing into the pareidolia / face area in the gaze measurement in NPT
    </Secondary_outcome>
    <Source_Support>Japan Society for the Promotion of Science
    </Source_Support>
    <Ethics_review_status>Approval
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>handai-nintei@hp-crc.med.osaka-u.ac.jp
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Osaka University Clinical Research Review Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+81-6-6210-8296
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>handai-nintei@hp-crc.med.osaka-u.ac.jp
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13646624
    </Internal_Number>
    <TrialID>DRKS00025875
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Neural network maturation underlying top-down motor control and movement initiation in childhood and adolescence
    </Public_title>
    <Scientific_title>Neural network maturation underlying top-down motor control and movement initiation in childhood and adolescence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Medizinische Fakultät der Universität zu Köln
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210720
    </Date_registration3>
    <Date_registration>20/07/2021
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00025875
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>5 Years
    </Inclusion_agemin>
    <Inclusion_agemax>16 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>27/10/2021
    </Date_enrollement>
    <Target_size>190
    </Target_size>
    <Study_type>observational
    </Study_type>
    <Study_design>Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: basic science  
    </Study_design>
    <Phase/>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Julia;Theresa
    </Contact_Firstname>
    <Contact_Lastname>Schmidgen;Heinen
    </Contact_Lastname>
    <Contact_Address>Robert-Koch-Straße 10;Neuenhofer Weg 21
    </Contact_Address>
    <Contact_Email>E-Mail: julia.schmidgen@uk-koeln.de;theinen@ukaachen.de
    </Contact_Email>
    <Contact_Tel>(0221) 478-82707;0241 80-80989
    </Contact_Tel>
    <Contact_Affiliation>AG Neurophysiologie und non-invasive Neuromodulation Klinik und Poliklinik für Psychiatrie, Psychosomatikund Psychotherapie des Kindes- und Jugendalters;LFG Klinische Neuropsychologie des Kindes- und Jugendalters, Uniklinik RWTH Aachen
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Inclusion criteria - Healthy Participants &#x0D;&lt;br&gt;--&gt;No psychiatric diagnosis according to DSM-V&#x0D;&lt;br&gt;--&gt;between 5 and 16 years of age &#x0D;&lt;br&gt;--&gt;Consent to be informed of any incidental findings&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;Inclusion criteria - Patients &#x0D;&lt;br&gt;--&gt;Tic disorder - Provisional Tic Disorder, Chronic Tic Disorder or Tourette-Syndrome according to DSM-V.&#x0D;&lt;br&gt;--&gt;between 5 and 16 years of age&#x0D;&lt;br&gt;--&gt;Consent to be informed of any incidental findings
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: --&gt; IQ&lt;70&#x0D;&lt;br&gt;--&gt;Epileptic seizures (participant or parents)&#x0D;&lt;br&gt;--&gt;Other CNS-impairing neurological medical history&#x0D;&lt;br&gt;--&gt;Preterm birth before 32nd week of gestation&#x0D;&lt;br&gt;--&gt;Limited vision despite visual acuity correction&#x0D;&lt;br&gt;--&gt;Use of psychoactive substances (legal and illegal drugs) on the day of examination or with continued effects on the day of examination (depending on half-life)&#x0D;&lt;br&gt;--&gt;Use of stimulants on the day of examination or in case of retard products within the last 48 hours (for coffee or cigarette use 24 hours)&#x0D;&lt;br&gt;--&gt;Intake of antipsychotics or tranquilizers (each within 4half-lives).&#x0D;&lt;br&gt;--&gt;Fear of confinement&#x0D;&lt;br&gt;--&gt;Metal parts in or on the body (screws, metal-containing tattoos, non-removable piercings, cochlear implants, fixed braces with metal parts, etc.)&#x0D;&lt;br&gt;--&gt;Electrical devices in the body (pacemakers, medication pumps, etc.)&#x0D;&lt;br&gt;--&gt;Severe back pain,&#x0D;&lt;br&gt;--&gt;Excessive overweight&#x0D;&lt;br&gt;--&gt;Pregnancy
    </Exclusion_Criteria>
    <Condition>Tic Disorders: Persistent (Chronic) Motor Tic Disorder, Provisional Tic Disorder, Tourette's Disorder &lt;br&gt;F95 &lt;br&gt;F95.0 &lt;br&gt;F95.1 &lt;br&gt;F95.2;Tic disorders;Transient tic disorder;Chronic motor or vocal tic disorder;Combined vocal and multiple motor tic disorder [de la Tourette];F95.0;F95.1;F95.2
    </Condition>
    <Intervention>Group 1: Neurophysiological and brain network correlates of movement preparation and inhibition during typical development in children and adolescents.&lt;br&gt;&lt;br&gt;-examination of movement correlated potentials (EEG)&lt;br&gt;-measurement of IQ (WISC-V o. WPPSI-III) &lt;br&gt;-MR examination &lt;br&gt;-Diagnosis of mental disorders (DIPS) &lt;br&gt;-Motor function tests: Edinburgh Handedness Questionnaire, Maximal Finger Tapping Frequency, Purdue Pegboard Test, Jepsen-Taylor Hand Function Test, Timed-Up-and-Go Test, Cologne Apraxia Screening, Trail Making Test. &lt;br&gt;&lt;br&gt;-For 5-11 year olds  EEG+MRI measurement are repeated after 18 months&lt;br&gt;Group 2: Tic study &lt;br&gt;&lt;br&gt;-EEG, IQ, MR examination, DIPS, motor function examinations as in arm 1. &lt;br&gt;-Tic symptomatology examination: Yale Global Tic Severity Scale, Premonitory Urges for Tics Scale, Rush Video-Based Tic-Rating Scale. &lt;br&gt;-TMS-EEG examination for 8-11 year olds &lt;br&gt;&lt;br&gt;-EEG+MRI measurement are repeated after 18 months.
    </Intervention>
    <Primary_outcome>EEG: The main outcome measure of study 1 (physiological maturation) is the reconstruction of the frontal sources of MRP or their development from age 5 to 16. Age-dependent differences in the brain areas involved provide information about the physiological maturation processes, as a result of which cortical motor control is formed.&lt;br&gt;Main outcome measure of study 2 (tic disorder) is the reconstruction of the sources of tics (tic generator) in the MRP in distinction to the physiological maturation of voluntary movements (intraindividual and in comparison to the healthy group).&lt;br&gt;&lt;br&gt;(f)MRI: Main target variables of studies 1 and 2 are differential activation and connectivity patterns in SMA, dorsal premotor cortex, basal ganglia and cerebellum (task 1) and insular, cingulate and parietal operculum.
    </Primary_outcome>
    <Secondary_outcome>EEG:&#x0D;&lt;br&gt;-Describing the maturation of cortico-cortical connectivity as the motor system matures (coherence analysis, directed connectivity).&#x0D;&lt;br&gt;-Description of MRP during voluntary tic inhibition (identification and maturation of networks for top-down control).&#x0D;&lt;br&gt;-Capture of modification of TEP during preparation of voluntary movements in subjects with tic disorders (do positive MRP represent inhibition or other form of pre-activation, processing of tic-like movements triggered by TMS).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;(f)MRI&#x0D;&lt;br&gt;Fronto-striatal, fronto-cerebellar functional connectivity (studies 1 and 2).
    </Secondary_outcome>
    <Source_Support>Deutsche Forschungsgemeinschaft
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>08/12/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>gs-ek@uni-koeln.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Medizinischen Fakultät der Universität zu Köln
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-221-478 82900
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>gs-ek@uni-koeln.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00025875#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13124926
    </Internal_Number>
    <TrialID>NCT04902521
    </TrialID>
    <Last_Refreshed_on>20 June 2023
    </Last_Refreshed_on>
    <Public_title>Use of Transcranial Magnetic Stimulation and Constraint Induced Movement Therapy in Pediatric Unilateral Cerebral Palsy
    </Public_title>
    <Scientific_title>Concurrent Use of Transcranial Magnetic Stimulation and Constraint Induced Movement Therapy in Children With Unilateral Cerebral Palsy: A Feasibility Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Manitoba
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210422
    </Date_registration3>
    <Date_registration>22/04/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04902521
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Months
    </Inclusion_agemin>
    <Inclusion_agemax>5 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 1, 2022
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Canada
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Florencia Ricci, MD, PhD;Florencia Ricci, MD, PhD
    </Contact_Lastname>
    <Contact_Email>fricci@hsc.mb.ca;fricci@hsc.ca
    </Contact_Email>
    <Contact_Tel>2042586549;
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosis of unilateral spastic CP&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  assessed as Gross Motor Function Classification System level I to III&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  assessed as Manual Ability Classification System level II to level IV&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  have received CIMT in the last 6 month&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  do not have neuroimaging studies to confirm clinical diagnosis of CP&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  severe impairments limiting their ability to participate&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cerebral Palsy
    </Condition>
    <Intervention>Device: Transcranial magnetic stimulation;Device: Sham Transcranial Magnetic stimulation
    </Intervention>
    <Primary_outcome>Evaluation of Participant recruitment;Evaluation of Participant retention during trial;Incidence of Treatment-Emergent Adverse Events as assessed by Parental Reports;Effectiveness of the transcrainial magnetic stimulation blinding process on patients and therapist;Evaluation of treatment intervention by parental guardians;Estimation of intervention costs
    </Primary_outcome>
    <Secondary_outcome>Assessment of mobility using Small Kids-AHA;Assessment of mobility using the Canadian Occupational Performance Measure (COPM)
    </Secondary_outcome>
    <Secondary_ID>HS24766(B2021:023)
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13627799
    </Internal_Number>
    <TrialID>NCT04795908
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Combined CBIT and rTMS to Improve Tourette's Syndrome
    </Public_title>
    <Scientific_title>STOP-TIC Study: Strengthening Tourette Treatment OPtions Using TMS to Improve CBIT
    </Scientific_title>
    <Acronym>STOP-TIC
    </Acronym>
    <Primary_sponsor>University of Florida
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210309
    </Date_registration3>
    <Date_registration>09/03/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04795908
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 17, 2021
    </Date_enrollement>
    <Target_size>3
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Aparna Wagle Shukla, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Florida
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any patient diagnosed with Tourette Syndrome &gt; 18 years of age with moderate tic&#x0D;&lt;br&gt;             severity.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants will be allowed to continue oral medications that they are taking for TS&#x0D;&lt;br&gt;             concurrently but will not be allowed to change their concurrent medication regimen&#x0D;&lt;br&gt;             throughout the duration of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of metallic objects or neurostimulators in the brain&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of active seizures or epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Contraindications to receiving fMRI, such as claustrophobia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to participate in CBIT due to other underlying cognitive or medical&#x0D;&lt;br&gt;             condition&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tourette Syndrome
    </Condition>
    <Intervention>Device: Transcranial Magnetic Stimulation;Behavioral: Comprehensive behavioral intervention
    </Intervention>
    <Primary_outcome>Tic Severity
    </Primary_outcome>
    <Secondary_outcome>Modified Rush Videotape Tic Rating Scale (mRVTRS);Beck Depression Inventory (BDI);Beck Anxiety Inventory (BAI);Yale-Brown Obsessive Compulsive Scale (Y-BOCS);Adult ADHD Self-Report Scale (ASRS);Gilles de la Tourette Syndrome - Quality of Life Scale (GTS-QOL);High Density Electroencephalography (EEG)
    </Secondary_outcome>
    <Secondary_ID>OCR40702;IRB202002701-A
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>12/01/2024
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT04795908
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>10793675
    </Internal_Number>
    <TrialID>NCT04804176
    </TrialID>
    <Last_Refreshed_on>29 March 2021
    </Last_Refreshed_on>
    <Public_title>Study on the Mode and Mechanism of Ultra-low Frequency rTMS for Sleep Disorders in Patients With Parkinson's Disease
    </Public_title>
    <Scientific_title>Study on the Mode and Mechanism of Ultra-low Frequency Repetitive Transcranial Magnetic Stimulation for Sleep Disorders in Patients With Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Qianfoshan Hospital
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210308
    </Date_registration3>
    <Date_registration>08/03/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04804176
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 20, 2019
    </Date_enrollement>
    <Target_size>99
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Xiuhua Li, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Qianfoshan Hospital,The First Affiliated Hospital of Shandong First Medical University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  in line with international Movement disorders association (the Movement Disorder&#x0D;&lt;br&gt;             Society, MDS) in 2015 the diagnosis of Parkinson's disease diagnosis standard and&#x0D;&lt;br&gt;             China standard (2016)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  can cooperate to complete rating scale, the sleep monitoring, imaging and blood test&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  have a sleep disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  aged 18 to 70 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  agree to participate in this experiment, and have signed the informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  superposition of diagnosed with Parkinson's syndrome&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  secondary diagnosed Parkinson's syndrome&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  is equipped with heart pacemakers and other metal implants&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  cannot achieve scale assessment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  has significant malignant diseases&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  has a history of seizures&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Repetitive Transcranial Magnetic Stimulation;Parkinson Disease;Sleep Disorder
    </Condition>
    <Intervention>Device: Ultra-low frequency repetitive transcranial magnetic stimulation
    </Intervention>
    <Primary_outcome>change from length of sleep at one week;change from ratio of stage 3 sleep in total sleep at one week;change from limb movement of sleep at one week;change from nocturnal arousal frequency at one week;change from Pittsburgh sleep quality index scale at one week;Interleukin 6;change from the Epworth sleepiness scale at one week;change from Parkinson's disease sleep scale at one week;change from movement disorders association - comprehensive rating scale of Parkinson's disease at one week;change from Parkinson's disease quality of life scale one week;change from Hamilton depression scale at one week;change from Hamilton anxiety scale at one week;change from simple mental state scale at one week;change from Montreal cognitive assessment scale at one week;change from magnetic resonance imaging of the brain at one month
    </Primary_outcome>
    <Secondary_ID>ULFRTMS-S
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>10897852
    </Internal_Number>
    <TrialID>ChiCTR2100042452
    </TrialID>
    <Last_Refreshed_on>26 April 2021
    </Last_Refreshed_on>
    <Public_title>Improvement of central cortical functional re-organization and compensation after ectopic neurorrhaphy for peripheral nerve injury using repetitive transcranial magnetic stimulation combined with biofeedback peripheral electrical stimulation
    </Public_title>
    <Scientific_title>Improvement of central cortical functional re-organization and compensation after ectopic neurorrhaphy for peripheral nerve injury using repetitive transcranial magnetic stimulation combined with biofeedback peripheral electrical stimulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
    </Scientific_title>
    <Primary_sponsor>Beijing Neurosurgical Institute
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210121
    </Date_registration3>
    <Date_registration>2021-01-21
    </Date_registration>
    <Source_Register>ChiCTR
    </Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=65511
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18
    </Inclusion_agemin>
    <Inclusion_agemax>65
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2021-03-01
    </Date_enrollement>
    <Target_size>1:50;2:50;3:50;
    </Target_size>
    <Study_type>Interventional study
    </Study_type>
    <Study_design>Parallel
    </Study_design>
    <Phase>0
    </Phase>
    <Countries>china
    </Countries>
    <Contact_Firstname>Liu Song
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>119 South Fourth Ring Road West, Fengtai District, Beijing 
    </Contact_Address>
    <Contact_Email>dr_songliu2018@163.com
    </Contact_Email>
    <Contact_Tel>+86 10-59975050
    </Contact_Tel>
    <Contact_Affiliation>Beijing Neurosurgical Institute
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged 18-65 years;&#x0D;&lt;br&gt;2. have facial nerve palsy symptoms between 0-24 months, the palsy could be triggered by all kinds of reason;&#x0D;&lt;br&gt;3. both sides of the Hypoglossal nerve can function normally;&#x0D;&lt;br&gt;4. right-handed;&#x0D;&lt;br&gt;5. no abnormal mental, cognitive, and language function, and qualified for fMRI and stimulations;&#x0D;&lt;br&gt;6. willing to undergo regular follow-up and related evaluation;&#x0D;&lt;br&gt;7. the consent form has been detailly informed and signed.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. The general condition can't experience operation;&#x0D;&lt;br&gt;2. not qualified to accept the magnetic or electrical stimulation based on the existing medical condition;&#x0D;&lt;br&gt;3. not qualified to accept the electrophysiology or fMRI test based on the existing mental and physical condition;&#x0D;&lt;br&gt;4. impairment cognitive or language function.
    </Exclusion_Criteria>
    <Condition>facial nerve palsy
    </Condition>
    <Intervention>1:Repetitive transcranial magnetic stimulation;2:peripheral electrical nerve stimulation;3:Repetitive transcranial magnetic stimulation and peripheral electrical nerve stimulation;
    </Intervention>
    <Primary_outcome>facial movement evaluation;Electrophysiology;Functional magnetic resonance imaging;
    </Primary_outcome>
    <Source_Support>self-financing
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>14/09/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Xiao Shuping
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>10519536
    </Internal_Number>
    <TrialID>NCT04707378
    </TrialID>
    <Last_Refreshed_on>25 January 2021
    </Last_Refreshed_on>
    <Public_title>Navigated Repetitive Transcranial Magnetic Stimulation for Parkinson's Disease With Depression or Cognitive Impairment
    </Public_title>
    <Scientific_title>Navigated Repetitive Transcranial Magnetic Stimulation for Parkinson's Disease With Depression or Cognitive Impairment
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Guangdong Provincial People's Hospital
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210111
    </Date_registration3>
    <Date_registration>11/01/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04707378
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 30, 2020
    </Date_enrollement>
    <Target_size>42
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Lijuan Wang, Ph.D;Lijuan Wang, Ph.D;Lijuan Wang, Ph.D, MD
    </Contact_Lastname>
    <Contact_Email>;wljgd68@163.com;wljgd68@163.com
    </Contact_Email>
    <Contact_Tel>;+86 020 83827812-10402;+86 020 83827812-10402
    </Contact_Tel>
    <Contact_Affiliation>Guangdong Provincial People's Hospital;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  1. Patients between 18 and 85 years of age with idiopathic PD (diagnosed as "confirmed&#x0D;&lt;br&gt;             PD" or "likely PD" according to the 2015 MDS Parkinson's diagnostic criteria),&#x0D;&lt;br&gt;             regardless of gender.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             2. Meet the DSM-IV diagnostic criteria for depressive episodes. 3. If there is a&#x0D;&lt;br&gt;             combination of anti-Parkinsonian medications, the anti-Parkinsonian medication regimen&#x0D;&lt;br&gt;             and dose must remain stable for = 28 days and be maintained at that dose for the&#x0D;&lt;br&gt;             duration of treatment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             4. Not taking any antidepressant medication for the last 2 months. 5. the&#x0D;&lt;br&gt;             subject/their legal representative is able to comply with the study protocol and visit&#x0D;&lt;br&gt;             schedule.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             6. The patient or his/her legal guardian agrees to participate in this trial and signs&#x0D;&lt;br&gt;             an informed consent form.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  1. Secondary Parkinson's syndrome caused by vascular factors, toxins, drugs, etc., or&#x0D;&lt;br&gt;             Parkinson's superimposed syndrome.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;             2. PD patients with persistent head tremor. 3. Dementia. 4. Patients with suicidal&#x0D;&lt;br&gt;             tendencies and psychotic symptoms. 5. Patients with consciousness disorders, history&#x0D;&lt;br&gt;             of stroke, severe neurological/psychiatric disorders such as transient ischemic attack&#x0D;&lt;br&gt;             and other severe organic diseases within 1 year prior to screening (Visit 1) 6. Have&#x0D;&lt;br&gt;             contraindications to rTMS(e.g., implantation of cochlear implants, deep brain&#x0D;&lt;br&gt;             stimulation, pacemakers, medical pumps, and other metal-containing devices near&#x0D;&lt;br&gt;             stimulation coils; history of epilepsy; history of traumatic brain injury, brain&#x0D;&lt;br&gt;             tumor, encephalitis, cerebrovascular disease, cerebral metabolic disease; sleep&#x0D;&lt;br&gt;             deprivation, unrecovered jet lag, intoxication, overexertion; pregnancy; severe or&#x0D;&lt;br&gt;             recent heart disease, etc.) 7. Have contraindications to MRI scanning (including metal&#x0D;&lt;br&gt;             implants, retractors, braces, or claustrophobia).&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Depression;Cognitive Impairment
    </Condition>
    <Intervention>Device: repetitive transcranial magnetic stimulation(rTMS)
    </Intervention>
    <Primary_outcome>Hamilton Depression Scale(HAMD);Beck Depression Inventory(BDI)
    </Primary_outcome>
    <Secondary_outcome>Logical memory test(LMT);Delayed memory test(DMT);Digit span test(DST);Ten point clock test;Uniform Parkinson's Disease Rating Scale ?(UPDRS?);Modified Hoehn &amp; Yahr scale(H-Y);Activity of Daily Living Scale(ADL);Parkinson's Disease Questionnaire(PDQ-39);Pittsburgh Sleep Quality Index (PSQI);Epworth Sleepiness Scale (ESS);Parkinson's Disease Sleep Scale (PDSS-2);Hamilton Anxiety Scale(HAMA);Beck Anxiety Inventory(BAI);Mini-mental State Examination(MMSE);Montreal Cognitive Assessment Scale(MoCA);Named test of the Aphasia Battery of Chinese;Similarity test;Symbol Digit modalities test(SDMT);Verbal fluency test(VFT)
    </Secondary_outcome>
    <Secondary_ID>GDREC2020181H(R1)
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13347250
    </Internal_Number>
    <TrialID>NCT04699149
    </TrialID>
    <Last_Refreshed_on>18 September 2023
    </Last_Refreshed_on>
    <Public_title>Combining rTMS and Video Game-based Dexterity Training to Improve Dexterity in Parkinson's Disease
    </Public_title>
    <Scientific_title>Combining rTMS and Video Game-based Dexterity Training to Improve Dexterity in Parkinson's Disease: a Randomized Controlled Pilot-study
    </Scientific_title>
    <Acronym>rTMSVR
    </Acronym>
    <Primary_sponsor>Luzerner Kantonsspital
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210106
    </Date_registration3>
    <Date_registration>06/01/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04699149
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 11, 2020
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Switzerland
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Tim Vanbellingen
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Luzerner Kantonsspital
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Confirmed PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Hoehn &amp; Yahr I to IV&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Age 50-80 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. written and signed informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. dexterous difficulties-&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Significant medical, psychiatric co-morbidity including dementia as defined by&#x0D;&lt;br&gt;             Montreal Cognitive Assessment (MOCA &lt; 21)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Inability to understand the scope of the study and to follow study procedures&#x0D;&lt;br&gt;             according to the protocol e.g. complete questionnaires (i.e. due to cognitive&#x0D;&lt;br&gt;             problems)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Exclusion criteria for TMS and Sham application, such as current pregnancy, personal&#x0D;&lt;br&gt;             history of epilepsy or epileptic fits, and any psychiatric, neurologic, or medical&#x0D;&lt;br&gt;             history.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Participation in another interventional trial.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: Transcranial magnetic stimulation;Other: Sham transcranial magnetic stimulation
    </Intervention>
    <Primary_outcome>DextQ-24
    </Primary_outcome>
    <Secondary_outcome>Nine Hole Peg test (9-HPT);Coin rotation task (CRT)
    </Secondary_outcome>
    <Secondary_ID>EKNZ 2019-00433
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>10600414
    </Internal_Number>
    <TrialID>ChiCTR2000039495
    </TrialID>
    <Last_Refreshed_on>1 February 2021
    </Last_Refreshed_on>
    <Public_title>Effect of high frequency repetitive transcranial magnetic stimulation combined with wrist ankle acupuncture on spastic state and motor function in children with spastic cerebral palsy
    </Public_title>
    <Scientific_title>Effect of high frequency repetitive transcranial magnetic stimulation combined with wrist ankle acupuncture on spastic state and motor function in children with spastic cerebral palsy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>Shanghai University of traditional Chinese Medicine
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20201030
    </Date_registration3>
    <Date_registration>2020-10-30
    </Date_registration>
    <Source_Register>ChiCTR
    </Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=62707
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>3
    </Inclusion_agemin>
    <Inclusion_agemax>7
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2020-08-01
    </Date_enrollement>
    <Target_size>Experimental group:14;control group:14;
    </Target_size>
    <Study_type>Interventional study
    </Study_type>
    <Study_design>Parallel
    </Study_design>
    <Phase>0
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>Li Jiamin
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>14 Building 11th, Lane 280, Huatuo Road, Pudong New Area, Shanghai, China
    </Contact_Address>
    <Contact_Email>851055428@qq.com
    </Contact_Email>
    <Contact_Tel>+86 13917245215
    </Contact_Tel>
    <Contact_Affiliation>Shanghai University of traditional Chinese Medicine
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Children with spastic cerebral palsy who met the diagnostic criteria of cerebral palsy, mainly manifested as hyperactivity of stretch reflex; &#x0D;&lt;br&gt;2. Aged from 3 to 7 years old, with GMFCS grade I-II; &#x0D;&lt;br&gt;3. Without coagulation dysfunction; &#x0D;&lt;br&gt;4. With the consent of the child's guardian and voluntary signing of informed consent.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. The patients who could not induce bilateral cortical motor evoked potential by single pulse transcranial magnetic stimulation and neurological function diagnostic instrument;&#x0D;&lt;br&gt;2. MRI showed intracranial space occupying lesions and hydrocephalus in children;&#x0D;&lt;br&gt;3. Children with heart, liver and kidney insufficiency, history of epilepsy, severe cognitive impairment or other serious diseases;&#x0D;&lt;br&gt;4. Children with involuntary movement or mixed cerebral palsy;&#x0D;&lt;br&gt;5. Patients with cardiac pacemaker, cochlear implant, intracranial vascular stent, metal internal fixation and other implants;&#x0D;&lt;br&gt;6. In recent one month, the patient took or injected anti spasmodic and other related drugs.
    </Exclusion_Criteria>
    <Condition>cerebral palsy
    </Condition>
    <Intervention>Experimental group:High frequency repetitive transcranial magnetic stimulation and wrist ankle acupuncture;control group:High frequency repetitive transcranial magnetic stimulation;
    </Intervention>
    <Primary_outcome>Gross Motor Function Measure-66;the Peabody Developmental Motor  Scales-Second Edition;Modified Tardieu Scale;
    </Primary_outcome>
    <Secondary_outcome>Latency and amplitude of motor evoked potential;motor threshold;central motor conduction time;central motor conduction tim;
    </Secondary_outcome>
    <Source_Support>Shanghai Yangzhi Rehabilitation Hospital
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>10/07/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Feng Ye
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13378232
    </Internal_Number>
    <TrialID>NCT04578912
    </TrialID>
    <Last_Refreshed_on>3 October 2023
    </Last_Refreshed_on>
    <Public_title>Transcranial Magnetic Stimulation to Augment Behavior Therapy for Tics
    </Public_title>
    <Scientific_title>Transcranial Magnetic Stimulation to Augment Behavior Therapy for Tics
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Minnesota
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200930
    </Date_registration3>
    <Date_registration>30/09/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04578912
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>12 Years
    </Inclusion_agemin>
    <Inclusion_agemax>21 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 1, 2020
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Christine Conelea, PhD;Claire Breitenfeldt;Christine Conelea, PhD
    </Contact_Lastname>
    <Contact_Email>;breit241@umn.edu;
    </Contact_Email>
    <Contact_Tel>;;
    </Contact_Tel>
    <Contact_Affiliation>University of Minnesota;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current chronic motor and/or vocal tics, defined as tics for at least 1 year without a&#x0D;&lt;br&gt;             tic-free period of more than 3 consecutive months. Tics must not be due to a medical&#x0D;&lt;br&gt;             condition or the direct physiological effects of a substance.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  At least moderate tic severity, defined as a Yale Global Tic Severity Scale total&#x0D;&lt;br&gt;             score =14 (=9 for those with motor or vocal tics only).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Full scale IQ greater than or equal to 70&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  English fluency to ensure comprehension of study measures and instructions.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Right-handed&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Medical conditions contraindicated or associated with altered TMS risk profile,&#x0D;&lt;br&gt;             including history of intracranial pathology, epilepsy or seizure disorders, traumatic&#x0D;&lt;br&gt;             brain injury, brain tumor, stroke, implanted medical devices or metallic objects in&#x0D;&lt;br&gt;             the head, current pregnancy or participants of childbearing age not using effective&#x0D;&lt;br&gt;             contraception, or any other medical condition deemed serious or contraindicated by a&#x0D;&lt;br&gt;             study physician&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to undergo MRI.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Left handedness.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active suicidality.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous diagnosis of psychosis or cognitive disability.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Substance abuse or dependence within the past year.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Concurrent psychotherapy focused on tics.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neuroleptic/antipsychotic medications.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Taking a medication that has not reached stability criterion (same medication and dose&#x0D;&lt;br&gt;             for 6 weeks with no planned changes over the intervention period)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tic Disorders;Tics;Tic, Motor;Tic Disorder, Childhood;Tourette Syndrome;Tourette Syndrome in Children;Tourette Syndrome in Adolescence
    </Condition>
    <Intervention>Behavioral: Comprehensive Behavioral Intervention for Tics (CBIT);Device: Repetitive Transcranial Magnetic Stimulation (rTMS);Device: Continuous Theta Burst Stimulation (cTBS)
    </Intervention>
    <Primary_outcome>Change in resting state fMRI connectivity of SMA-mediated brain circuits;Change in SMA activation
    </Primary_outcome>
    <Secondary_outcome>Safety: Measured as Rate of Adverse Events Related to Study Treatment;Change in Tic Suppression Task;Feasibility: Measured as Participant Treatment Completion
    </Secondary_outcome>
    <Secondary_ID>PSYCH-2020-29064
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13644324
    </Internal_Number>
    <TrialID>DRKS00022356
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Transcranial Magnetic Stimulation in Parkinson's disease
    </Public_title>
    <Scientific_title>Transcranial Magnetic Stimulation in Parkinson's disease - TMS Parkinson's                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
    </Scientific_title>
    <Primary_sponsor>UKB
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200716
    </Date_registration3>
    <Date_registration>16/07/2020
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00022356
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>15/01/2021
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Randomized controlled study; Masking: Blinded (masking used); Control: placebo; Assignment: parallel; Study design purpose: treatment 
    </Study_design>
    <Phase>4
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Oliver
    </Contact_Firstname>
    <Contact_Lastname>Kaut
    </Contact_Lastname>
    <Contact_Address>Venusberg Campus
    </Contact_Address>
    <Contact_Email>oliver.kaut@ukbonn.de
    </Contact_Email>
    <Contact_Tel>022828714431
    </Contact_Tel>
    <Contact_Affiliation>UKB
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Parkinson's disease
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: atypical Parkinson
    </Exclusion_Criteria>
    <Condition>PARKINSON &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: TMS real treatment&lt;br&gt;Group 2: TMS sham treatment
    </Intervention>
    <Primary_outcome>WHAT improvement of posturale stability&lt;br&gt;WHEN last day of Treatment&lt;br&gt;HOW PosturoMed
    </Primary_outcome>
    <Secondary_outcome>improvement of UPDRS III
    </Secondary_outcome>
    <Source_Support>UKB
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>08/07/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ethik@ukbonn.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethik-Kommission Medizinische Fakultät Bonn
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+49-228-28751282
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ethik@ukbonn.de
    </Ethics_review_contact_email>
    <results_url_link>http://drks.de/search/en/trial/DRKS00022356#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13035081
    </Internal_Number>
    <TrialID>NCT04468932
    </TrialID>
    <Last_Refreshed_on>8 May 2023
    </Last_Refreshed_on>
    <Public_title>Transcranial Magnetic Stimulation in Progressive Supranuclear Palsy
    </Public_title>
    <Scientific_title>Cerebellar Transcranial Magnetic Stimulation for Motor Control in Progressive Supranuclear Palsy
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Oregon Health and Science University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200707
    </Date_registration3>
    <Date_registration>07/07/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04468932
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 17, 2020
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Marian L Dale, MD, MCR;Graham Harker;Graham Harker
    </Contact_Lastname>
    <Contact_Email>;balance@ohsu.edu;balance@ohsu.edu
    </Contact_Email>
    <Contact_Tel>;5034182601;503-418-2601
    </Contact_Tel>
    <Contact_Affiliation>Oregon Health and Science University;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  probable or possible PSP by the revised MDS PSP Criteria (Hoglinger 2017)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  age 40-85 at time of screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ability to understand and cooperate with simple instructions in English&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ability to read at 6th grade reading level in English&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ability to stand unassisted for at least 30 seconds and to be able walk independently&#x0D;&lt;br&gt;             with a walker&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ability to refrain from new physical and speech therapy programs for the duration of&#x0D;&lt;br&gt;             the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ability to remain on stable doses of any cholinergic, dopaminergic, serotonergic&#x0D;&lt;br&gt;             sedative or NMDA receptor antagonists for the duration of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  females of child-bearing age must perform a urine pregnancy test and be on reliable&#x0D;&lt;br&gt;             birth control during the course of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  other significant neurological or vestibular disorders&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  presence of electrically, magnetically or mechanically activated implants or history&#x0D;&lt;br&gt;             of injurious metal exposure in eyes, head, or body&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Palsy Supranuclear;Supranuclear Palsy, Progressive
    </Condition>
    <Intervention>Device: Repetitive transcranial magnetic stimulation (rTMS)
    </Intervention>
    <Primary_outcome>objective posturography
    </Primary_outcome>
    <Secondary_outcome>fNIRS;speech analysis
    </Secondary_outcome>
    <Secondary_ID>KL2TR002370;P2CHD086844;STUDY0020341
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Center of Neuromodulation for Rehabilitation;Collins Medical Trust;National Institutes of Health (NIH);Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);Department of Health and Human Services
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>10353231
    </Internal_Number>
    <TrialID>NCT04238000
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Cerebellar rTMS Theta Burst for Dual-task Walking in Parkinson's Disease
    </Public_title>
    <Scientific_title>Cerebellar rTMS Theta Burst for Dual-task Walking in Parkinson's Disease:a Double Blind Cross-over Sham-controlled Study Using Wearing Sensors Technology
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Fondazione Europea di Ricerca Biomedica Ferb Onlus
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200118
    </Date_registration3>
    <Date_registration>18/01/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04238000
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2018
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Italy
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Andrea Pilotto, MD;Andrea Pilotto, MD;Andrea Pilotto, MD
    </Contact_Lastname>
    <Contact_Email>;pilottoandreae@gmail.com;pilottoandreae@gmail.com
    </Contact_Email>
    <Contact_Tel>;00393396245281;3396245281
    </Contact_Tel>
    <Contact_Affiliation>FERB Onlus;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  established Parkinson's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ability to stand alone and walk without support&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  dementia or behavioral alterations&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  contraindication to stimulation&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson;Parkinson Disease;Gait Disorders, Neurologic;Parkinsonism;Gait, Festinating
    </Condition>
    <Intervention>Device: repetitive transcranial magnetic stimulation
    </Intervention>
    <Primary_outcome>Step variability in dual-task walking;Step length in dual-task walking;Gait speed in dual-task walking
    </Primary_outcome>
    <Secondary_outcome>Turning speed in timed up and go tests;total distance of dual-task walking
    </Secondary_outcome>
    <Secondary_ID>19/03
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Kiel;Università degli Studi di Brescia
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>10352017
    </Internal_Number>
    <TrialID>NCT04222218
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Cerebellar rTMS Theta Burst for Postural Instability in Progressive Supranuclear Palsy
    </Public_title>
    <Scientific_title>Cerebellar rTMS Theta Burst for Postural Instability in Progressive Supranuclear Palsy: a Double Blind Cross-over Sham-controlled Study Using Wearing Sensors Technology
    </Scientific_title>
    <Acronym>CerTI-PSP
    </Acronym>
    <Primary_sponsor>Fondazione Europea di Ricerca Biomedica Ferb Onlus
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20191231
    </Date_registration3>
    <Date_registration>31/12/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04222218
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 1, 2017
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Italy
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Andrea Pilotto, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Università degli Studi di Brescia
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  probable PSP diagnosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ability to stand alone without support for at least 5 seconds&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ability to walk without aid for at least three meters&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  dementia or behavioral alterations&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  contraindications of stimulation&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Progressive Supranuclear Palsy;Fall;Gait, Rigid;Parkinsonism
    </Condition>
    <Intervention>Device: repetitive transcranial magnetic stimulation
    </Intervention>
    <Primary_outcome>Short Physical Performance Battery, total time (SPPB);Timed up and Go tests, total time (TUG);Static Balance tests, total time;Tinetti Balance test (TBT);Static Balance- area of sway
    </Primary_outcome>
    <Secondary_outcome>PSP rating scale (PSP-RS);Static Balance: wearable sensor analyses - velocity;Static Balance: wearable sensor analyses - acceleration;Static Balance: wearable sensor analyses - jerk
    </Secondary_outcome>
    <Secondary_ID>191201
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Brescia, Neurology Department;University of Kiel, Neurogeriatric Department
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13089401
    </Internal_Number>
    <TrialID>RBR-3rvfwt
    </TrialID>
    <Last_Refreshed_on>29 May 2023
    </Last_Refreshed_on>
    <Public_title>Effect of combination therapy with Noninvasive Brain Stimulation and Gamotherapy in patients with Parkinson's Disease
    </Public_title>
    <Scientific_title>Effect analysis of combined therapy with repetitive Transcranial Magnetic Stimulation (rTMS) and gametherapy on motor and cognitive functional capacity of individuals with PD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Universidade Federal da Paraíba-
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20191226
    </Date_registration3>
    <Date_registration>26/12/2019
    </Date_registration>
    <Source_Register>REBEC
    </Source_Register>
    <web_address>http://ensaiosclinicos.gov.br/rg/RBR-3rvfwt
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>35Y
    </Inclusion_agemin>
    <Inclusion_agemax>80Y
    </Inclusion_agemax>
    <Inclusion_gender>-
    </Inclusion_gender>
    <Date_enrollement>01/08/2018
    </Date_enrollement>
    <Target_size/>
    <Study_type>Intervention
    </Study_type>
    <Study_design>Treatment clinical trial, randomized, controlled, double blind, parallel, 4 intervention arms.
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname>Maíra 
    </Contact_Firstname>
    <Contact_Lastname>Lopes
    </Contact_Lastname>
    <Contact_Address>Cidade Universitária
    </Contact_Address>
    <Contact_Email>mairalopesc@gmail.com
    </Contact_Email>
    <Contact_Tel>+55(83)987621343
    </Contact_Tel>
    <Contact_Affiliation>Universidade Federal da Paraiba
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: The study included individuals with clinical diagnosis of PD, of both sexes, with clinical diagnosis of PD, with staging of PD between 1 and 3 on the Hoehn and Modified Yahr scale, who are assisted by SUS, and who agree to participate in the study.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Excluded from this study were: Individuals with PD associated with another chronic neurodegenerative disease; diagnosed with parkinsonian syndrome; individuals with a history of epilepsy; carriers of another disabling condition; and to participate in other physical therapy interventions; have previous experience with Kinect; individuals with functional deficit that makes it impossible to perform the practice proposed by Kinect.
    </Exclusion_Criteria>
    <Condition>Parkinson Disease; Pathological conditions; signs and symptoms; Cognition; Motor Activity.;F02.463.188;F01.145.632
    </Condition>
    <Intervention>Allocation, randomization, evaluation and intervention procedures were performed by independent researchers who did not have access to each other's work.&lt;br&gt;Initially, 26 patients were recruited, 20 of which met the inclusion criteria of the study. Participants were randomly allocated to 1 of 4 groups at a 1: 1 ratio. A random number generator was used through an online randomization program (www.random.org). Blinding was also extended to participants who were unaware of the allocation group.&lt;br&gt;During the intervention period each group performed a total of 6 sessions over three consecutive days in two weeks, the group that underwent neurostimulation followed by gamma therapy and the session lasted one hour. The groups were divided as follows: group 1 received the active Transcranial Repetitive Magnetic Stimulation (rTMS) then underwent gameterapy ((n = 6), group 2 received the placebo rTMS followed by gameterapy (n = 6), the group 3 received active rTMS (n = 4) and group 4 received placebo rTMS only (n = 4).&lt;br&gt;&lt;br&gt;Active Repetitive Transcranine Magnetic Stimulation (rTMS)&lt;br&gt;The rTMS was performed using Neurosoft MS and MSD (Russia) equipment and the Miotec MIOTOOL 400 Electromyograph (EMG) with MiotecSuite 1.0 software, research version. The individuals were submitted to the following assembly: through the cortical mapping performed by the international system 10/20 (Jasper, 1958) which has as reference the head circumference and the ear lobes (biauricular) to identify M1 (C3) and SMA ( F3), the SMA was located sagittal 15% ahead of the Cz point of the cortical mapping. The coil used in the equipment was the format in eight. Then, the motor threshold (LM) was identified, which corresponds to the lowest stimulus intensity capable of generating a Motor Evoked Potentia;Other;E02.621.820
    </Intervention>
    <Primary_outcome>An increase in motor functional capacity is expected through the Unified Parkinson's Disease Rating Scale - UPDRS, from the finding of a variation with a significant difference (p &lt;0.05) in pre and post intervention measurements.&lt;br&gt;It is expected an increase in cognitive capacity verified through the Scales for Outcomes of Parkinson's Disease - Cognition - SCOPA-Cog, from the finding of a variation with a significant difference (p &lt;0.05) in the pre and post intervention measurements.;Through UPDRS, the motor functional capacity was evaluated. In the item falls of the evaluation instrument the results showed a significant improvement, with a value of&lt;br&gt;p = 0.0038. An intergroup analysis was developed to identify in which groups&lt;br&gt;there was improvement and it was identified that the Active Stimulation Group (GEA) and the Active Stimulation Group (p = 0.033) and median of 1 (0.25-1) and 0 (0-0) in the reevaluation, a result similar to that found in the Comparison between GEA and Gamete Therapy Simulated Stimulation Group reiterating the positive effect of active stimulation and gamotherapy for falls in individuals with PD&lt;br&gt;-Regarding gait, the results presented were assertive for the combination therapy with active rTMS when compared to the simulated stimulation group. We observed a value of p = 0.0069 for gait, when comparing the GEAG and Simulated Stimulation Group (GES), we also observed the following values of p = 0.0023, median of 0 (0-1) for the GEAG and median 1 (1-2) for GES.&lt;br&gt;-In the rapid and alternate movement of the hands, the individuals presented significant difference before and after the intervention with the value of p = 0.012 and for the comparison between the group. The GEAG and GES presented p = 0.019 with a median of 0 (0-1) for GEAG and a median of 2 (1-2) for GES;The cognitive capacity of the study subjects was performed using the SCOPA Scale.&lt;br&gt;-For the attention domain of the scalara the results presented a significance level with the value of p = 0.014 and in the comparison between groups the value of p = 0.095 for the GEAG and GES with median values 4 (3-4) and 1 (2 -3) respectively, showing improvements to attention.&lt;br&gt;-There was a significant improvement in the executive functions of the sample, with a value of p = 0.018 and in the comparison between the groups GEAG and the GES the individuals presented a value of p = 0.023 with a median of 8 (7-9) for the GEAG. and 5 (5-7) for GES.&lt;br&gt;-Visuospatial function showed a significant difference when comparing the GEAG and GES with p = 0.023 and median of 4 (4-5) for GEAG and GES of 2 (1-4)
    </Primary_outcome>
    <Secondary_outcome>No Secondary Outcomes Expected
    </Secondary_outcome>
    <Source_Support>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
    </Source_Support>
    <Secondary_Sponsor>Universidade Estadual da Paraíba
    </Secondary_Sponsor>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>10350588
    </Internal_Number>
    <TrialID>NCT04203615
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Effect of Noninvasive Brain Stimulation on Hypokinetic Dysarthria in Parkinson's Disease
    </Public_title>
    <Scientific_title>Effect of Noninvasive Brain Stimulation on Hypokinetic Dysarthria and Brain Plasticity in Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Masaryk University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20191209
    </Date_registration3>
    <Date_registration>09/12/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04203615
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>50 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 1, 2019
    </Date_enrollement>
    <Target_size>39
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Czechia
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients with clinically established PD (Postuma et al. 2016)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  psychiatric disorders, including major depression, hallucinations&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  any MRI-incompatible metal in the body&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  lack of cooperation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  presence of dementia&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Transcranial magnetic stimulation- sham rTMS;Device: Transcranial magnetic stimulation- real rTMS
    </Intervention>
    <Primary_outcome>Changes in score of the 3F Test (the unabbreviated title- "the 3F Test Dysarthric Profile")
    </Primary_outcome>
    <Secondary_outcome>Resting state
    </Secondary_outcome>
    <Secondary_ID>NV16-30805A
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>10348731
    </Internal_Number>
    <TrialID>NCT04179435
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Cognitive and Brain Development in Adolescents With Gilles de la Tourette Syndrome
    </Public_title>
    <Scientific_title>Développement Cognitif et cérébral Chez Les Adolescents Souffrants d'un Syndrome de Gilles de la Tourette
    </Scientific_title>
    <Acronym>CADETS
    </Acronym>
    <Primary_sponsor>Institut National de la Santé Et de la Recherche Médicale, France
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191120
    </Date_registration3>
    <Date_registration>20/11/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04179435
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>13 Years
    </Inclusion_agemin>
    <Inclusion_agemax>18 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 2019
    </Date_enrollement>
    <Target_size>132
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Worbe Yulia, MD, PhD;Worbe Yulia, MD, PhD
    </Contact_Lastname>
    <Contact_Email>;Yulia.worbe@aphp.fr
    </Contact_Email>
    <Contact_Tel>;+ 33 1 57 43 55
    </Contact_Tel>
    <Contact_Affiliation>Institut National de la Santé Et de la Recherche Médicale, France;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Tourette syndrome&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ages 13 - 18&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Acceptance to perform the Brain MRI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Acceptance to perform the cognitive testing&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Acceptance to perform the TMS measures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Learning disability&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Incompatibility with MRI procedure (metal body implants, pregnancy)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tourette Syndrome in Adolescence
    </Condition>
    <Intervention>Behavioral: Behavioral testing on cognitive computerized tasks;Other: brain MRI;Other: TMS
    </Intervention>
    <Primary_outcome>Behavioral test main outcome measures [1];Behavioral test main outcome measures [2];Behavioral test main outcome measures [3];Behavioral test main outcome measures [4];Brain MRI scan measures;Transcranial magnetic stimulation
    </Primary_outcome>
    <Secondary_ID>2019-A00992-55;C19-11
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>10343876
    </Internal_Number>
    <TrialID>NCT04116216
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>rTMS on Motor Function of Parkinson's Disease Patients With Different Phenotypes
    </Public_title>
    <Scientific_title>Effects of rTMS Associated to Physical Therapy on Motor Function of Parkinson's Disease Patients With Different Phenotypes
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Universidade Federal de Pernambuco
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190923
    </Date_registration3>
    <Date_registration>23/09/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04116216
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 15, 2019
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Kátia M Silva, PhD;Kátia M Silva, PhD;Kátia M Silva
    </Contact_Lastname>
    <Contact_Email>;monte.silvakk@gmail.com;monte.silvakk@gmail.com
    </Contact_Email>
    <Contact_Tel>;8121268939;8121268939
    </Contact_Tel>
    <Contact_Affiliation>Universidade Federal de Pernambuco;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinical diagnosis of PD provided by neurologist;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Aged 40 or over, of both gender;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Regular antiparkinsonian pharmacological treatment;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  With staging from I to IV on the modified Hoehn &amp; Yahr scale.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Prior neurological diseases&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Metal implant in the skull and face&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pacemaker&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of seizures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other disorders that affect the performance of the tests and proposed intervention&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other osteomioarticular diseases in the lower limbs that interfere with performance&#x0D;&lt;br&gt;             and locomotion&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Submitted to previous surgical intervention for PD&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Combination Product: High frequency repetitive transcranial magnetic stimulation;Combination Product: Low frequency repetitive transcranial magnetic stimulation;Combination Product: Sham repetitive transcranial magnetic stimulation
    </Intervention>
    <Primary_outcome>Change in Unified Parkinson's disease Rating Scale - Session III
    </Primary_outcome>
    <Secondary_outcome>Changes on cortical excitability level;Changes on quality of life;Changes on Patient Global Impression of Change Scale
    </Secondary_outcome>
    <Secondary_ID>TMS_PD_phenotype
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>11237763
    </Internal_Number>
    <TrialID>NCT04101994
    </TrialID>
    <Last_Refreshed_on>10 August 2021
    </Last_Refreshed_on>
    <Public_title>Augmented Effects of Virtual-reality Cycling Training on Upper Limb Motor Functions by NIBS in Patients With CP
    </Public_title>
    <Scientific_title>Augmented Effects of Virtual-reality Cycling Training on Upper Limb Motor Functions by Noninvasive Brain Stimulation in Patients With Cerebral Palsy
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Chang Gung Memorial Hospital
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190922
    </Date_registration3>
    <Date_registration>22/09/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04101994
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>5 Years
    </Inclusion_agemin>
    <Inclusion_agemax>20 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 26, 2018
    </Date_enrollement>
    <Target_size>80
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Taiwan
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Chia-Ling Chen, MD, PhD;Chia-Ling Chen, MD, PhD;Chia-Ling Chen, MD, PhD
    </Contact_Lastname>
    <Contact_Email>;clingchen@gmail.com;clingchen@gmail.com
    </Contact_Email>
    <Contact_Tel>;+886-3-3281200;+886-3-3281200
    </Contact_Tel>
    <Contact_Affiliation>Chang Gung Memorial Hospital;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of CP according to clinical criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 5-20 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No use of botulinum toxin in the past 4 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No significant perceptual or communication disturbances&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No other peripheral or central nervous system dysfunction&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No active inflammatory or pathologic changes in upper limb joints during the previous&#x0D;&lt;br&gt;             6 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No active medical problems, such as pneumonia, upper gastrointestinal bleeding, or&#x0D;&lt;br&gt;             urinary tract infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No active problems of epilepsy and EEG without epileptiform discharge&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Metabolic disorders, such as inborn error of metabolism, electrolyte, and endocrine&#x0D;&lt;br&gt;             disorders&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active infectious disease, such as meningitis and encephalitis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with active medical problems, such as pneumonia, upper gastrointestinal&#x0D;&lt;br&gt;             bleeding, or urinary tract infection&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Poor compliance or intolerance for the TMS therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects with metallic implants or pregnancy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  EEG show epileptiform discharge&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with family history of epilipsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with symptoms that are restricted from tDCS, such as epilepsy, migraine and&#x0D;&lt;br&gt;             unstable health condition&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cerebral Palsy
    </Condition>
    <Intervention>Device: Virtual cycling training;Device: Repetitive transcranial magnetic stimulation;Device: Transcranial electric stimulation
    </Intervention>
    <Primary_outcome>Change from baseline Bruininks- Oseretsky Test of Motor Proficiency II at after six weeks of treatment and three month;Change from baseline Goal Attainment Scale at after six weeks of treatment and three month
    </Primary_outcome>
    <Secondary_outcome>Change from baseline Melbourne Assessment 2 at after six weeks of treatment and three month;Change from baseline Quality of upper extremity skills test at after six weeks of treatment and three month;Change from baseline Box and block test at after six weeks of treatment and three month;Change from baseline Nine-Hole test at after six weeks of treatment and three month;Change from baseline Functional Independence Measure at after six weeks of treatment and three month;Change from baseline Pediatric Motor Activity Log at after six weeks of treatment and three month;Change from baseline ABILHAND Questionnaire at after six weeks of treatment and three month;Change from baseline Assessment of Preschool Children's Participation at after six weeks of treatment and three month;Change from baseline Children Assessment of Participation and Enjoyment at after six weeks of treatment and three month;Change from baseline Cerebral Palsy Quality of Life at after six weeks of treatment and three month;Change from baseline Motor Evoked Potential at after six weeks of treatment and three month;Change from baseline Myoton at after six weeks of treatment and three month;Change from baseline Hand dynamometer at after six weeks of treatment and three month;Change from baseline Motion analysis at after six weeks of treatment and three month
    </Secondary_outcome>
    <Secondary_ID>201701518A0
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>10338654
    </Internal_Number>
    <TrialID>NCT04048265
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>TMS Treatment in Parkinson's Disease With Pain.
    </Public_title>
    <Scientific_title>Study of rTMS in the Treatment of Early/Moderate Parkinson's Disease With Pain.
    </Scientific_title>
    <Acronym>TMSPDP
    </Acronym>
    <Primary_sponsor>Xuanwu Hospital, Beijing
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190806
    </Date_registration3>
    <Date_registration>06/08/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04048265
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 6, 2019
    </Date_enrollement>
    <Target_size>52
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Biao Chen, MD,PHD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Xuanwu Hospital of Capital Medical University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patients with Parkinson's disease diagnosed as "clinically confirmed" or "very likely"&#x0D;&lt;br&gt;             according to the 2015 MDS clinical diagnostic criteria;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Age = 18 Aged = 80 years old;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. PD patients with pain, exclude tumors, diabetes, osteoarthritis, rheumatoid rheumatism&#x0D;&lt;br&gt;             and other diseases, the use of analgesic drugs is not effective or insignificant.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. After treatment with anti-Parkinson's disease drug regimen, anti-anxiety and&#x0D;&lt;br&gt;             depression, sleep drugs, analgesic drugs, etc. for = 14 days, and the dosage is&#x0D;&lt;br&gt;             maintained during the treatment;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Ability to follow research plans and visit plans.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Secondary Parkinson's syndrome caused by vascular factors, toxins, drugs, etc., or&#x0D;&lt;br&gt;             Parkinson's superposition syndrome.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. PD patients with persistent head tremors.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Dementia, simple intelligent state check (mmse) = 24 points.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patients with suicidal tendencies and psychotic symptoms. 5, previously accepted dbs&#x0D;&lt;br&gt;             or damage surgery.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        6. Contraindications for TMS (such as history of seizures, pregnant women, installation of&#x0D;&lt;br&gt;        pacemakers, metal inclusions in the body, intracranial hypertension, severe bleeding&#x0D;&lt;br&gt;        tendency, etc.)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Transcranial Magnetic Stimulation;Parkinson Disease;Pain
    </Condition>
    <Intervention>Device: Repetitive Transcranial Magnetic Stimulation
    </Intervention>
    <Primary_outcome>Changes in the pain caused by Parkinson's Disease as measured by Visual Analogue Scale Score.
    </Primary_outcome>
    <Secondary_outcome>Changes in the patient's parkinson's disease as measured by Unified Parkinson's Disease Rating Scale III(UPDRS III) score.
    </Secondary_outcome>
    <Secondary_ID>chen biao
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>11880844
    </Internal_Number>
    <TrialID>NCT05209516
    </TrialID>
    <Last_Refreshed_on>31 January 2022
    </Last_Refreshed_on>
    <Public_title>Study of Motor Inhibition in Parkinson's Disease and Focal Hand Dystonia
    </Public_title>
    <Scientific_title>Study of Motor Inhibition in Parkinson's Disease and Focal Hand Dystonia (PART 1: Two Parkinson's Disease Projects)
    </Scientific_title>
    <Acronym>PD-INHIB
    </Acronym>
    <Primary_sponsor>Cliniques universitaires Saint-Luc- Université Catholique de Louvain
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190723
    </Date_registration3>
    <Date_registration>23/07/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05209516
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 31, 2018
    </Date_enrollement>
    <Target_size>200
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Diagnostic. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Belgium
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Adrian IVANOIU, MD, PhD;Julie DUQUE, PhD;Adrian IVANOIU, MD, PhD;Emmanuelle WILHELM, MD
    </Contact_Lastname>
    <Contact_Email>;;adrian.ivanoiu@uclouvain.be;emmanuelle.wilhelm@uclouvain.be
    </Contact_Email>
    <Contact_Tel>;;+ 32 2 764 1086;
    </Contact_Tel>
    <Contact_Affiliation>Cliniques universitaires Saint-Luc;Université Catholique de Louvain;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of idiopathic PD (according to the United Kingdom PD Society Brain Bank&#x0D;&lt;br&gt;             Clinical Diagnostic Criteria) (for PD participants)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Good response to levodopa (improvement on the UPDRS-III scale) (for PD participants)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hoehn and Yahr stage: &lt; or = 3 (for PD participants)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Absence of severe tremor (for PD participants)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Absence of dyskinesia (for PD participants)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Between 18 and 85 years old (for all participants)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Normal or corrected-to-normal vision (for all participants)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria (for all participants):&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe cognitive impairment (Score of &lt;21/30 with the Montreal Cognitive Assessment&#x0D;&lt;br&gt;             (MoCA))&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  MRI-incompatible metal device in the body&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of major psychiatric or neurological disorder (other than PD for the patient&#x0D;&lt;br&gt;             group)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Personal or family history of epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of substance use disorder (except nicotine)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Untreated or unstable medical conditions that could interfere with cognitive&#x0D;&lt;br&gt;             functioning&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Undergoing any drug treatment that can significantly alter task performance or neural&#x0D;&lt;br&gt;             activity&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Behavioral: Behavioral data;Diagnostic Test: Single-pulse transcranial magnetic stimulation (TMS);Other: Questionnaires;Other: MDS (Movement Disorder Society) UPDRS (Unified Parkinson's Disease Rating Scale) Part 3 (Motor Part)
    </Intervention>
    <Primary_outcome>TMS measures of preparatory Inhibition;Reaction times and movement times during the task
    </Primary_outcome>
    <Secondary_ID>2018/27AVR/194
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>10336289
    </Internal_Number>
    <TrialID>NCT04017481
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Non Invasive Neuromodulation for Patients With Motor Control Disorders
    </Public_title>
    <Scientific_title>Development and Clinical Validation of a Rehabilitation Platform Based on Neuromodulation for Patients With Motor Control Disorders
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Universidad Francisco de Vitoria
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190702
    </Date_registration3>
    <Date_registration>02/07/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04017481
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 1, 2016
    </Date_enrollement>
    <Target_size>50
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Juan Pablo Romero Muñoz, MD PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Universidad Francisco de Vitoria, Facultad de Ciencias Experimentales
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Idiopathic Parkinsons Disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hoehn Yahr Scale I-III&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No drug changes in the last 90 days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No exclusion criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia (Minimental scale score &lt;25)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dependency (modified Rankin scale &gt; 3)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy or pregnancy plans&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pacemaker&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Implanted metal devices&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  cochlear implants&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  claustrophobia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  drug infusion pumps&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  epilepsy / epileptiform anomalies in electroencephalography (EEG)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  known structural alterations in magnetic resonance imaging (MRI)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Atypical Parkinsonism&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous repetitive transcranial magnetic stimulation (rTMS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe comorbidity (cancer, severe debilitating diseases, etc.)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: Repetitive transcranial magnetic stimulation (rTMS);Other: EEG guided Neurofeedback (NFB)
    </Intervention>
    <Primary_outcome>Motor changes;Motor changes;Neurophysiological cortical changes;Neurophysiological cortical changes
    </Primary_outcome>
    <Secondary_outcome>Quality of life changes;Encephalographic changes;Cognitive changes in objective measures of processing speed
    </Secondary_outcome>
    <Secondary_ID>NeuroMOD
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>National Research Council, Spain;Hospital Beata María Ana, Madrid;Hospital Universitario de Fuenlabrada
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>12763426
    </Internal_Number>
    <TrialID>NCT03714854
    </TrialID>
    <Last_Refreshed_on>16 January 2023
    </Last_Refreshed_on>
    <Public_title>Study of Motor Control Mechanisms in DBS-implanted Parkinson's Disease Patients
    </Public_title>
    <Scientific_title>Study of Motor Control Mechanisms in DBS-implanted Parkinson's Disease Patients
    </Scientific_title>
    <Acronym>PARKMOTEUR
    </Acronym>
    <Primary_sponsor>University Hospital, Grenoble
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20181016
    </Date_registration3>
    <Date_registration>16/10/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03714854
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>30 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 5, 2018
    </Date_enrollement>
    <Target_size>6
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>France
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  PD patients that are monitored for the tuning of their DBS stimulator by Grenoble's&#x0D;&lt;br&gt;             Hospital.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  PD patients that are hospitalized for the tuning routine 12 months after the surgical&#x0D;&lt;br&gt;             implantation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Good tolerance following temporary stops of the DBS stimulator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Affiliated to a social security system&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mental abilities sufficient for performing the behavioral tasks (MMSE score &gt;= 24,&#x0D;&lt;br&gt;             tested less than 6 months ago)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients that are concerned by articles L1121-5, L1121-6, L1121-7 and L1121-8 of&#x0D;&lt;br&gt;             French Code de la Santé Publique,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of psychiatric or neurological illness other than PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients that are currently excluded from an other clinical trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Contraindications for TMS practice&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to stay seated without pain for two hours&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: transcranial magnetic stimulation
    </Intervention>
    <Primary_outcome>Corticospinal excitability
    </Primary_outcome>
    <Secondary_outcome>Cortical excitability;Cortico-subcortical connectivity;Correlation between behavioral and neural responses
    </Secondary_outcome>
    <Secondary_ID>2017-A03016-47
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13169366
    </Internal_Number>
    <TrialID>NCT03628703
    </TrialID>
    <Last_Refreshed_on>18 July 2023
    </Last_Refreshed_on>
    <Public_title>Response Inhibition in Tourette Syndrome
    </Public_title>
    <Scientific_title>Using Repetitive Transcranial Magnetic Stimulation to Modulate Response Inhibition in Tourette Syndrome
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Children's Hospital Medical Center, Cincinnati
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180810
    </Date_registration3>
    <Date_registration>10/08/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT03628703
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>10 Years
    </Inclusion_agemin>
    <Inclusion_agemax>17 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 22, 2019
    </Date_enrollement>
    <Target_size>15
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Steve W. Wu, MD;Hannah Jackson;Hannah Jackson
    </Contact_Lastname>
    <Contact_Email>;hannah.jackson@cchmc.org;hannah.jackson@cchmc.org
    </Contact_Email>
    <Contact_Tel>;513-803-2670;513-803-2670
    </Contact_Tel>
    <Contact_Affiliation>Children's Hospital Medical Center, Cincinnati;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Tourette Syndrome&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Autism spectrum disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mood disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Implanted medical device (e.g. pacemaker, shunt, pumps)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tourette Syndrome
    </Condition>
    <Intervention>Device: Repetitive TMS
    </Intervention>
    <Primary_outcome>Stop Signal Reaction Time (SSRT)
    </Primary_outcome>
    <Secondary_ID>CIN001 - TAA2018
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>7204398
    </Internal_Number>
    <TrialID>ChiCTR1800017143
    </TrialID>
    <Last_Refreshed_on>16 July 2018
    </Last_Refreshed_on>
    <Public_title>Repetitive Transcranial Magnetic Stimulation and Paired Associative Stimulation for Tourette Syndrome
    </Public_title>
    <Scientific_title>Repetitive Transcranial Magnetic Stimulation and Paired Associative Stimulation for Tourette Syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>Capital Medical University Affiliated Xuanwu Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180713
    </Date_registration3>
    <Date_registration>2018-07-13
    </Date_registration>
    <Source_Register>ChiCTR
    </Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=20342
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6
    </Inclusion_agemin>
    <Inclusion_agemax>40
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2018-07-13
    </Date_enrollement>
    <Target_size>rTMS:11;PAS-25:11;PAS-50:11;false stimulation:11;
    </Target_size>
    <Study_type>Interventional study
    </Study_type>
    <Study_design>Randomized parallel controlled trial
    </Study_design>
    <Phase>New Treatment Measure Clinical Study
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>Yuping Wang
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>614 Outpatient Building, Xuanwu Hospital, 45 Changchun Street, Xicheng District, Beijing, China
    </Contact_Address>
    <Contact_Email>wangyuping01@sina.cn
    </Contact_Email>
    <Contact_Tel>+86 010-83198273
    </Contact_Tel>
    <Contact_Affiliation>Capital Medical University Affiliated Xuanwu Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: gender unlimited, aged 6-40 years; patients did not take any anti-TS drugs or change the type and dose of anti-TS drugs in his or her latest month; physical examination of nervous system shows no positive signs; no other chronic disease, YGTSS score above 25 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: The type and dose of oral medication change during the treatment or within one month after the end of treatment; secondary treatment of TS; severe circulatory, respiratory, metabolic disease, epilepsy, traumatic brain injury; drugs that affect the excitability of the cerebral cortex, coffee and tea have been taken; Patients with metal in the body, or pregnant, or while breastfeeding
    </Exclusion_Criteria>
    <Condition>Tourette Syndrome
    </Condition>
    <Intervention>rTMS:repetitive transcranial magnetic stimulation;PAS-25:paired associative stimulation, interval of 25 milliseconds;PAS-50:paired associative stimulation, interval of 50 milliseconds;false stimulation:false stimulation;
    </Intervention>
    <Primary_outcome>Yale Global Tie Severityb Scale;
    </Primary_outcome>
    <Source_Support>no
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>26/08/2013
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Zhuoran Zhang
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13455387
    </Internal_Number>
    <TrialID>JPRN-UMIN000021257
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>Development of a novel facial nerve rehabilitation by the transcranial magnetic stimulation
    </Public_title>
    <Scientific_title>Development of a novel facial nerve rehabilitation by the transcranial magnetic stimulation - Facial nerve rehabilitation by the transcranial magnetic stimulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
    </Scientific_title>
    <Primary_sponsor>Dept. of Otolaryngology, Graduate School of Medical Sciences, Nagoya City University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180401
    </Date_registration3>
    <Date_registration>01/04/2018
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024503
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20years-old
    </Inclusion_agemin>
    <Inclusion_agemax>70years-old
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2014/08/01
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Single arm Non-randomized
    </Study_design>
    <Phase>Not selected
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname>Akira Inagaki
    </Contact_Lastname>
    <Contact_Address>1 Kawasumi, Mizuho-cho-aza, Mizuho-ku, Nagoya City
    </Contact_Address>
    <Contact_Email>meijo_ent@hotmail.com
    </Contact_Email>
    <Contact_Tel>052-853-8256
    </Contact_Tel>
    <Contact_Affiliation>Nagoya City University Hospital Department of Otolaryngology
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1)  Being , or planning to be registered to other clinical trials during the period of this clinical trial.  2)  Being treated or planning to be treated by other treatment methods which significantly affect to the facial movement, such as electric stimulation on the face, facial nerve block, acupuncture.  3)   Performance status 3 or higher  4)   Diaabetes (HbA1c &amp;gt; 6.5%).  5)   Neurological disorders with facial palsy.   6)   History of clinically significant intracranial abnormalities.  7)   Implantation of following devices a) aneurysm clip b) Cardiac catheter  8)    Significantly increased intracranial pressure
    </Exclusion_Criteria>
    <Condition>Facial nerve palsy
    </Condition>
    <Intervention>Facial nerve rehabilitation by the transcranial magnetic stimulation
    </Intervention>
    <Primary_outcome>Scores by the facial nerve grading system (Yanagihara&amp;#39;s score, Scores by Sunnybrook facial grading system and  House-Brackmann grading system)
    </Primary_outcome>
    <Source_Support>Scientific Grant in Aids (KAKENHI)
    </Source_Support>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>10312836
    </Internal_Number>
    <TrialID>NCT03712072
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Multi-modal Neuroimaging in Children With Cerebral Palsy or Brachial Plexus Birth Palsy
    </Public_title>
    <Scientific_title>Multi-modal Neuroimaging in Children With Cerebral Palsy or Brachial Plexus Birth Palsy to Assess Functional and Anatomical Reorganization in Relation to Sensory and Motor Functions
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Boston Children's Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180124
    </Date_registration3>
    <Date_registration>24/01/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03712072
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>18 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 1, 2018
    </Date_enrollement>
    <Target_size>32
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Christos Papadelis, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Boston Children's Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Children with Cerebral Palsy should have:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  An evaluation by a pediatric neurologist with a diagnosis of CP due to PV-WMI,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Absence of any genetic syndrome diagnosis,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No history of trauma or brain operation,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Classified as high-functioning (I or II) at the Gross Motor Function Classification&#x0D;&lt;br&gt;             System (GMFCS)32.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Children with Brachial Plexus Birth Palsy should have:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  An evaluation by a hand and upper extremity surgeon with a diagnosis of BPBP&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  May or may not have undergone primary microsurgical or secondary reconstructive&#x0D;&lt;br&gt;             operations prior to this study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Typically Developing children should have:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No history of neurological disorder or brain injury.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Children will be excluded if they meet any of the follow criteria, determined via their&#x0D;&lt;br&gt;        medical and developmental history:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Having a hard time sitting still,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of any metal implants,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Baclofen pumps,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of traumatic brain injury or brain operation.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cerebral Palsy;Brachial Plexus; Injury, Newborn
    </Condition>
    <Intervention>Device: Magnetoencephalography (MEG);Device: Electroencephalography (EEG);Device: Transcranial Magnetic Stimulation (TMS)
    </Intervention>
    <Primary_outcome>Somatosensory evoked potentials as assessed using MEG
    </Primary_outcome>
    <Secondary_outcome>Motor evoked amplitude as assessed using MEG;Somatosensory evoked potentials as assessed using EEG;Motor evoked potentials as assessed using EEG;Cortical excitability of motor cortex assessed using TMS
    </Secondary_outcome>
    <Secondary_ID>IRB-P00023570
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13310112
    </Internal_Number>
    <TrialID>NCT03350464
    </TrialID>
    <Last_Refreshed_on>4 September 2023
    </Last_Refreshed_on>
    <Public_title>Repetitive Transcranial Magnetic Stimulation as a Treatment for Pain in Parkinson's Disease
    </Public_title>
    <Scientific_title>Open-label Pilot Study Using Repetitive Transcranial Magnetic Stimulation as a Treatment for Pain in Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Walton Centre NHS Foundation Trust
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20171020
    </Date_registration3>
    <Date_registration>20/10/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT03350464
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 5, 2018
    </Date_enrollement>
    <Target_size>11
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United Kingdom
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Patients who have a diagnosis of Parkinson's Disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Medical treatment for the movement disorder to be optimized prior to the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Despite optimum medical therapy neuropathic pain is a major complaint for the patient:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. A minimum total score on the King's Pain Scale of 12 or&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. A minimum subset domain score on Fluctuation-related Pain of 6 or&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               3. A minimum subset domain score on Nocturnal pain of 5 or&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               4. A minimum subset domain score on Radicular Pain of 3 or&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. No other cause for the pain is identified.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Age 18-80&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Weekly average pain levels of 3/10 or more at the time of entry&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. The patient is capable of and willing to give informed consent for their&#x0D;&lt;br&gt;             participation.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. The patient is capable of and willing to fill in a daily Pain diary during the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Patients will be excluded from the trial if they:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Are suffering from pain not attributable from Parkinson's Disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Are suffering from any neurological or psychiatric disease that could interfere with&#x0D;&lt;br&gt;             provision of reliable data (dementia, major depression, drug abuse, alcoholism)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Are suffering from a rapidly progressing malignant disease or other systemic disease&#x0D;&lt;br&gt;             that is likely to significantly interfere with their participation in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Are candidates or have been listed for surgery or other major medical intervention&#x0D;&lt;br&gt;             requiring hospitalisation and/or rehabilitation (e.g., hip replacement).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Have a history of seizures or epilepsy,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Require high doses of medication known to lower the threshold for seizures (e.g.,&#x0D;&lt;br&gt;             amitriptyline &gt; 100mg/d,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Have cerebral space occupying lesion,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Have a history of severe head injury (associated with a suspicion of brain injury,&#x0D;&lt;br&gt;             e.g. resulting in unconsciousness for over 24 hrs)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Have metal located in head (e.g. shrapnel, surgical clips, fragments from welding),&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Have a cochlear implant,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Have a cardiac pacemaker in situ,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. Have a deep brain or vagal nerve stimulator in situ,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Are pregnant&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Neuropathic Pain;Pain
    </Condition>
    <Intervention>Device: Repetitive Transcranial Magnetic Stimulation
    </Intervention>
    <Primary_outcome>No change in the patient's parkinson's disease as measured by Unified Parkinson's Disease Rating Scale III
    </Primary_outcome>
    <Secondary_outcome>An improvement by a minimum of 30% in the pain caused by Parkinson's Disease as measured by the King's Parkinson's Disease Pain Scale
    </Secondary_outcome>
    <Secondary_ID>PS024 RG237-18
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13455357
    </Internal_Number>
    <TrialID>JPRN-UMIN000021227
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>Refinement of facial Rehabilitation for facial palsy patients with Transcranial Magnetic Stimulation
    </Public_title>
    <Scientific_title>Refinement of facial Rehabilitation for facial palsy patients with Transcranial Magnetic Stimulation - Refinement of facial Rehabilitation for facial palsy patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
    </Scientific_title>
    <Primary_sponsor>Department of Otolaryngology, Nagoya City University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170901
    </Date_registration3>
    <Date_registration>01/09/2017
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024487
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20years-old
    </Inclusion_agemin>
    <Inclusion_agemax>70years-old
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2014/09/30
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel Non-randomized
    </Study_design>
    <Phase>Phase I
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname>Akira Inagaki
    </Contact_Lastname>
    <Contact_Address>1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya Japan
    </Contact_Address>
    <Contact_Email>meijo_ent@hotmail.com
    </Contact_Email>
    <Contact_Tel>052-853-8256
    </Contact_Tel>
    <Contact_Affiliation>Nagoya City University Hospital Dept of Otolaryngology
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: The patient with intracranial lesions, diabetes, or PS3 or higher
    </Exclusion_Criteria>
    <Condition>Facial nerve palsy
    </Condition>
    <Intervention>Rehabilitation with transcranial magnetic stimulation and systemic steroids treatment&lt;br&gt;Standard systemic steroids treatment
    </Intervention>
    <Primary_outcome>Compare the facial nerve palsy scores between the groups with and without intervention
    </Primary_outcome>
    <Source_Support>Magnetic Health Science Foundation
    </Source_Support>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>10281347
    </Internal_Number>
    <TrialID>NCT03273270
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Effects of Neuromodulation and Rehabilitation of the Locomotor Network in Freezing of Gait
    </Public_title>
    <Scientific_title>Effects of Neuromodulation and Rehabilitation of the Locomotor Network in Freezing of Gait
    </Scientific_title>
    <Acronym>TMS/FOG
    </Acronym>
    <Primary_sponsor>Medical University of South Carolina
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170828
    </Date_registration3>
    <Date_registration>28/08/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03273270
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 31, 2017
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Gonzalo Revuelta, DO
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Medical University of South Carolina
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Subjects meeting diagnostic criteria for PD and documented FoG&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        -&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects with contraindications to MRI, or TMS (no history of seizures, no metal&#x0D;&lt;br&gt;             implants in head, no pregnancy) dementia, or inability to complete the walk 30 feet in&#x0D;&lt;br&gt;             the off state without assistance will be excluded.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease With Freezing of Gait
    </Condition>
    <Intervention>Radiation: transcranial magnetic stimulation
    </Intervention>
    <Primary_outcome>functional MRI
    </Primary_outcome>
    <Secondary_outcome>new Freezing of Gait Questionnaire;Objective Gait Assessment
    </Secondary_outcome>
    <Secondary_ID>TMS/FOG
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>10281260
    </Internal_Number>
    <TrialID>NCT03271736
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Effects of Rhythmic Auditory Cueing on Stepping in Place in Patients With Parkinson's Disease
    </Public_title>
    <Scientific_title>Effects of Rhythmic Auditory Cueing on Stepping in Place in Patients With Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>HsiuYun Chang
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170806
    </Date_registration3>
    <Date_registration>06/08/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03271736
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 8, 2018
    </Date_enrollement>
    <Target_size>21
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Taiwan
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Jau Yih Tsauo, PT, phD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>department of physical therapy, college of medicine, National Taiwan University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        [Patients with Parkinson's disease]&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosed with idiopathic Parkinson's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No hearing impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to walk independently for at least 10m&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to follow command (MMSE &gt;=24)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        [Healthy subjects]&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No hearing impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to walk independently for at least 10m&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to follow command (MMSE &gt;=24)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  With other neurological diseases or psychological diseases&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Family history of epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of head trauma, surgery, or metal implants&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Having pacemaker or other electrical stimulators&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of syncopes or frequent migraines&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Behavioral: Stepping-in-place exercise with external auditory cues;Device: Transcranial magnetic stimulation (TMS)
    </Intervention>
    <Primary_outcome>Changes of transcranial magnetic stimulation (TMS) parameters
    </Primary_outcome>
    <Secondary_outcome>Variation of walking step time;Walking ability;Variation of stepping-in-place movement
    </Secondary_outcome>
    <Secondary_ID>201609085RINA
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13462186
    </Internal_Number>
    <TrialID>JPRN-UMIN000028079
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>Effect of sensory input to voluntary movement in patients with central movement disorders.
    </Public_title>
    <Scientific_title>Effect of sensory input to voluntary movement in patients with central movement disorders. - Effect of sensory input to voluntary movement in patients with central movement disorders.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>Shinshu University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170706
    </Date_registration3>
    <Date_registration>06/07/2017
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032144
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20years-old
    </Inclusion_agemin>
    <Inclusion_agemax>Not applicable
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2017/07/04
    </Date_enrollement>
    <Target_size>50
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Single arm Non-randomized
    </Study_design>
    <Phase>Not applicable
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname>Hiroshi
    </Contact_Firstname>
    <Contact_Lastname>Morita
    </Contact_Lastname>
    <Contact_Address>Asahi 3-1-1 Matsumoto
    </Contact_Address>
    <Contact_Email>hmorita@shinshu-u.ac.jp
    </Contact_Email>
    <Contact_Tel>0263372156
    </Contact_Tel>
    <Contact_Affiliation>Shinshu University Center for Health, Safety and Environmental Management
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients as having other neurological disorders including dementia.
    </Exclusion_Criteria>
    <Condition>Parkinson&amp;#39;s disease, Spasticity
    </Condition>
    <Intervention>peripheral nerve stimulation  transcranial magnetic stimulation
    </Intervention>
    <Primary_outcome>The extent of conditioning effect to H-reflex
    </Primary_outcome>
    <Source_Support>Shinshu University
    </Source_Support>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>04/07/2017
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>mdrinri@shinshu-u.ac.jp
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethical comittee Shinshu University Department of Medicie
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>0263-37-2572
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>mdrinri@shinshu-u.ac.jp
    </Ethics_review_contact_email>
    <results_date_completed>31/03/2022
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13603857
    </Internal_Number>
    <TrialID>NCT03217110
    </TrialID>
    <Last_Refreshed_on>8 January 2024
    </Last_Refreshed_on>
    <Public_title>Cerebellar Stimulation and Cognitive Control
    </Public_title>
    <Scientific_title>Cerebellar Transcranial Magnetic Stimulation and Cognitive Control
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Krystal Parker, PhD
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170630
    </Date_registration3>
    <Date_registration>30/06/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT03217110
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 30, 2017
    </Date_enrollement>
    <Target_size>200
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: Single (Participant). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Krystal L Parker, Ph.D;Krystal L Parker, Ph.D;Krystal L Parker, Ph.D
    </Contact_Lastname>
    <Contact_Email>;CT201610712@gmail.com;krystal-parker@uiowa.edu
    </Contact_Email>
    <Contact_Tel>;319-353-4554;319-353-3554
    </Contact_Tel>
    <Contact_Affiliation>Univeristy of Iowa;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A clinical diagnosis consistent with enrollment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of recurrent seizures or epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any other neurological or psychiatric diagnosis outside the diagnosis for which the&#x0D;&lt;br&gt;             participant is enrolled.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Active substance use disorder in the past 6 months other than tobacco use disorder.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inability to consent for study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pacemaker&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Coronary Stent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Defibrillator&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neurostimulation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Claustrophobia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Uncontrolled high blood pressure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Atrial fibrillation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Significant heart disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hemodynamic instability&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Kidney disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant, trying to become pregnant, or breast feeding&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Schizophrenia;Autism Spectrum Disorder;Bipolar Disorder;Depression;Parkinson Disease
    </Condition>
    <Intervention>Device: Repetitive Transcranial Magnetic Stimulation (rTMS);Device: Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
    </Intervention>
    <Primary_outcome>Change in disease-specific symptom rating scale, one scale identified for each group (MADRS for bipolar group; PANSS for schizophrenia group; UPDRS in Parkinson's patient group).
    </Primary_outcome>
    <Secondary_outcome>Change in brain rhythms;Change in cognitive function;Changes in functional MRI;Change in NIH Toolbox emotion battery;Change in motor function;Schizophrenia group: Change in Calgary depression scale.;Bipolar group: Change in Young Mania Rating Scale.;Bipolar group: Change in Columbia Suicide Severity Rating Scale.;Change in PHQ9 score.;Change in CGI.;Change in cognitive function.;Changes in structural MRI.;Changes in MRI-based timing task.;Changes in DTI.;Changes in T1 rho MRI signal.
    </Secondary_outcome>
    <Secondary_ID>201610712
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>6282858
    </Internal_Number>
    <TrialID>ACTRN12617000934347
    </TrialID>
    <Last_Refreshed_on>4 July 2017
    </Last_Refreshed_on>
    <Public_title>Transcranial Magnetic Stimulation in the diagnosis of Atypical Parkinsonism&#x0D;
&#x0D;

    </Public_title>
    <Scientific_title>Transcranial Magnetic Stimulation in the diagnosis of Atypical Parkinsonism&#x0D;
&#x0D;

    </Scientific_title>
    <Primary_sponsor>Monash University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170628
    </Date_registration3>
    <Date_registration>28/06/2017
    </Date_registration>
    <Source_Register>ANZCTR
    </Source_Register>
    <web_address>http://www.anzctr.org.au/ACTRN12617000934347.aspx
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax/>
    <Inclusion_gender>Both males and females
    </Inclusion_gender>
    <Date_enrollement>7/07/2016
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Phase/>
    <Condition>PROGRESSIVE SUPRANUCLEAR PALSY;MULTIPLE SYSTEM ATROPHY;PARKINSON'S DISEASE
    </Condition>
    <Intervention>Transcranial Magnetic Stimulation (TMS)&#x0D;&lt;br&gt;TMS will be performed on each participant  including measures of&#x0D;&lt;br&gt;intracortical inhibition and facilitation, resting motor thresholds and motor evoked potentials before and after theta burst stimulation. The TMS protocol is expected to take 2-3 hours. In addition each participant will undergo standardised cognitive tests. &#x0D;&lt;br&gt;
    </Intervention>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>10286078
    </Internal_Number>
    <TrialID>NCT03354455
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Investigating the Causal Role of preSMA in Levodopa-induced Dyskinesia in Parkinson's Disease
    </Public_title>
    <Scientific_title>Targeting the Pre-supplementary Motor Area With Repetitive Transcranial Magnetic Stimulation to Alleviate Levodopa-induced Dyskinesia in Parkinson´s Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Danish Research Centre for Magnetic Resonance
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170601
    </Date_registration3>
    <Date_registration>01/06/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03354455
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 1, 2017
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Basic Science. Masking: Single (Participant). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Denmark
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Hartwig R Siebner, MD, DMSci
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Danish Research Centre for Magnetic Resonance
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinical diagnosis of Parkinson's Disease (Hoehn &amp; Yahr 1-3)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Peak-of-dose levodopa-induced dyskinesia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Insufficient Danish language skills&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neurological disease other than Parkinson's Disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Major psychiatric illness&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Sedatives or serotonergic medication in their current treatment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe tremor&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Montreal Cognitive Assessment score &lt; 26&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Contraindication for transcranial magnetic stimulation:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Epilepsy or epilepsy in 1st degree relatives&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Contraindications for MRI-scanning:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pacemaker&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Metallic foreign objects inside the body&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe claustrophobia&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Dyskinesia, Drug-Induced;Parkinson Disease
    </Condition>
    <Intervention>Device: Repetitive transcranial magnetic stimulation
    </Intervention>
    <Primary_outcome>Levodopa-induced change in task-related regional neural activity as indexed by the blood oxygen level dependent (BOLD) signal
    </Primary_outcome>
    <Secondary_outcome>Onset of LID;Severity of LID
    </Secondary_outcome>
    <Secondary_ID>H-15017863
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University Hospital Bispebjerg and Frederiksberg;Danish Movement Disorder Society (DANMODIS);Danish Parkinson Association
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13661866
    </Internal_Number>
    <TrialID>TCTR20170202002
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>The relationship of brain and functions from young adults to elders and disability
    </Public_title>
    <Scientific_title>The relationship of brain and functions from young adults to elders and disability                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
    </Scientific_title>
    <Primary_sponsor>Faculty of Physical Therapy&amp;#44; Mahidol University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170202
    </Date_registration3>
    <Date_registration>02/02/2017
    </Date_registration>
    <Source_Register>TCTR
    </Source_Register>
    <web_address>https://www.thaiclinicaltrials.org/show/TCTR20170202002
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>02/02/2017
    </Date_enrollement>
    <Target_size>140
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Thailand
    </Countries>
    <Contact_Firstname>Jarugool
    </Contact_Firstname>
    <Contact_Lastname>Tretriluxana
    </Contact_Lastname>
    <Contact_Address>999 Phuttamonthon 4 Road&amp;#44; Salaya&amp;#44; Nakhon Pathom 73170 Thailand
    </Contact_Address>
    <Contact_Email>jarugool.tre@mahidol.ac.th
    </Contact_Email>
    <Contact_Tel>084-6686831
    </Contact_Tel>
    <Contact_Affiliation>&amp;#45;
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Age&amp;#45;matched group&amp;#44; Parkinson&amp;#39;s disease&amp;#44; Ankle instability&amp;#44; Non&amp;#45;ankle instability
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: contraindication of Transcranial Magnetic Stimulation 
    </Exclusion_Criteria>
    <Condition>No adverse events &lt;br&gt;Brain Stimulation&amp;#44; Parkinson&amp;#39;s disease&amp;#44; Motor training;Brain Stimulation&amp;#44; Parkinson&amp;#39;s disease&amp;#44; Motor training
    </Condition>
    <Intervention>High frequency repetitive TMS and task specific training ,High frequency repetitive TMS and Usual care;Experimental Other,Sham Comparator Other;Repetitive Transcranial Magnetic Stimulation (TMS),Sham Stimulation
    </Intervention>
    <Primary_outcome>Corticospinal excitability  Baseline&amp;#44; immediate effect&amp;#44; followed&amp;#45;up test Transcranial Magnetic Stimulation
    </Primary_outcome>
    <Secondary_outcome>Hand performance Baseline&amp;#44; immediate effect&amp;#44; followed&amp;#45;up test Motion monitor
    </Secondary_outcome>
    <Source_Support>Faculty of Physical Therapy&amp;#44; Mahidol University&amp;#44; RGJ&amp;#45;Ph.D. scholarship
    </Source_Support>
    <Secondary_Sponsor>RGJ&amp;#45;Ph.D. scholarship
    </Secondary_Sponsor>
    <Ethics_review_status/>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>02/02/2018
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>10265057
    </Internal_Number>
    <TrialID>NCT02969941
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment for Parkinson Disease
    </Public_title>
    <Scientific_title/>
    <Acronym/>
    <Primary_sponsor>Anhui Medical University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20161117
    </Date_registration3>
    <Date_registration>17/11/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02969941
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 1, 2016
    </Date_enrollement>
    <Target_size>46
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of Parkinson disease (PD) according to the United Kingdom Brain Bank&#x0D;&lt;br&gt;             Criteria, confirmed by a neurologist with expertise in movement disorders.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Minimum of 3 years since the formal diagnosis of PD, and requiring dopaminergic&#x0D;&lt;br&gt;             therapy (at a minimum, on levodopa and/or dopamine agonist therapy).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  On a stable dose of all medications for 2 months; and no anti-PD medication&#x0D;&lt;br&gt;             adjustments in the next 3 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 40 years or older.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mini-mental state examination &gt; 27.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any history or clinical signs of other severe psychiatric illnesses (like major&#x0D;&lt;br&gt;             depression, psychosis or obsessive compulsive disorder).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of head injury, stroke, or other neurologic disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Organic brain defects on T1 or T2 images.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of seizures or unexplained loss of consciousness.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Family history of medication refractory epilepsy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of substance abuse within the last 6 months.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Transcranial Magnetic Stimulation;Functional Magnetic Resonance Imaging;Parkinson Disease
    </Condition>
    <Intervention>Other: transcranial magnetic stimulation
    </Intervention>
    <Primary_outcome>Symptom improvement assessed by Unified Parkinson's Disease Rating Scale III
    </Primary_outcome>
    <Secondary_outcome>Timed up and go test;20m walking test;Non-motor symptoms questionnaire;Unified Parkinson's Disease Rating Scale III
    </Secondary_outcome>
    <Secondary_ID>NSFC-81171273-02
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>6850191
    </Internal_Number>
    <TrialID>IRCT2016092525568N2
    </TrialID>
    <Last_Refreshed_on>22 February 2018
    </Last_Refreshed_on>
    <Public_title>Improvement of motor function and neuromuscular disorders by repetitive transcranial magnetic stimulation therapy in children with cerebral palsy
    </Public_title>
    <Scientific_title>Therapeutic effects of repetitive transcranial magnetic stimulation therapy on central nervous system structure and function, neuromuscular properties and gait in children with cerebral palsy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Vice chancellor for research of Tehran University of Medical Sciences
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20161110
    </Date_registration3>
    <Date_registration>2016-11-10
    </Date_registration>
    <Source_Register>IRCT
    </Source_Register>
    <web_address>http://en.irct.ir/trial/21355
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>4 years
    </Inclusion_agemin>
    <Inclusion_agemax>14 years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2015-11-22
    </Date_enrollement>
    <Target_size>100
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: coin-flip.
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Iran (Islamic Republic of);Iran (Islamic Republic of)
    </Countries>
    <Contact_Firstname>Parmida Moradi Birgani
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Tehran University of Medical Sciences, Pour Sina St., Ghods St., Enqelab Sq.
    </Contact_Address>
    <Contact_Email>parmida.mb@gmail.com
    </Contact_Email>
    <Contact_Tel>+98 21 6646 6383
    </Contact_Tel>
    <Contact_Affiliation>Tehran University of Medical Sciences
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Inclusion criteria: hemiplegic patients diagnosed by a pediatric neurologist; spasticity in lower extremities (Modified Ashworth Scale score more than 1); ability to attend training or test sessions; ability of following commands&#x0D;&lt;br&gt;Exclusion criteria: having severe mental retardation; epilepsy; chromosomal anomaly; or genetic syndrome; severe brain structural anomaly; pacemaker or any other metallic implants; not attending treatment sessions regularly
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 
    </Exclusion_Criteria>
    <Condition>spastic hemiplegic cerebral palsy. &lt;br&gt;Spastic hemiplegic cerebral palsy;Spastic hemiplegic cerebral palsy
    </Condition>
    <Intervention>Intervention 1: Intervention group: will receive 25 minutes of 1 Hz repetitive transcranial magnetic stimulation (1500 pulses) with air film coil for 3 days per week for 8 weeks. The stimulation may be paused based on subject's tolerance. Intervention 2: Control group: will receive 25 minutes of 1 Hz repetitive transcranial magnetic stimulation (1500 pulses) with sham coil for 3 days per week for 8 weeks.;Treatment - Devices;Treatment - Devices;Intervention group: will receive 25 minutes of 1 Hz repetitive transcranial magnetic stimulation (1500 pulses) with air film coil for 3 days per week for 8 weeks. The stimulation may be paused based on subject's tolerance.;Control group: will receive 25 minutes of 1 Hz repetitive transcranial magnetic stimulation (1500 pulses) with sham coil for 3 days per week for 8 weeks.
    </Intervention>
    <Primary_outcome>Mean Diffusivity. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Magnetic Resonance Imaging Acquisition; Post Analysis.;Berg Balance Scale. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Clinical evaluations.;Center of Pressure Distance. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Gait Analaysis.;Stride Velocity. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Gait Analaysis.;Maximum Voluntary Conraction. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Isokinetic.;Fractional Anisotropy. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Magnetic Resonance Imaging Acquisition; Post Analysis.;Transcranial Magnetic Stimulation Motor threshold. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Transcranial Magnetic Stimulation Device; Electromyography Device.;Hoffman Reflex. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Electromyography Device.;Muscle Weakness. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Electromyography Device.;Tissue Elasticity. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Sonoelastography.;Velocity and Endorance. Timepoint: before intervention; one month after the beginning of intervention; at the end of intervention; one month after the end of intervention. Method of measurement: Clinical evaluations.
    </Primary_outcome>
    <Secondary_outcome>-. Timepoint: -. Method of measurement: -.
    </Secondary_outcome>
    <Source_Support>Vice chancellor for research of Tehran University of Medical Sciences
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Ethics committee of Tehran University of Medical Sciences
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>11634084
    </Internal_Number>
    <TrialID>CTRI/2016/08/007166
    </TrialID>
    <Last_Refreshed_on>24 November 2021
    </Last_Refreshed_on>
    <Public_title>Magnetic Brain treatment for Cerebral Palsy
    </Public_title>
    <Scientific_title>To study relief of muscles spasticity in CP Kids by employing r-TMS - r-TMS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    </Scientific_title>
    <Primary_sponsor>Department of Science and Technology
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20160809
    </Date_registration3>
    <Date_registration>09-08-2016
    </Date_registration>
    <Source_Register>CTRI
    </Source_Register>
    <web_address>http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=15243
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin/>
    <Inclusion_agemax/>
    <Inclusion_gender/>
    <Date_enrollement>01-05-2015
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized, Crossover Trial&lt;br&gt;  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Not Applicable  Blinding and masking:Participant and Outcome Assessor Blinded
    </Study_design>
    <Phase>Phase 1/ Phase 2
    </Phase>
    <Countries>India
    </Countries>
    <Contact_Firstname>Dr Arun Mukherjee
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>C-27, Dayanand Colony, Lajpat Nagar IV, New Delhi 
    </Contact_Address>
    <Contact_Email>bhatiadinesh@rediffmail.com
    </Contact_Email>
    <Contact_Tel>0364-2723853
    </Contact_Tel>
    <Contact_Affiliation>North Eastern Hill University, Shillong
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Spastic Cerebral Palsy patients &lt;br/ &gt;&lt;br&gt;2. Muscle tightness more than one on the Modified Ashworth Scale (MAS). &lt;br/ &gt;&lt;br&gt;3. Cognitive deficiency of nil to moderate. &lt;br/ &gt;&lt;br&gt;4. Children with seizures, if it was controlled with appropriate medication. &lt;br/ &gt;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Any metallic implant like ventriculo-peritoneal shunt, pacemaker or metallic foreign body present in the subject. &lt;br/ &gt;&lt;br&gt;2. Congenital disorders like Downâ??s syndrome, Fragile- X syndrome or any congenital anomalies. &lt;br/ &gt;&lt;br&gt;3. Uncontrolled seizures or unstable physical conditions. &lt;br/ &gt;&lt;br&gt;4. Any co-morbid condition such as infections, etc. &lt;br/ &gt;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Health Condition 1: null- Spastic Cerebral Palsy

    </Condition>
    <Intervention>Intervention1: Intervention Group: 5/10Hz r-TMS therapy of 15 minutes duration followed by 30 minutes of physical therapy daily for 20 days (5 days per week for 4 weeks).&lt;br&gt;&lt;br&gt;Control Intervention1: Control Group: Spastic CP children administered only physical therapy of 30 minutes duration daily for 20 days (5 days per week for 4 weeks.&lt;br&gt;
    </Intervention>
    <Primary_outcome>Efficacy of repetitive transcranial magnetic stimulation in spastic cerebral palsy childrenTimepoint: 3 years
    </Primary_outcome>
    <Secondary_outcome>Determination of optimum dose and duration of r-TMS for spastic CP patientsTimepoint: 3 years
    </Secondary_outcome>
    <Secondary_ID>NIL
    </Secondary_ID>
    <Source_Support>Department of Science and Technology, Government of India
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>18/04/2016
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Institutional Ethics Committee of Human Samples or Participants, North Eastern Hill University, Shillong
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>10258912
    </Internal_Number>
    <TrialID>NCT02840760
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia.
    </Public_title>
    <Scientific_title>Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia.
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Shanghai Mental Health Center
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20160719
    </Date_registration3>
    <Date_registration>19/07/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02840760
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>65 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 2016
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Dengtang Liu;Dengtang Liu, MD
    </Contact_Lastname>
    <Contact_Email>erliu110@126.com;erliu110@126.com
    </Contact_Email>
    <Contact_Tel>+86 21 64387250-73775;+862164387250-73775
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  The diagnosis of schizophrenia according to DSM-IV;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  At least two item of Abnormal Involuntary Movement Scale(AIMS) must be 2 points or&#x0D;&lt;br&gt;             higher&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  these symptoms are not from Parkinson,tourette's syndrome,huntington disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signed an informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  rTMS contraindications: intracranial metal substance, with heart pacemakers and&#x0D;&lt;br&gt;             cochlear implants, intracranial pressure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients to be diagnosed according to DSM-IV for substance abused, development delayed&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  current treatment with anticonvulsant acting drugs such as anticonvulsants,&#x0D;&lt;br&gt;             benzodiazepines&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Acute risk of suicide and impulse&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  history of epileptic seizures or the presence of epileptic activity documented on the&#x0D;&lt;br&gt;             basis of EEG&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  pregnant and lactant women&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tardive Dyskinesia
    </Condition>
    <Intervention>Device: Repetitive Transcranial Magnetic Stimulation
    </Intervention>
    <Primary_outcome>Change from baseline in motor evoked potential(MEP);Change from baseline in Abnormal Involuntary Movement Scale(AIMS)
    </Primary_outcome>
    <Secondary_outcome>Change from baseline in cortical silent period;Change from baseline in short interval intracortical inhibition(SICI);Change from baseline in intracortical facilitation(ICF);Change from baseline in Simpson-Angus Scale(SAS);Change from baseline in Barnes Akathisia Rating Scale(BARS);Change from baseline in Positive and Negative Syndrome Scale(PANSS);Change from baseline in clinical global impression (CGI)
    </Secondary_outcome>
    <Secondary_ID>15ZR1435600
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13152435
    </Internal_Number>
    <TrialID>NCT02734485
    </TrialID>
    <Last_Refreshed_on>3 July 2023
    </Last_Refreshed_on>
    <Public_title>Deep TMS for the Treatment of Patients With Parkinson's Disease and Progressive Supranuclear Palsy
    </Public_title>
    <Scientific_title>The Use of Deep TMS for the Treatment and Rehabilitation of Patients With Parkinson's Disease and Progressive Supranuclear Palsy
    </Scientific_title>
    <Acronym>DeepTMSPARK
    </Acronym>
    <Primary_sponsor>IRCCS San Raffaele Roma
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20160331
    </Date_registration3>
    <Date_registration>31/03/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02734485
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>30 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2013
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Supportive Care. Masking: Triple (Participant, Care Provider, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Italy
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Fabrizio Stocchi, MD, PHD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>IRCCS SAN RAFFAELE PISANA
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  outpatients with PSP according to NINDS-SPSP criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  contraindications for DTMS (history of seizures, pacemakers, or any other electric&#x0D;&lt;br&gt;             device)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Progressive Supranuclear Palsy;Parkinson's Disease
    </Condition>
    <Intervention>Device: active Deep TMS;Device: sham Deep TMS
    </Intervention>
    <Primary_outcome>Change in PSP rating scale total score between baseline evaluations (T0 orT2) and end of treatment (T1 or T3)
    </Primary_outcome>
    <Secondary_outcome>Change in MoCA total score between baseline evaluations (T0 orT2) and end of treatment (T1 or T3);Change in PDQ 39 total score between baseline evaluations (T0 orT2) and end of treatment (T1 or T3);Change in NMS total score between baseline evaluations (T0 orT2) and end of treatment (T1 or T3);Change in Hamilton rating scale for depression total score between baseline evaluations (T0 orT2) and end of treatment (T1 or T3)
    </Secondary_outcome>
    <Secondary_ID>RP 16/13
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13452032
    </Internal_Number>
    <TrialID>JPRN-UMIN000017888
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>Influence of repetitive transcranial magnetic stimulation of cerebral cortex on eye movement of Parkinson&amp;#39;s disease and syndrome
    </Public_title>
    <Scientific_title>Influence of repetitive transcranial magnetic stimulation of cerebral cortex on eye movement of Parkinson&amp;#39;s disease and syndrome - Influence of rTMS of brain on eye movement of Parkinson&amp;#39;s syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
    </Scientific_title>
    <Primary_sponsor>Osaka University ospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150612
    </Date_registration3>
    <Date_registration>12/06/2015
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020680
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20years-old
    </Inclusion_agemin>
    <Inclusion_agemax>Not applicable
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2015/06/12
    </Date_enrollement>
    <Target_size>5
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Single arm Non-randomized
    </Study_design>
    <Phase>Not selected
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname>Tomoo
    </Contact_Firstname>
    <Contact_Lastname>Mano
    </Contact_Lastname>
    <Contact_Address>Yamadaoka 2-2, Suita, Osaka
    </Contact_Address>
    <Contact_Email>mano@neuromod.med.osaka-u.ac.jp
    </Contact_Email>
    <Contact_Tel>06-6210-8435
    </Contact_Tel>
    <Contact_Affiliation>Osaka University Graduate School of Medicine Department of Neuromodulation and Neurosurgery
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1 cannot sit for an hour  2 cognitive disorder MMSE under 24 points  3 hallucination  4 astigmatism  5 narrowing of visual field  6 intake of drug which may induce Parkinsonism within 6 months  7 combination with other neuro-mascular diseases  8 past history of cerebro-vascular disease and infectious diseases of CNS  9 cerebral infarction in basal ganglia and brain stem with MRI  10 metal in the patient&amp;#39;s head without mouse  11 patients receiving pace maker and drug delivery pump  12 severe heart diseases  13 patients receiving DBS and SCS  14 cerebral infarction with stem arteries, brain tumors, traumatic brain injuries, epilepsy  15 pregnant and women who plan to be pregnant  16 patients who the doctors consider inappropriate
    </Exclusion_Criteria>
    <Condition>Parkinson&amp;#39;s disease and syndrome
    </Condition>
    <Intervention>repetitive transcranial magnetic stimulation of bilateral motor cortex
    </Intervention>
    <Primary_outcome>Evaluation of improvement of eye movements
    </Primary_outcome>
    <Source_Support>Japan Agency for Medical Research and Development
    </Source_Support>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>10/12/2014
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>shiken@hp-crc.med.osaka-u.ac.jp
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Osaka University Ethics Commitee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>06-6879-8290
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>shiken@hp-crc.med.osaka-u.ac.jp
    </Ethics_review_contact_email>
    <results_date_completed>31/12/2020
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>10238867
    </Internal_Number>
    <TrialID>NCT02356003
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Transcranial Magnetic Stimulation for Children With Tourette's Syndrome
    </Public_title>
    <Scientific_title>TICS: Transcranial Magnetic Stimulation for Children With Tourette's Syndrome
    </Scientific_title>
    <Acronym>TICS
    </Acronym>
    <Primary_sponsor>University of Calgary
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150131
    </Date_registration3>
    <Date_registration>31/01/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02356003
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>7 Years
    </Inclusion_agemin>
    <Inclusion_agemax>12 Years
    </Inclusion_agemax>
    <Inclusion_gender>Male
    </Inclusion_gender>
    <Date_enrollement>May 2015
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Canada
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Frank p MacMaster, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Calgary
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Males&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Right-handed&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Female&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Left-handed&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Comorbid Attention Deficit Hyperactivity Disorder&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tourette Syndrome
    </Condition>
    <Intervention>Device: Low frequency repetitive transcranial magnetic stimulation
    </Intervention>
    <Primary_outcome>Yale Global Tic Severity Scale
    </Primary_outcome>
    <Secondary_outcome>Glutamate Concentration;Functional Connectivity
    </Secondary_outcome>
    <Secondary_ID>REB14-1839
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>13/04/2020
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT02356003
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>10235695
    </Internal_Number>
    <TrialID>NCT02265315
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Augmenting Treatment Effects of Voice Therapy in Parkinson Disease
    </Public_title>
    <Scientific_title>Augmenting Treatment Effects of Voice Therapy in Parkinson Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Le Bonheur Children's Hospital
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20141009
    </Date_registration3>
    <Date_registration>09/10/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02265315
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>45 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 2014
    </Date_enrollement>
    <Target_size>70
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Shalini Narayana, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>LeBonheur Children's Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals with Idiopathic Parkinson's disease (IPD) between the ages of 45 and 80&#x0D;&lt;br&gt;             years with moderate to severe hypophonia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  None or mild cognitive impairment or depression&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Stable medication therapy for at least 3 months. Must be "optimally medicated" at the&#x0D;&lt;br&gt;             start of the study. This means that there should be no change in mediction type or&#x0D;&lt;br&gt;             dosage in 3 months prior to enrolling in the study. The medications should not be&#x0D;&lt;br&gt;             causing significant or serious advese effects&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of drug abuse or neurological condition other than or in addition to IPD (for&#x0D;&lt;br&gt;             example stroke)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals with advanced IPD (stage V) or who had LSVT within 3 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant females&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of seizures, history of major head trauma, metal objects implanted in the&#x0D;&lt;br&gt;             head, ferrous metal filings in the eye, brain damage, inflammation of the brain,&#x0D;&lt;br&gt;             cardiac pacemaker, implanted medication pump, cardiac lines, heart disease, currently&#x0D;&lt;br&gt;             taking certain types of medication for depression or seizures (tricyclic&#x0D;&lt;br&gt;             antidepressants or neuroleptics which lower seizure threshold&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: Transcranial Magnetic Stimulation;Behavioral: Lee Silverman Voice Treatment
    </Intervention>
    <Primary_outcome>Clinical assessment:;Patient assessment:;Physiological assessment:
    </Primary_outcome>
    <Secondary_outcome>Clinical assessment;Patient self-assessment
    </Secondary_outcome>
    <Secondary_ID>14-03265-FB UM
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Michael J. Fox Foundation for Parkinson's Research;University of Tennessee Health Science Center;University of Memphis
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>4761358
    </Internal_Number>
    <TrialID>NCT02249715
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Development of a Monitoring Set-up and Algorithm Using Functional MRI (fMRI) and EEG for Prediction of Response to Repetitive Deep Transcranial Magnetic Stimulation (rDTMS) for Patients With Parkinson's Disease
    </Public_title>
    <Scientific_title>Pilot Study for Development of a Monitoring Set-up and Algorithm Using Functional MRI (fMRI) and EEG for Prediction of Response to Repetitive Deep Transcranial Magnetic Stimulation (rDTMS) for Patients With Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Sheba Medical Center
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140923
    </Date_registration3>
    <Date_registration>23/09/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT02249715
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>November 2014
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>N/A
    </Phase>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Oren Cohen, M.D
    </Contact_Lastname>
    <Contact_Email>Oren.Cohen@sheba.health.gov.il
    </Contact_Email>
    <Contact_Tel>972-3-5305296
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Idiopathic PD patients aged 40-75 years;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Hoehn and Yahr stages II to IV&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patients on stable antiparkinsonian therapy for 1 month&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Right hand dominance with right afflicted side.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Participation in current clinical study or clinical study within 30 days prior to&#x0D;&lt;br&gt;             this study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subject has an atypical parkinsonian syndrome or secondary parkinsonism (e.g., due to&#x0D;&lt;br&gt;             drugs, metabolic neurogenetic disorders, encephalitis, cerebrovascular disease or&#x0D;&lt;br&gt;             other degenerative disease)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Patients with significant psychiatric symptoms or history.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Patients with psychotic symptoms or active depressive symptoms&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Treatment with neuroleptics.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Beck depression inventory (BDI) score &lt;14&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Mini Mental status examination (MMSE) score &lt;25&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. History of migraine or frequent or severe headaches.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Significant sensory deficits, e.g., deafness or blindness History of head injury or&#x0D;&lt;br&gt;             neurosurgical interventions.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Subjects who have concomitant epilepsy, a history of seizure/s, heat convulsions or&#x0D;&lt;br&gt;             history of epilepsy in first degree relative.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. History of any metal in the head (outside the mouth).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         12. The presence of cochlear implants&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         13. Known history of any metallic particles in the eye, implanted cardiac pacemaker,&#x0D;&lt;br&gt;             implanted neurostimulators, surgical clips (above the shoulder line) or any medical&#x0D;&lt;br&gt;             pumps.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         14. Subjects with an unstable medical disorder.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         15. Current drug abuse (including Cannabis) or alcoholism.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         16. Pregnancy or not using a reliable method of birth control.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         17. Patients with severe tremor or dyskinesia&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson
    </Condition>
    <Intervention>Device: Brainsway Multiway deep TMS device (two channels)
    </Intervention>
    <Primary_outcome>Unified Parkinson's Disease Rating Scale (UPDRS)
    </Primary_outcome>
    <Secondary_ID>SHEBA-1293-14-OC-CTIL
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Brainsway;ElMindA Ltd
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>12088481
    </Internal_Number>
    <TrialID>NCT02236832
    </TrialID>
    <Last_Refreshed_on>4 April 2022
    </Last_Refreshed_on>
    <Public_title>Study of the Neural Basis of Analogical Reasoning
    </Public_title>
    <Scientific_title>Organisation du Cortex préfrontal ventrolatéral Pour l'Analogie: Approche Bimodale Chez le Sujet Sain et Chez le Patient Ayant un Syndrome Frontal.
    </Scientific_title>
    <Acronym>ANALOG
    </Acronym>
    <Primary_sponsor>Institut National de la Santé Et de la Recherche Médicale, France
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140828
    </Date_registration3>
    <Date_registration>28/08/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02236832
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 2015
    </Date_enrollement>
    <Target_size>130
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Non-Randomized. Intervention model: Crossover Assignment. Primary purpose: Basic Science. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>France
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Richard Levy, MD, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Institut du Cerveau et de la Moelle épinière, Paris
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Healthy subjects:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  subject affiliated to national health insurance&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  informed consent signed&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  normal neurological examination&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  subject aged at least 20&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Patients:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  FTD or PSP diagnostic criteria filled&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patient affiliated to national health insurance&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  informed consent signed&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe psychiatric symptomatology and psychotropic drug use&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  unability to understand or perform the cognitive tasks.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Frontotemporal Dementia;Progressive Supranuclear Palsy;Healthy Subjects
    </Condition>
    <Intervention>Device: transcranial magnetic stimulation;Other: MRI imaging;Other: EEG recording;Behavioral: Neuropsychological examination
    </Intervention>
    <Primary_outcome>Performance in the implicat task;Performance in the Similitude task
    </Primary_outcome>
    <Secondary_outcome>recording of EEG;Analysis of MRI
    </Secondary_outcome>
    <Secondary_ID>140662B-31;2014-A00649-38;C14-17'
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Fondation pour la Recherche Médicale
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>6634771
    </Internal_Number>
    <TrialID>NCT02057276
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Repetitive TMS and Occupational Therapy in Children and Young Adults With Chronic Hemiparesis
    </Public_title>
    <Scientific_title>Motor Control Enhancement Through Repetitive Transcranial Magnetic Stimulation Plus Rehabilitation in Hemiparetic Cerebral Palsy and Stroke
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Children's Hospital Medical Center, Cincinnati
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20130605
    </Date_registration3>
    <Date_registration>05/06/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02057276
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>10 Years
    </Inclusion_agemin>
    <Inclusion_agemax>20 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 2012
    </Date_enrollement>
    <Target_size>2
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States;United States;United States;United States;United States
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Steve W Wu, MD;Steve W Wu, MD;Steve W Wu, MD;Steve W Wu, MD;Steve W Wu, MD
    </Contact_Lastname>
    <Contact_Email>;;;;
    </Contact_Email>
    <Contact_Tel>;;;;
    </Contact_Tel>
    <Contact_Affiliation>Children's Hospital Medical Center, Cincinnati;Children's Hospital Medical Center, Cincinnati;Children's Hospital Medical Center, Cincinnati;Children's Hospital Medical Center, Cincinnati;Children's Hospital Medical Center, Cincinnati
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age = 10 years; &lt; 21 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hemiparesis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Manual Ability Classification System (MACS) level I through IV&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Provision of written informed consent by the patient and/or guardian, including&#x0D;&lt;br&gt;             understanding that insurance may be billed for the occupational therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written assent form signed by participants younger than 18 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Underlying degenerative or metabolic disorder or supervening medical illness&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe depression or other psychiatric disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any participant who is pregnant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any contraindication to TMS (i.e., intracranial metal implants, shunts, ports,&#x0D;&lt;br&gt;             pacemaker, baclofen pumps)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any changes or addition of neuropsychiatric medications within 1 month of starting the&#x0D;&lt;br&gt;             study or during course of the study (if applicable)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any botulinum toxin (Botox, Myobloc) or phenol injection within the last 3 months&#x0D;&lt;br&gt;             prior to the study or during the course of the study (if applicable)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any upper extremity surgery within the last 6 months prior to the study or scheduled&#x0D;&lt;br&gt;             during the course of the study (if applicable)&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age = 10 years; &lt; 21 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hemiparesis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Manual Ability Classification System (MACS) level I through IV&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Provision of written informed consent by the patient and/or guardian, including&#x0D;&lt;br&gt;             understanding that insurance may be billed for the occupational therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written assent form signed by participants younger than 18 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Underlying degenerative or metabolic disorder or supervening medical illness&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe depression or other psychiatric disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any participant who is pregnant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any contraindication to TMS (i.e., intracranial metal implants, shunts, ports,&#x0D;&lt;br&gt;             pacemaker, baclofen pumps)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any changes or addition of neuropsychiatric medications within 1 month of starting the&#x0D;&lt;br&gt;             study or during course of the study (if applicable)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any botulinum toxin (Botox, Myobloc) or phenol injection within the last 3 months&#x0D;&lt;br&gt;             prior to the study or during the course of the study (if applicable)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any upper extremity surgery within the last 6 months prior to the study or scheduled&#x0D;&lt;br&gt;             during the course of the study (if applicable)&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age = 10 years; &lt; 21 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hemiparesis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Manual Ability Classification System (MACS) level I through IV&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Provision of written informed consent by the patient and/or guardian, including&#x0D;&lt;br&gt;             understanding that insurance may be billed for the occupational therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written assent form signed by participants younger than 18 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Underlying degenerative or metabolic disorder or supervening medical illness&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe depression or other psychiatric disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any participant who is pregnant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any contraindication to TMS (i.e., intracranial metal implants, shunts, ports,&#x0D;&lt;br&gt;             pacemaker, baclofen pumps)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any changes or addition of neuropsychiatric medications within 1 month of starting the&#x0D;&lt;br&gt;             study or during course of the study (if applicable)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any botulinum toxin (Botox, Myobloc) or phenol injection within the last 3 months&#x0D;&lt;br&gt;             prior to the study or during the course of the study (if applicable)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any upper extremity surgery within the last 6 months prior to the study or scheduled&#x0D;&lt;br&gt;             during the course of the study (if applicable)&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age = 10 years; &lt; 21 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hemiparesis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Manual Ability Classification System (MACS) level I through IV&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Provision of written informed consent by the patient and/or guardian, including&#x0D;&lt;br&gt;             understanding that insurance may be billed for the occupational therapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Written assent form signed by participants younger than 18 years of age&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Underlying degenerative or metabolic disorder or supervening medical illness&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe depression or other psychiatric disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any participant who is pregnant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any contraindication to TMS (i.e., intracranial metal implants, shunts, ports,&#x0D;&lt;br&gt;             pacemaker, baclofen pumps)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any changes or addition of neuropsychiatric medications within 1 month of starting the&#x0D;&lt;br&gt;             study or during course of the study (if applicable)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any botulinum toxin (Botox, Myobloc) or phenol injection within the last 3 months&#x0D;&lt;br&gt;             prior to the study or during the course of the study (if applicable)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any upper extremity surgery within the last 6 months prior to the study or scheduled&#x0D;&lt;br&gt;             during the course of the study (if applicable)&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Pediatric Stroke;Cerebral Palsy;Chronic Hemiparesis;Pediatric Stroke;Cerebral Palsy;Chronic Hemiparesis;Pediatric Stroke;Cerebral Palsy;Chronic Hemiparesis;Pediatric Stroke;Cerebral Palsy;Chronic Hemiparesis
    </Condition>
    <Intervention>Device: Repetitive Transcranial Magnetic Stimulation;Device: Sham Repetitive Transcranial Magnetic Stimulation;Other: Occupational Therapy;Device: Repetitive Transcranial Magnetic Stimulation;Device: Sham Repetitive Transcranial Magnetic Stimulation;Other: Occupational Therapy;Device: Repetitive Transcranial Magnetic Stimulation;Device: Sham Repetitive Transcranial Magnetic Stimulation;Other: Occupational Therapy;Device: Repetitive Transcranial Magnetic Stimulation;Device: Sham Repetitive Transcranial Magnetic Stimulation;Other: Occupational Therapy
    </Intervention>
    <Primary_outcome>Change in the "Melbourne Assessment of Unilateral Upper Limb Function";Change in the "Melbourne Assessment of Unilateral Upper Limb Function";Change in the "Melbourne Assessment of Unilateral Upper Limb Function"
    </Primary_outcome>
    <Secondary_ID>2012-1533;CIN001 - rTMS/hemiparesis
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>03/08/2015
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT02057276
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13444697
    </Internal_Number>
    <TrialID>JPRN-UMIN000010539
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>Low frequency repetitive transcranial magnetic stimulation in the treatment of svere Tourette&amp;#39;s syndrome
    </Public_title>
    <Scientific_title>Low frequency repetitive transcranial magnetic stimulation in the treatment of svere Tourette&amp;#39;s syndrome - rTMS therapy for Tourette&amp;#39;s syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>Hokkaido University Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20130501
    </Date_registration3>
    <Date_registration>01/05/2013
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012322
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15years-old
    </Inclusion_agemin>
    <Inclusion_agemax>Not applicable
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2013/05/01
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Single arm Non-randomized
    </Study_design>
    <Phase>Not applicable
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname>Hideaki
    </Contact_Firstname>
    <Contact_Lastname>Shiraishi
    </Contact_Lastname>
    <Contact_Address>North 15, West 7, Kita-ku, Sapporo, Japan
    </Contact_Address>
    <Contact_Email>siraisi@med.hokudai.ac.jp
    </Contact_Email>
    <Contact_Tel>011-706-5954
    </Contact_Tel>
    <Contact_Affiliation>Hokkaido University Graduate School of Medicine Department of Pediatrics
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients with psychiatric disease  Patients with intracranial magnetic particles  Patients with cardiac pacemaker or vagas nerve stimulation  Patients with epilepsy  Pregnant patients  Patients with acoustic duct
    </Exclusion_Criteria>
    <Condition>Tourette&amp;#39;s syndrome
    </Condition>
    <Intervention>low frequency transcranial magnetic stimulation
    </Intervention>
    <Primary_outcome>Yale Global Tic Severity Scale (YGTSS)
    </Primary_outcome>
    <Secondary_outcome>Hamilton Depression Rating Scale  Hamilton Anxiety Rating Scale  Social-Adaptation Self-evaluation Scale
    </Secondary_outcome>
    <Source_Support>Hokkaido University Graduate School of Medicine
    </Source_Support>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>11/03/2013
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>recjimu@huhp.hokudai.ac.jp
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Hokkaido University Clinical Research Review
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>011-706-7934
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>recjimu@huhp.hokudai.ac.jp
    </Ethics_review_contact_email>
    <results_date_completed>31/03/2019
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>8758203
    </Internal_Number>
    <TrialID>ACTRN12612000119897
    </TrialID>
    <Last_Refreshed_on>13 January 2020
    </Last_Refreshed_on>
    <Public_title>Transcranial Magnetic Stimulation in Progressive Supranuclear Palsy diagnosis: a longitudinal study.
    </Public_title>
    <Scientific_title>Transcranial Magnetic Stimulation in Progressive Supranuclear Palsy diagnosis: a longitudinal study.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
    </Scientific_title>
    <Primary_sponsor>A/Prof David Williams
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20120124
    </Date_registration3>
    <Date_registration>24/01/2012
    </Date_registration>
    <Source_Register>ANZCTR
    </Source_Register>
    <web_address>https://anzctr.org.au/ACTRN12612000119897.aspx
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>No limit
    </Inclusion_agemax>
    <Inclusion_gender>Both males and females
    </Inclusion_gender>
    <Date_enrollement>03/05/2012
    </Date_enrollement>
    <Target_size>65
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design>Purpose: Natural history;Duration: Longitudinal;Selection: Defined population;Timing: Prospective;
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Australia
    </Countries>
    <Inclusion_Criteria>Inclusion criteria: Four groups to be recruited:&#x0D;&lt;br&gt;1. 20 People with Progressive Supranuclear Palsy as defined by National Institute of Neurological Diseases and Stroke criteria&#x0D;&lt;br&gt;2. 10 People with "probable" or "possible" Multiple System Atrophy according to published consensus criteria&#x0D;&lt;br&gt;3. 10 People with Parkinson's Disease according to Queens Square Brain Bank criteria&#x0D;&lt;br&gt;4. 10 normal controls
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1.People with epilepsy&#x0D;&lt;br&gt;2.People with intracranial metal whith may increase the risk of seizures or injury due to Transcranial Magnetic Stimulation&#x0D;&lt;br&gt;3. People not able to complete clinical rating scales including cognitive assessment at baseline&#x0D;&lt;br&gt;4. Patients deemed not cabable of consenting to involvement in the study and for whom an appropriate person responsible is not available to participate in the consenting process
    </Exclusion_Criteria>
    <Condition>PROGRESSIVE SUPRANUCLEAR PALSY;MULTIPLE SYSTEM ATROPHY;PARKINSON'S DISEASE; &lt;br&gt;PROGRESSIVE SUPRANUCLEAR PALSY &lt;br&gt;MULTIPLE SYSTEM ATROPHY &lt;br&gt;PARKINSON'S DISEASE;Neurological - Neurodegenerative diseases;Neurological - Parkinson's disease
    </Condition>
    <Intervention>Transcranial Magnetic Stimulation (TMS)&lt;br&gt;TMS will be performed on each participant at each 6 month reveiw period. This will include measures of intracortical inhibition and facilitation, resting motor thresholds and motor evoked potentials before and after theta burst stimulation. The TMS protocol is expected to take 2-3 hours each session, and will be conducted on 5 occasions for each participant, separated by 6 months each time, for a total study duration of 2 years.
    </Intervention>
    <Primary_outcome>1. Do measured responses in short interval cortical inhibition to theta burst stimulation correlate with clinical features as measured by physical and cognitive rating scales in Progressive Supranuclear Palsy.[Measured 6 monthly for 2 years]
    </Primary_outcome>
    <Secondary_outcome>2. Do Transcranial Magnetic Stimulation parameters distinguish between parkinsonian syndromes, ie. Progressive Supranuclear Palsy, Multiple System Atrophy and Parkinson's Disease.[Measured 6 monthly for 2 years]
    </Secondary_outcome>
    <Secondary_ID>nil
    </Secondary_ID>
    <Source_Support>Monash University
    </Source_Support>
    <Secondary_Sponsor>Alfred Hospital
    </Secondary_Sponsor>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>THE ALFRED HUMAN ETHICS COMMITTEE
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>6499323
    </Internal_Number>
    <TrialID>NCT01258790
    </TrialID>
    <Last_Refreshed_on>19 October 2017
    </Last_Refreshed_on>
    <Public_title>Repetitive Transcranial Magnetic Stimulation to Reduce Tics
    </Public_title>
    <Scientific_title>Using Transcranial Magnetic Stimulation to Reduce Tics
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Children's Hospital Medical Center, Cincinnati
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20101210
    </Date_registration3>
    <Date_registration>10/12/2010
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01258790
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>10 Years
    </Inclusion_agemin>
    <Inclusion_agemax>60 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 2010
    </Date_enrollement>
    <Target_size>12
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design/>
    <Phase>N/A
    </Phase>
    <Countries>United States;United States;United States;United States
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Steve Wu, MD;Steve Wu, MD;Steve Wu, MD;Steve Wu, MD
    </Contact_Lastname>
    <Contact_Email>;;;
    </Contact_Email>
    <Contact_Tel>;;;
    </Contact_Tel>
    <Contact_Affiliation>Cincinnati Children's;Cincinnati Children's;Cincinnati Children's;Cincinnati Children's
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:1. Children or adults with Tourette Syndrome, tic disorder, chronic&#x0D;&lt;br&gt;        motor or vocal tics disorder ages 10 to 60 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        2. Current tics with Yale Global Tic Severity Scale (YGTSS) score &gt; 10. 3. If subject is on&#x0D;&lt;br&gt;        tic-suppressing medication(s) at the time of recruitment, no medication or dose changes&#x0D;&lt;br&gt;        allowed within the past seven days.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        4. If subject receives botulinum toxin injection for tic management, the injection must be&#x0D;&lt;br&gt;        at least twelve weeks prior to the day of the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        5. After the TBS sessions, no tic-suppression medications can be changed for at least one&#x0D;&lt;br&gt;        week.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        6. All patients ages 10 to 60 years old with Tourette Syndrome, tic disorder, chronic motor&#x0D;&lt;br&gt;        or vocal tics disorder will be offered to participate in the study. If the patient decides&#x0D;&lt;br&gt;        to participate in the study, our study coordinator will obtain informed consent from the&#x0D;&lt;br&gt;        adult participant, or at least one parent of the pediatric participant. The consent form is&#x0D;&lt;br&gt;        written in English; the form is also written in a manner understandable by the person&#x0D;&lt;br&gt;        signing the form. The adult participant, the parent(s) of participant or the pediatric&#x0D;&lt;br&gt;        participant does not have to make a decision at the time of clinic visit, thus, minimizing&#x0D;&lt;br&gt;        coercion to participate.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:1. Implanted brain stimulator, vagal nerve stimulator, VP shunt,&#x0D;&lt;br&gt;        aneurysm clip, cardiac pacemaker, or implanted medication port.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        2. Prior ischemic or hemorrhagic stroke or traumatic brain injury. 3. History of seizure or&#x0D;&lt;br&gt;        epilepsy 4. If female, pregnant or sexually active and not using birth control. Abstinence&#x0D;&lt;br&gt;        will be permitted at the discretion of the TS clinicians, consistent with other IRB&#x0D;&lt;br&gt;        approved studies involving this population.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:1. Children or adults with Tourette Syndrome, tic disorder, chronic&#x0D;&lt;br&gt;        motor or vocal tics disorder ages 10 to 60 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        2. Current tics with Yale Global Tic Severity Scale (YGTSS) score &gt; 10. 3. If subject is on&#x0D;&lt;br&gt;        tic-suppressing medication(s) at the time of recruitment, no medication or dose changes&#x0D;&lt;br&gt;        allowed within the past seven days.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        4. If subject receives botulinum toxin injection for tic management, the injection must be&#x0D;&lt;br&gt;        at least twelve weeks prior to the day of the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        5. After the TBS sessions, no tic-suppression medications can be changed for at least one&#x0D;&lt;br&gt;        week.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        6. All patients ages 10 to 60 years old with Tourette Syndrome, tic disorder, chronic motor&#x0D;&lt;br&gt;        or vocal tics disorder will be offered to participate in the study. If the patient decides&#x0D;&lt;br&gt;        to participate in the study, our study coordinator will obtain informed consent from the&#x0D;&lt;br&gt;        adult participant, or at least one parent of the pediatric participant. The consent form is&#x0D;&lt;br&gt;        written in English; the form is also written in a manner understandable by the person&#x0D;&lt;br&gt;        signing the form. The adult participant, the parent(s) of participant or the pediatric&#x0D;&lt;br&gt;        participant does not have to make a decision at the time of clinic visit, thus, minimizing&#x0D;&lt;br&gt;        coercion to participate.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:1. Implanted brain stimulator, vagal nerve stimulator, VP shunt,&#x0D;&lt;br&gt;        aneurysm clip, cardiac pacemaker, or implanted medication port.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        2. Prior ischemic or hemorrhagic stroke or traumatic brain injury. 3. History of seizure or&#x0D;&lt;br&gt;        epilepsy 4. If female, pregnant or sexually active and not using birth control. Abstinence&#x0D;&lt;br&gt;        will be permitted at the discretion of the TS clinicians, consistent with other IRB&#x0D;&lt;br&gt;        approved studies involving this population.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:1. Children or adults with Tourette Syndrome, tic disorder, chronic&#x0D;&lt;br&gt;        motor or vocal tics disorder ages 10 to 60 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        2. Current tics with Yale Global Tic Severity Scale (YGTSS) score &gt; 10. 3. If subject is on&#x0D;&lt;br&gt;        tic-suppressing medication(s) at the time of recruitment, no medication or dose changes&#x0D;&lt;br&gt;        allowed within the past seven days.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        4. If subject receives botulinum toxin injection for tic management, the injection must be&#x0D;&lt;br&gt;        at least twelve weeks prior to the day of the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        5. After the TBS sessions, no tic-suppression medications can be changed for at least one&#x0D;&lt;br&gt;        week.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        6. All patients ages 10 to 60 years old with Tourette Syndrome, tic disorder, chronic motor&#x0D;&lt;br&gt;        or vocal tics disorder will be offered to participate in the study. If the patient decides&#x0D;&lt;br&gt;        to participate in the study, our study coordinator will obtain informed consent from the&#x0D;&lt;br&gt;        adult participant, or at least one parent of the pediatric participant. The consent form is&#x0D;&lt;br&gt;        written in English; the form is also written in a manner understandable by the person&#x0D;&lt;br&gt;        signing the form. The adult participant, the parent(s) of participant or the pediatric&#x0D;&lt;br&gt;        participant does not have to make a decision at the time of clinic visit, thus, minimizing&#x0D;&lt;br&gt;        coercion to participate.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:1. Implanted brain stimulator, vagal nerve stimulator, VP shunt,&#x0D;&lt;br&gt;        aneurysm clip, cardiac pacemaker, or implanted medication port.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        2. Prior ischemic or hemorrhagic stroke or traumatic brain injury. 3. History of seizure or&#x0D;&lt;br&gt;        epilepsy 4. If female, pregnant or sexually active and not using birth control. Abstinence&#x0D;&lt;br&gt;        will be permitted at the discretion of the TS clinicians, consistent with other IRB&#x0D;&lt;br&gt;        approved studies involving this population.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:1. Children or adults with Tourette Syndrome, tic disorder, chronic&#x0D;&lt;br&gt;        motor or vocal tics disorder ages 10 to 60 years.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        2. Current tics with Yale Global Tic Severity Scale (YGTSS) score &gt; 10. 3. If subject is on&#x0D;&lt;br&gt;        tic-suppressing medication(s) at the time of recruitment, no medication or dose changes&#x0D;&lt;br&gt;        allowed within the past seven days.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        4. If subject receives botulinum toxin injection for tic management, the injection must be&#x0D;&lt;br&gt;        at least twelve weeks prior to the day of the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        5. After the TBS sessions, no tic-suppression medications can be changed for at least one&#x0D;&lt;br&gt;        week.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        6. All patients ages 10 to 60 years old with Tourette Syndrome, tic disorder, chronic motor&#x0D;&lt;br&gt;        or vocal tics disorder will be offered to participate in the study. If the patient decides&#x0D;&lt;br&gt;        to participate in the study, our study coordinator will obtain informed consent from the&#x0D;&lt;br&gt;        adult participant, or at least one parent of the pediatric participant. The consent form is&#x0D;&lt;br&gt;        written in English; the form is also written in a manner understandable by the person&#x0D;&lt;br&gt;        signing the form. The adult participant, the parent(s) of participant or the pediatric&#x0D;&lt;br&gt;        participant does not have to make a decision at the time of clinic visit, thus, minimizing&#x0D;&lt;br&gt;        coercion to participate.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:1. Implanted brain stimulator, vagal nerve stimulator, VP shunt,&#x0D;&lt;br&gt;        aneurysm clip, cardiac pacemaker, or implanted medication port.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        2. Prior ischemic or hemorrhagic stroke or traumatic brain injury. 3. History of seizure or&#x0D;&lt;br&gt;        epilepsy 4. If female, pregnant or sexually active and not using birth control. Abstinence&#x0D;&lt;br&gt;        will be permitted at the discretion of the TS clinicians, consistent with other IRB&#x0D;&lt;br&gt;        approved studies involving this population.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tourette Syndrome;Tourette Syndrome;Tourette Syndrome;Tourette Syndrome
    </Condition>
    <Intervention>Device: Sham Repetitive Transcranial Magnetic Stimulation;Device: Active Repetitive Transcranial Magnetic Stimulation;Device: Sham Repetitive Transcranial Magnetic Stimulation;Device: Active Repetitive Transcranial Magnetic Stimulation;Device: Sham Repetitive Transcranial Magnetic Stimulation;Device: Active Repetitive Transcranial Magnetic Stimulation;Device: Sham Repetitive Transcranial Magnetic Stimulation;Device: Active Repetitive Transcranial Magnetic Stimulation
    </Intervention>
    <Primary_outcome>Yale Global Tic Severity Scale;Yale Global Tic Severity Scale
    </Primary_outcome>
    <Secondary_ID>IRB #: 2010-2689
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>01/07/2014
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT01258790
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>4680209
    </Internal_Number>
    <TrialID>NCT01189058
    </TrialID>
    <Last_Refreshed_on>19 February 2015
    </Last_Refreshed_on>
    <Public_title>Modulation of Brain Plasticity After Perinatal Stroke
    </Public_title>
    <Scientific_title>Modulation of Brain Plasticity After Perinatal Stroke: The PLASTIC CHAMPS Trial
    </Scientific_title>
    <Acronym>PLASTIC CHAMPS
    </Acronym>
    <Primary_sponsor>University of Calgary
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20100820
    </Date_registration3>
    <Date_registration>20/08/2010
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT01189058
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Years
    </Inclusion_agemin>
    <Inclusion_agemax>18 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>August 2010
    </Date_enrollement>
    <Target_size>64
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>Canada
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Adam Kirton, MD MSc FRCPC
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Calgary
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Symptomatic hemiplegic CP with impairment(s) of the upper extremity including the&#x0D;&lt;br&gt;             hand (Pediatric Stroke Outcome Measure motor &gt;0.5; AND Manual Ability Classification&#x0D;&lt;br&gt;             System I, II,III, or IV; AND both child and parent perceive functional limitations&#x0D;&lt;br&gt;             (able to identify personally meaningful deficits in function).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. MRI confirmed AIS-MCA or PVI (neuroradiological syndrome classified by two blinded,&#x0D;&lt;br&gt;             experienced investigators according to previously validated methods)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Age at enrollment: 6-18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Resident in province of Alberta for period of study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Informed consent/assent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Multifocal perinatal stroke or other brain injury/abnormality&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Severe hemiparesis (no voluntary contraction in paretic hand, MACS level V)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Intellectual disability causing an inability to comply with study protocol&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Unstable epilepsy (&gt;1 seizure/month or &gt;2 medication changes (dose or agent) in the&#x0D;&lt;br&gt;             last 6 months or history of recurrent status epilepticus)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Any TMS contraindication including implanted electronic devices&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Botulinum toxin A injection in the affected upper extremity within the preceding 6&#x0D;&lt;br&gt;             months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Orthopedic surgery in the affected upper extremity in the previous 12 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Unwilling to delay any new therapeutic rehabilitational intervention directed towards&#x0D;&lt;br&gt;             upper limb function (aside from study home program) for the 6 month duration of the&#x0D;&lt;br&gt;             study&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Stroke;Cerebral Palsy
    </Condition>
    <Intervention>Procedure: Repetitive Transcranial Magnetic Stimulation (rTMS);Procedure: Constraint-induced movement therapy (CIMT)
    </Intervention>
    <Primary_outcome>Canadian Occupational Performance Measure (COPM).;Canadian Occupational Performance Measure (COPM);Canadian Occupational Performance Measure (COPM);Canadian Occupational Performance Measure (COPM)
    </Primary_outcome>
    <Secondary_outcome>PedsQL Cerebral Palsy Module version 3.0 Young child report (ages 5-7), Child report (ages 8-12), Teen report (ages 8-12);PedsQL Cerebral Palsy Module version 3.0 Young child report (ages 5-7), Child report (ages 8-12), Teen report (ages 8-12);PedsQL Cerebral Palsy Module version 3.0 Young child report (ages 5-7), Child report (ages 8-12), Teen report (ages 8-12);PedsQL Cerebral Palsy Module version 3.0 Young child report (ages 5-7), Child report (ages 8-12), Teen report (ages 8-12);Pediatric Stroke Outcome Measure Short Neuro Exam Child Version (&gt;2 years)(PSOM);PedsQL Cerebral Palsy Module version 3.0 Parent Report for young child(ages 5-7), Parent Report for Child(ages 8-12), Parent report for teen(ages 8-12);PedsQL Cerebral Palsy Module version 3.0 Parent Report for young child(ages 5-7), Parent Report for Child(ages 8-12), Parent report for teen(ages 8-12);PedsQL Cerebral Palsy Module version 3.0 Parent Report for young child(ages 5-7), Parent Report for Child(ages 8-12), Parent report for teen(ages 8-12);PedsQL Cerebral Palsy Module version 3.0 Parent Report for young child(ages 5-7), Parent Report for Child(ages 8-12), Parent report for teen(ages 8-12);SHUEE (Shriners Hospital Upper Extremity Evaluation);SHUEE (Shriners Hospital Upper Extremity Evaluation);SHUEE (Shriners Hospital Upper Extremity Evaluation);SHUEE (Shriners Hospital Upper Extremity Evaluation);Box and Blocks Test;Box and Blocks Test;Box and Blocks Test;Box and Blocks Test;TMS Tolerability Measure;TMS Tolerability Measure;TMS Tolerability Measure;TMS Tolerability Measure;Grip and Pinch Strength Measures (GS, PS);Grip and Pinch Strength Measures (GS, PS);Grip and Pinch Strength Measures (GS, PS);Grip and Pinch Strength Measures (GS, PS);Assisting Hand Assessment (AHA);Assisting Hand Assessment (AHA);Assisting Hand Assessment (AHA);Assisting Hand Assessment (AHA);Melbourne Assessment of Unilateral Upper Limb Function (MAUULF);Melbourne Assessment of Unilateral Upper Limb Function (MAUULF);Melbourne Assessment of Unilateral Upper Limb Function (MAUULF);Melbourne Assessment of Unilateral Upper Limb Function (MAUULF);ABILHAND-Kids -Manual ability measure;ABILHAND-Kids -Manual ability measure;ABILHAND-Kids -Manual ability measure;ABILHAND-Kids -Manual ability measure;The Revised Pediatric Motor Activity Log and the Tween Motor Activity Log (PMAL / TMAL);The Revised Pediatric Motor Activity Log and the Tween Motor Activity Log (PMAL / TMAL);The Revised Pediatric Motor Activity Log and the Tween Motor Activity Log (PMAL / TMAL);The Revised Pediatric Motor Activity Log and the Tween Motor Activity Log (PMAL / TMAL);Biometrics Data Sheet;Paediatric Stroke Outcome Measure Short Neuro Exam (PSOM-SNE)-Child Version (Children Aged 2yrs and Older);Home Program Log;Home Program Log;Home Program Log;Camp Evaluation Form
    </Secondary_outcome>
    <Secondary_ID>22163
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Heart and Stroke Foundation of Canada;University of Alberta
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>6495149
    </Internal_Number>
    <TrialID>NCT00977184
    </TrialID>
    <Last_Refreshed_on>19 October 2017
    </Last_Refreshed_on>
    <Public_title>50 Hz Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Parkinson's Disease
    </Public_title>
    <Scientific_title>Controlled Study of 50 Hz Repetitive Transcranial Magnetic Stimulation for the Treatment of Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20090912
    </Date_registration3>
    <Date_registration>12/09/2009
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00977184
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 2009
    </Date_enrollement>
    <Target_size>26
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design/>
    <Phase>Phase 1/Phase 2
    </Phase>
    <Countries>United States;United States;United States;United States
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        -  INCLUSION CRITERIA:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Men and women aged 40 to 80 years with DOPA-responsive PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Hoehn and Yahr grade of 2 to 4 while off&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Must be on a regimen including levodopa&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Total dose of levodopa and dopamine agonists (using dopamine equivalents) has to be equal&#x0D;&lt;br&gt;        to or more than 300 milligrams per day&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        problems with walking and gait time for a 10-meter distance greater than six seconds or&#x0D;&lt;br&gt;        more&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        EXCLUSION CRITERIA:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Any active psychiatric disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        History of seizures and epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Concurrent use of tricyclic antidepressants, neuroleptic agents, or any other licit or&#x0D;&lt;br&gt;        illicit drugs other than anti-parkinsonian agents that could lower the seizure threshold&#x0D;&lt;br&gt;        except for SSRI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Pallidotomy, implanted electrodes and generator for deep brain stimulation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Surgically or traumatically implanted foreign bodies such as a pacemaker, implanted medical&#x0D;&lt;br&gt;        pump, implanted hearing aids, metal plate in the skull, or metal implant in the skull or&#x0D;&lt;br&gt;        eyes (other than dental appliances or fillings) that may pose a physical hazard during TEP.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Study would cause undue risk or stress for reasons such as tendency to fall, excessive&#x0D;&lt;br&gt;        fatigue, general frailty, or excessive apprehensiveness.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Dementia as assessed by the Folstein's Mini-Mental Test Examination (MMSE less than or&#x0D;&lt;br&gt;        equal to 24/30) or mentally impaired patients having no capacity to provide their own&#x0D;&lt;br&gt;        consent (the physician establishing the diagnosis and applying UPDRS will evaluate&#x0D;&lt;br&gt;        patient's mental capacity using conventional clinical interview)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Unable to walk a 10-meter distance.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        More than occasional falls, i.e. daily falls (corresponding to a score greater than or&#x0D;&lt;br&gt;        equal to 3 and more in UPDRS item 13), history of fall(s) with significant injuries,&#x0D;&lt;br&gt;        absence of postural response in the on and/or spontaneous loss of balance in the off&#x0D;&lt;br&gt;        condition (corresponding to a score of greater than or equal to 2 and greater than or equal&#x0D;&lt;br&gt;        to 3 in on/off condition, respectively, in UPDRS item 30)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Pregnancy is unusual in patients with PD, grade 2-4. Urine sample for the pregnancy test&#x0D;&lt;br&gt;        will be obtained in patients of childbearing potential prior to starting the 50 Hz rTMS and&#x0D;&lt;br&gt;        also at the initial interview after signing the consent form. Women of childbearing&#x0D;&lt;br&gt;        potential will be asked to take appropriate measures to prevent a pregnancy during the&#x0D;&lt;br&gt;        study.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        -  INCLUSION CRITERIA:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Men and women aged 40 to 80 years with DOPA-responsive PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Hoehn and Yahr grade of 2 to 4 while off&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Must be on a regimen including levodopa&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Total dose of levodopa and dopamine agonists (using dopamine equivalents) has to be equal&#x0D;&lt;br&gt;        to or more than 300 milligrams per day&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        problems with walking and gait time for a 10-meter distance greater than six seconds or&#x0D;&lt;br&gt;        more&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        EXCLUSION CRITERIA:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Any active psychiatric disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        History of seizures and epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Concurrent use of tricyclic antidepressants, neuroleptic agents, or any other licit or&#x0D;&lt;br&gt;        illicit drugs other than anti-parkinsonian agents that could lower the seizure threshold&#x0D;&lt;br&gt;        except for SSRI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Pallidotomy, implanted electrodes and generator for deep brain stimulation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Surgically or traumatically implanted foreign bodies such as a pacemaker, implanted medical&#x0D;&lt;br&gt;        pump, implanted hearing aids, metal plate in the skull, or metal implant in the skull or&#x0D;&lt;br&gt;        eyes (other than dental appliances or fillings) that may pose a physical hazard during TEP.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Study would cause undue risk or stress for reasons such as tendency to fall, excessive&#x0D;&lt;br&gt;        fatigue, general frailty, or excessive apprehensiveness.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Dementia as assessed by the Folstein's Mini-Mental Test Examination (MMSE less than or&#x0D;&lt;br&gt;        equal to 24/30) or mentally impaired patients having no capacity to provide their own&#x0D;&lt;br&gt;        consent (the physician establishing the diagnosis and applying UPDRS will evaluate&#x0D;&lt;br&gt;        patient's mental capacity using conventional clinical interview)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Unable to walk a 10-meter distance.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        More than occasional falls, i.e. daily falls (corresponding to a score greater than or&#x0D;&lt;br&gt;        equal to 3 and more in UPDRS item 13), history of fall(s) with significant injuries,&#x0D;&lt;br&gt;        absence of postural response in the on and/or spontaneous loss of balance in the off&#x0D;&lt;br&gt;        condition (corresponding to a score of greater than or equal to 2 and greater than or equal&#x0D;&lt;br&gt;        to 3 in on/off condition, respectively, in UPDRS item 30)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Pregnancy is unusual in patients with PD, grade 2-4. Urine sample for the pregnancy test&#x0D;&lt;br&gt;        will be obtained in patients of childbearing potential prior to starting the 50 Hz rTMS and&#x0D;&lt;br&gt;        also at the initial interview after signing the consent form. Women of childbearing&#x0D;&lt;br&gt;        potential will be asked to take appropriate measures to prevent a pregnancy during the&#x0D;&lt;br&gt;        study.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        -  INCLUSION CRITERIA:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Men and women aged 40 to 80 years with DOPA-responsive PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Hoehn and Yahr grade of 2 to 4 while off&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Must be on a regimen including levodopa&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Total dose of levodopa and dopamine agonists (using dopamine equivalents) has to be equal&#x0D;&lt;br&gt;        to or more than 300 milligrams per day&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        problems with walking and gait time for a 10-meter distance greater than six seconds or&#x0D;&lt;br&gt;        more&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        EXCLUSION CRITERIA:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Any active psychiatric disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        History of seizures and epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Concurrent use of tricyclic antidepressants, neuroleptic agents, or any other licit or&#x0D;&lt;br&gt;        illicit drugs other than anti-parkinsonian agents that could lower the seizure threshold&#x0D;&lt;br&gt;        except for SSRI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Pallidotomy, implanted electrodes and generator for deep brain stimulation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Surgically or traumatically implanted foreign bodies such as a pacemaker, implanted medical&#x0D;&lt;br&gt;        pump, implanted hearing aids, metal plate in the skull, or metal implant in the skull or&#x0D;&lt;br&gt;        eyes (other than dental appliances or fillings) that may pose a physical hazard during TEP.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Study would cause undue risk or stress for reasons such as tendency to fall, excessive&#x0D;&lt;br&gt;        fatigue, general frailty, or excessive apprehensiveness.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Dementia as assessed by the Folstein's Mini-Mental Test Examination (MMSE less than or&#x0D;&lt;br&gt;        equal to 24/30) or mentally impaired patients having no capacity to provide their own&#x0D;&lt;br&gt;        consent (the physician establishing the diagnosis and applying UPDRS will evaluate&#x0D;&lt;br&gt;        patient's mental capacity using conventional clinical interview)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Unable to walk a 10-meter distance.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        More than occasional falls, i.e. daily falls (corresponding to a score greater than or&#x0D;&lt;br&gt;        equal to 3 and more in UPDRS item 13), history of fall(s) with significant injuries,&#x0D;&lt;br&gt;        absence of postural response in the on and/or spontaneous loss of balance in the off&#x0D;&lt;br&gt;        condition (corresponding to a score of greater than or equal to 2 and greater than or equal&#x0D;&lt;br&gt;        to 3 in on/off condition, respectively, in UPDRS item 30)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Pregnancy is unusual in patients with PD, grade 2-4. Urine sample for the pregnancy test&#x0D;&lt;br&gt;        will be obtained in patients of childbearing potential prior to starting the 50 Hz rTMS and&#x0D;&lt;br&gt;        also at the initial interview after signing the consent form. Women of childbearing&#x0D;&lt;br&gt;        potential will be asked to take appropriate measures to prevent a pregnancy during the&#x0D;&lt;br&gt;        study.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        -  INCLUSION CRITERIA:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Men and women aged 40 to 80 years with DOPA-responsive PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Hoehn and Yahr grade of 2 to 4 while off&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Must be on a regimen including levodopa&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Total dose of levodopa and dopamine agonists (using dopamine equivalents) has to be equal&#x0D;&lt;br&gt;        to or more than 300 milligrams per day&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        problems with walking and gait time for a 10-meter distance greater than six seconds or&#x0D;&lt;br&gt;        more&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        EXCLUSION CRITERIA:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Any active psychiatric disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        History of seizures and epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Concurrent use of tricyclic antidepressants, neuroleptic agents, or any other licit or&#x0D;&lt;br&gt;        illicit drugs other than anti-parkinsonian agents that could lower the seizure threshold&#x0D;&lt;br&gt;        except for SSRI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Pallidotomy, implanted electrodes and generator for deep brain stimulation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Surgically or traumatically implanted foreign bodies such as a pacemaker, implanted medical&#x0D;&lt;br&gt;        pump, implanted hearing aids, metal plate in the skull, or metal implant in the skull or&#x0D;&lt;br&gt;        eyes (other than dental appliances or fillings) that may pose a physical hazard during TEP.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Study would cause undue risk or stress for reasons such as tendency to fall, excessive&#x0D;&lt;br&gt;        fatigue, general frailty, or excessive apprehensiveness.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Dementia as assessed by the Folstein's Mini-Mental Test Examination (MMSE less than or&#x0D;&lt;br&gt;        equal to 24/30) or mentally impaired patients having no capacity to provide their own&#x0D;&lt;br&gt;        consent (the physician establishing the diagnosis and applying UPDRS will evaluate&#x0D;&lt;br&gt;        patient's mental capacity using conventional clinical interview)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Unable to walk a 10-meter distance.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        More than occasional falls, i.e. daily falls (corresponding to a score greater than or&#x0D;&lt;br&gt;        equal to 3 and more in UPDRS item 13), history of fall(s) with significant injuries,&#x0D;&lt;br&gt;        absence of postural response in the on and/or spontaneous loss of balance in the off&#x0D;&lt;br&gt;        condition (corresponding to a score of greater than or equal to 2 and greater than or equal&#x0D;&lt;br&gt;        to 3 in on/off condition, respectively, in UPDRS item 30)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Pregnancy is unusual in patients with PD, grade 2-4. Urine sample for the pregnancy test&#x0D;&lt;br&gt;        will be obtained in patients of childbearing potential prior to starting the 50 Hz rTMS and&#x0D;&lt;br&gt;        also at the initial interview after signing the consent form. Women of childbearing&#x0D;&lt;br&gt;        potential will be asked to take appropriate measures to prevent a pregnancy during the&#x0D;&lt;br&gt;        study.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Parkinson Disease;Parkinson Disease;Parkinson Disease
    </Condition>
    <Intervention>Procedure: 50 HZ Repetitive TMS;Procedure: Sham rTMS;Procedure: 50 HZ Repetitive TMS;Procedure: Sham rTMS;Procedure: 50 HZ Repetitive TMS;Procedure: Sham rTMS;Procedure: 50 HZ Repetitive TMS;Procedure: Sham rTMS
    </Intervention>
    <Primary_outcome>Gait Speed;Gait Speed
    </Primary_outcome>
    <Secondary_outcome>Bradykinesia;Total UPDRS Score;Motor UPDRS;Activities of Daily Living UPDRS
    </Secondary_outcome>
    <Secondary_ID>09-N-0221;090221
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>27/12/2012
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT00977184
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>13435746
    </Internal_Number>
    <TrialID>JPRN-UMIN000001576
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>A randomized, double-blind, placebo- controlled, multi-center, parallel study concerning the efficacy of repetitive transcranial magnetic stimulation over the supplementary motor area in treatment of motor and non- motor symptoms in Parkinson&amp;#39;s disease
    </Public_title>
    <Scientific_title>A randomized, double-blind, placebo- controlled, multi-center, parallel study concerning the efficacy of repetitive transcranial magnetic stimulation over the supplementary motor area in treatment of motor and non- motor symptoms in Parkinson&amp;#39;s disease - The efficacy of repetitive transcranial magnetic stimulation over the supplementary motor area in treatment of Parkinson&amp;#39;s disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
    </Scientific_title>
    <Primary_sponsor>Department of neurology, Fukushima medical university
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20081217
    </Date_registration3>
    <Date_registration>17/12/2008
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001899
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20years-old
    </Inclusion_agemin>
    <Inclusion_agemax>Not applicable
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2008/11/01
    </Date_enrollement>
    <Target_size>150
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel Randomized
    </Study_design>
    <Phase>Not selected
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname>Hiroyuki Enomoto
    </Contact_Lastname>
    <Contact_Address>1, Hikarigaoka, Fukushima, 960-1295, Japan
    </Contact_Address>
    <Contact_Email/>
    <Contact_Tel>024-547-1248
    </Contact_Tel>
    <Contact_Affiliation>Fukushima medical university Department of neurology
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1)The patients who underwent the TMS treatment before 2)No implantation of metal in head, except in the mouth 3) Those having heart pacemaker or drug infusion pomp 4) Serious heart disease 5)History of massive cerebral infarction, head injury, brain tumor, or epilepsy 6)Pregnant or intend to be pregnant
    </Exclusion_Criteria>
    <Condition>Parkinson&amp;#39;s disease
    </Condition>
    <Intervention>Repetitive transcranial magnetic stimulation over the supplementary motor area, high-frequency stimulation&lt;br&gt;Repetitive transcranial magnetic stimulation over the supplementary motor area, low-frequency stimulation&lt;br&gt;Sham stimulation
    </Intervention>
    <Primary_outcome>Unified Parkinson&amp;#39;s Disease Rating Scale(UPDRS) part 3
    </Primary_outcome>
    <Secondary_outcome>UPDRS part 1,2,4, 5-point scale for daily life and tremor, Apathy scale, 17 item of Hamilton depression scale, Non-Motor Symptoms Questionnaire
    </Secondary_outcome>
    <Source_Support>Ministry of Health, Labor and Welfare
    </Source_Support>
    <Secondary_Sponsor>Univ: Occupational Environ Health,Tokushima,Kyusyu,Tottori,Tokyo,Hokkaido,Saitama Med,Osaka, Hamamatsu Med,Kinki)  Tokyo neurological hos,Kumamoto Kinoh hos, Nagasaki Med center of Neurol
    </Secondary_Sponsor>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>01/03/2011
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:31:52</Export_date>
    <Internal_Number>10203327
    </Internal_Number>
    <TrialID>NCT00529308
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette's Syndrome
    </Public_title>
    <Scientific_title>Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome
    </Scientific_title>
    <Acronym>TMS
    </Acronym>
    <Primary_sponsor>Yale University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20070913
    </Date_registration3>
    <Date_registration>13/09/2007
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT00529308
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 2007
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Antonio Mantovani, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>New York State Psychiatric Institute
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Primary diagnosis of Tourette's Syndrome, as confirmed by the DSM-IV-TR criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Residual TS symptoms, defined as a total Y-GTSS total motor tic or phonic tic score &gt;&#x0D;&lt;br&gt;             20, despite treatment with an adequate trial of medications (defined as a failure to&#x0D;&lt;br&gt;             respond to a trial of commonly used medications for TS such as clonidine, guanfacine,&#x0D;&lt;br&gt;             or neuroleptic medications, given at recommended dosage and duration based on the&#x0D;&lt;br&gt;             clinician's judgment)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Persistent high level of tic severity for 4 months despite efforts to control the tics&#x0D;&lt;br&gt;             using medications, or the presence of self injurious tics&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Duration of the index episode of at least a year&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals who cannot tolerate medications of class and dose at the specified&#x0D;&lt;br&gt;             duration as described above will also be included&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients currently on medication must be at the same stable dose(s) for one month&#x0D;&lt;br&gt;             prior to enrollment and be willing to continue at the same dose(s) through the&#x0D;&lt;br&gt;             duration of the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals diagnosed with major depressive disorder (current) of moderate or severe&#x0D;&lt;br&gt;             intensity (CGI = 4), bipolar disorder (lifetime), any psychotic disorder (lifetime),&#x0D;&lt;br&gt;             or an Axis II personality disorder; with a history of substance abuse or dependence&#x0D;&lt;br&gt;             within the past year (except nicotine and caffeine); or at significant acute suicide&#x0D;&lt;br&gt;             risk will be excluded&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Other exclusion criteria include those common to every TMS protocol:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Individuals with a clinically defined neurological disorder, with an increased risk of&#x0D;&lt;br&gt;             seizure for any reason, with a history of treatment with TMS, deep brain stimulation&#x0D;&lt;br&gt;             for any disorder will be excluded&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with cardiac pacemakers, implanted medication pumps, intracardiac lines, or&#x0D;&lt;br&gt;             acute, unstable cardiac disease, with intracranial implants (e.g. aneurysm clips,&#x0D;&lt;br&gt;             shunts, stimulators, cochlear implants, or electrodes) or any other metal object&#x0D;&lt;br&gt;             within or near the head, excluding the mouth, that cannot be safely removed will be&#x0D;&lt;br&gt;             excluded&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current use of any investigational drug, any medications with proconvulsive action,&#x0D;&lt;br&gt;             such as bupropion, maprotiline, tricyclic antidepressant, clomipramine, classical&#x0D;&lt;br&gt;             antipsychotics, and daily use of any medications with a known inhibitory effect on&#x0D;&lt;br&gt;             cortical excitability measures (e.g., anticonvulsants, standing doses of&#x0D;&lt;br&gt;             benzodiazepines, sedative/hypnotics, and atypical antipsychotics) will not be&#x0D;&lt;br&gt;             permitted&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If participating in psychotherapy, patients must have been in stable treatment for at&#x0D;&lt;br&gt;             least three months prior to entry into the study, with no anticipation of change in&#x0D;&lt;br&gt;             frequency therapeutic sessions, or the therapeutic focus over the duration of the TMS&#x0D;&lt;br&gt;             trial&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Finally, current significant laboratory abnormality, known or suspected pregnancy,&#x0D;&lt;br&gt;             women who are breast-feeding or women of childbearing potential not using a medically&#x0D;&lt;br&gt;             accepted form of contraception when engaging in sexual intercourse will also be&#x0D;&lt;br&gt;             excluded.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tourette Syndrome
    </Condition>
    <Intervention>Device: Transcranial Magnetic Stimulation (active);Device: Transcranial Magnetic Stimulation (sham)
    </Intervention>
    <Primary_outcome>Yale Global Tic Severity Scale (Y-GTSS);Motor Cortex Excitability Normalization-Right Motor Threshold;Number of Patients With "Much Improved or Very Much Improved" on Clinical Global Impression-Improvement (CGI) Scale;Motor Cortex Excitability Normalization-Left Motor Threshold;Number of Patients With "Improved or Minimally Improved" in Clinical Global Impression-Improvement (CGI) Scale
    </Primary_outcome>
    <Secondary_ID>5480
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Tourette Association of America
    </Secondary_Sponsor>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>15/02/2013
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT00529308
    </results_url_link>
    
  </Trial>
</Trials_downloaded_from_ICTRP>